

# Index to Volume 48

The index to Volume 48 is composed of three parts: a subject index, an author index, and an advertising index.

The subject index is made up mainly of terms constructed by *International Pharmaceutical Abstracts*. The IPA index is an alphabetical, open-ended, controlled-vocabulary index that makes use of standardized headings. (The primary index terms for each article are listed routinely in *AJHP* as "index terms" after abstracts.) *IPA* covers all authored papers and editorials in *AJHP*, as well as selected letters and news reports. Items that were published in the ASHP Reports section, including official ASHP statements and guidelines, are indexed under "American Society of Hospital

Pharmacists." The subject index also notes all regular *AJHP* columns and, under the respective column headings, the titles of items in the "News," "ASHP Foundation Reports," "Questions and Answers," "Joint Commission Dialogue," "Student and Resident Forum," "Management Consultation," "How To," "Letters," "Editorials," "Book Reviews," and "Software Reviews" sections, and the individual reports from affiliated chapters in "ASHP Affiliates." The subject index also contains, under the heading "Correction Notices," the title and issue of publication of items for which corrections were printed, as well as the page numbers on which the corrections appear.

Issue	Pages
January	1-182
February	183-380
March	381-598
April	599-854
May	855-1106
June	1107-1366
July	1367-1626

Issue	Pages
August	1627-1832
September	1833-2054
October	2055-2326
October, Supplement 1	S1-S56
November	2327-2542
December	2543-2740

## Subject Index

### A

#### Absorption

didanosine; AIDS therapy, clinical studies, 1298  
water; magnesium tablets, stability, unit dose packaging, 1266

**Accreditation;** hospitals; manuals, revision, JCAHO standards, 434

**Acetazolamide;** suspensions; stability, temperature, storage, 1241

**Acquired immunodeficiency syndrome vaccines;** research; NIH programs, 2662

#### Acquired immunodeficiency syndrome

didanosine; protocols, treatment IND, 1299; therapy, clinical studies, 1298  
drugs, investigational; therapy, research, 1296  
foscarnet sodium, comparison, ganciclovir sodium; cytomegalic inclusion disease therapy, 2478  
ganciclovir sodium, comparison, foscarnet sodium; cytomegalic inclusion disease therapy, 2478  
megestrol acetate; cachexia therapy, 2479  
opiate antagonists; therapy, 2480  
pentamidine isethionate; aerosols, environmental toxicity, 557; aerosols, toxicity, asthma, 556  
therapy; research, NIH, 2662

**Acylovir;** incompatibilities; morphine, meperidine, i.v. injections, patient-controlled analgesia, 123

**Addicts;** drug abuse; programs, increased budgets, recommendations, 13

**Additives;** injections, amphotericin B, incompatibilities, dextrose, i.v. admixtures, 283; amphotericin B, incompatibilities, dextrose, stability, 2635; amphotericin B-dextrose incompatibilities, stability, 2430; amrinone incompatibilities, i.v. admixtures, 1245; antipyrine-caffeine incompatibilities, stability, storage, 1267; cefazolin stability, peritoneal dialysis solutions, 291; cefoperazone-cimetidine incompatibilities, 111; cefoperazone-furosemide incompatibilities, 108; cefotaxime-metronidazole incompatibilities, storage, 2638; ceftazidime, incompatibilities, parenteral nutrition, stability, 1515; cimetidine-methylprednisolone incompatibilities, admixtures, 1237; ciprofloxacin, incompatibilities, stability, storage, 2166; compounding, hospitals, ASHP conferences, 2391; compounding, hospitals, U.S., survey, 2398; compounding, quality assurance, improvement, hospital pharmacy, 2387; dobutamine stability, peritoneal dialysis solutions, 1234; fluconazole incompatibilities, 744; fludabine, incompatibilities, 2186; fluorouracil, incompatibilities, mannitol, lack, 2158; ganciclovir-dextrose incompatibilities, stability, 2641; hospital pharmacy

services, establishment, 1463; incompatibilities, ceftriaxone and vancomycin, precipitation, 77; incompatibilities, opiates, patient-controlled analgesia, 123; incompatibilities, polyolefin containers, 2184; indomethacin, incompatibilities, stability, 2442; insulin human incompatibilities, 125; medication orders, fax, hospital pharmacy, 2653; methadone, stability, storage, 515; miconazole-polyvinyl chloride incompatibilities, dialysis solutions, 286; nizatidine-fat emulsions, incompatibilities, 1507; octreotide-TPN incompatibilities, 2172; ondansetron incompatibilities, i.v. admixtures, 968; pharmaceutical services, psychiatric facilities, survey, 974; phenytoin sodium, pH variations, stability, 510; propofol, incompatibilities, PVC, 2627; TPN, compounding, computer programs, 270; TPN, sterility tests, Septi-Chek, 2419; zidovudine, incompatibilities, vehicles, stability, 280

#### Administration

American Society of Hospital Pharmacists; strategic planning, 1991-92, 1776

Board of Pharmaceutical Specialties; certification, 480  
clinical pharmacists; hospitals, time studies, methodology, 1211

drug distribution systems; pharmacists' role, ASHP guidelines, 1782

education, pharmaceutical; continuing, ASHP programs, ACCRUE, 1992

Food and Drug Administration; advisory committee, recommended changes, 1632

health care; home, i.v. therapy, databases, pharmacy, 1535

health maintenance organizations; drug-use review, 1712

health professions; specialties, certification, 476

hospital pharmacy; clinical services, staff development, pharmacists, 1956; clinical services documentation, 2647; contracts, clerkships, pharmacy schools, 1994; cost justification, clinical pharmacist, intensive-care units, 2154; documentation, pharmacists' interventions, forms, 2649; dosage monitoring, kidney failure, clinical pharmacists, 1962; drug-use review, 518; employment interviews, guidelines, 670; employment, pharmacists, drug abuse recovery, 326; establishment, 1463; exit interviews, guidelines, 1433; formulary system, development, ASHP guidelines, 791; handling, investigational drugs, material safety data sheets, 1679; hours, women pharmacists, 85; issues, U.S., 1990, review, 720; ketorolac vs. opiates, cost savings, 2128; laminar-airflow hoods, certification, standards, 654; management, employment requirements, advertisements, 1680; management, super-

visors, interaction techniques, 2598; Navy ships, Persian Gulf, 530, 730; patient-care standards, Missouri, 1257; pediatrics, services, guidelines, 2475; performance appraisal, guidelines, 2600; personnel involvement, professional organizations, 444; pharmacists' interventions, drug therapy, clinical impact, 2644; pharmacist shortages, survey, 1114; pact, 2644; pharmacist shortages, development, 1937; quality assurance indicators, patient care, 1931; quality assurance, patient outcomes, 1908; recycling programs, 6; role, *AJHP*, 81; satellite services, obstetrics, neonates, 1533; satellite, surgery and anesthesiology, ASHP guidelines, 319; services, quality assurance, guidelines, 1901; staff development, clinical services, 1704; staff development, TPN monitoring programs, 980; sterile products, compounding, ASHP role, 386; technology, impact, review, Oct suppl S24; therapeutic substitution programs, 1471; training program, community pharmacists, 666; U.S. Army services, Saudi Arabia, 533  
hospitals; employment discrimination, HIV infections, pharmacists, 606; medication errors, reports, quality assurance, 2611; QA consultants, effects, pharmacy department, 1891  
long-term-care facilities; personal-care homes, pharmaceutical services, 1530  
personnel, pharmacy; job description, revisions, suggestions, 2118  
pharmaceutical services; quality assurance, processes, 1917  
pharmacists, hospital; hospital administrators' attitudes, survey, 1846; management, hospital administrators' turnover, 2372; pharmacists interventions, drug therapy, clinical impact, 2644; professional relations, unfair criticism, 1884  
pharmacy; drug purchasing, manufacturers, suppliers selection, ASHP guidelines, 523; schools, contracts, hospitals, clerkships, 1994; specialties, certification, 469; specialties, conference recommendations, 712; specialties, structure, development, 706  
pharmacy, institutional; pharmacists' dispensing errors, control, management, 1675; reimbursement, Medicare regulations, 2434  
policies and procedures; antibiotics, automatic stop orders, recommendations, 2602; controlled substances, VA pharmacies, 2062; drug allergy documentation, hospital pharmacy, 260; hospital pharmacy, antibiotic-use restrictions, 1220; hospital pharmacy, environmental toxicity, pregnant employees, 1281; hospital pharmacy, JCAHO standards, 926; hospital pharmacy, sterile products, U.S., survey, 2398; pharmacy recycling programs,

## Annual Index

- 118; psychiatric facilities, medicated shampoos, toxicity, 937; Veterans Affairs, pharmacist education, employment, 732  
 research; AIDS, NIH, 2662
- Administrators**  
 education, pharmaceutical; ASHP programs, ACCRUE, 1992  
 hospital pharmacy; directors, hospital administrators' attitudes, survey, 1846; directors, hospital administrators' attitudes, survey, 1948; employment requirements, advertisements, 1680; management, supervisors, interaction techniques, 2598; new, problems, guidelines, pharmacy directors, 2372; professional relations, unfair criticism, 1884; salaries, survey, 249  
 hospitals; attitudes, pharmacy directors, survey, 1846; attitudes, pharmacy directors, survey, 1948  
 pharmacists, hospital; women, part-time, 85
- Additives**  
**Adrenergic agents**, see **Sympathomimetic agents**  
**Adsorption**; urokinase; incompatibilities, polyvinyl chloride, containers, 1511
- Advanced Health Care Services**; litigation; Radford Community Hospital, medical equipment, vendor exclusivity, 1542
- Advanced Health Care Services v. Radford Community Hospital**; litigation; medical equipment, vendor exclusivity, 1542
- Adverse reactions**, see **Drugs, adverse reactions**
- Advertising**; administrators; employment, hospital pharmacy, management, requirements, 1680
- Advertising Index**, 182, 380, 598, 854, 1106, 1366, 1626, 1832, 2054, 2326, 2542, 2712
- Aerosols**  
 pentamidine; *P. carinii*, prophylaxis, hospital protocols, forms, 2440  
 pentamidine isethionate; environmental toxicity, health professions, 557; toxicity, asthma, AIDS, 556
- AIDS**, see **Acquired immunodeficiency syndrome**
- AIDS Facts**, 556, 1298, 2478
- AJHP**, see **American Journal of Hospital Pharmacy**
- AJHP Continuing Education**, 151, 1301, 2256, Oct suppl 554, 2484, 2670
- Alcoholism**; pharmacists; employment, recovery, considerations, 326
- Alcohols, ethyl**; abuse; students, U.S., survey, 622
- Allergies**  
 drugs; documentation, hospital policies, 260  
 muromonab-CD3; adverse reactions, topical exposure, 1442
- Ambulatory care**  
 hospital pharmacy; services, establishment, 1463  
 pharmaceutical services; ASHP guidelines, 311; models, 245  
 services; clinical pharmacists, nurses' and physicians' attitudes, 1189
- American Association of Colleges of Pharmacy**; role; implementation, pharmaceutical care, 1697
- American Council on Pharmaceutical Education**; role; implementation, pharmaceutical care, 1697
- American Home Products**; litigation; Good Samaritan Hospital, Inc., quality assurance, hospitals, 1989
- American Hospital Association**  
 hospitals; community, definition, ASHP survey, 1668  
 manpower; personnel shortages, survey, 1114
- American Journal of Hospital Pharmacy**  
 acknowledgment to reviewers, November 1, 1990, to October 31, 1991, 2667  
 instructions for submitting computer disks with revised manuscripts, 146  
 manuscripts; editorial processing system, 2388; editorial processing system, 909  
 policies and procedures; paper submission, conflict-of-interest information, 1168  
 procedure for submission of manuscripts to journals of the American Society of Hospital Pharmacists, 144  
 publications; role, pharmacists, practice, 81; stability studies, criteria, 1454  
 sections, 146  
 updated guidelines on competing manuscripts based on the same study, 2668  
 update to "Uniform requirements for manuscripts submitted to biomedical journals," 1784
- American Medical Association**; drug use; review, principles, 2062
- American Nurses Association**; rational therapy; polypharmacy, recommendations, geriatrics, 862
- American Pharmaceutical Association**  
 drug use; review, principles, 2062; role; implementation, pharmaceutical care, 1697
- American Society of Hospital Pharmacists**  
 affiliated state chapter officers, 1773  
 Annual Meeting, 1991; call for submissions, 1545; contributed papers and exhibitors' theaters, 1025; program, 750  
 annual report, 1009  
 attitudes; pharmacy inspections, JCAHO standards, 914  
 Board of Directors; actions, September 28, 1990, meeting, 147; actions, November 14-15, 1990, meeting, 525; actions, April 24-25, 1991, meeting, 1782; actions, June 2, 1991, meeting, 1783  
 Council on Administrative Affairs; report of, 769  
 Council on Educational Affairs; report of, 772  
 Council on Legal and Public Affairs; report of, 775  
 Council on Organizational Affairs; report of, 779  
 Council on Professional Affairs; report of, 783  
 drugs, adverse reactions; standards, monitoring, reporting, 1428  
 education, pharmaceutical; CE programs, administration, ACCRUE, 1992  
 electronic bulletin boards; PharmNet, access information, advantages, 1174  
 executive summary of petition requesting recognition of psychopharmacy, 1284  
 Executive Vice President; report of, 1764  
 guidelines; ambulatory care, pharmaceutical services, 311; drug distribution, control, pharmacists' role, 1782; drugs, environmental toxicity, women, 1281; drugs, purchasing, manufacturers, suppliers selection, 523; formulary system, development, 791; investigational drugs, institutional use, 315; manuscripts, seminars, publication, *Clinical Pharmacy*, 442; pharmaceutical research, pharmacists' involvement, 1781; pharmaceutical services, surgery and anesthesiology, 319; pharmacists' role, patient-education programs, 1780; quality assurance, pharmaceutical services, 1941  
 Harvey A. K. Whitney Lecture Award; 1991, 1697  
 health care; home, Specialty Practice Group, need, 75  
 House of Delegates; 42nd annual session, members of 1740; proceedings, 1739  
 meetings; sterile products compounding, quality assurance, 2391  
 members invited to comment on pharmacists' Code of Ethics, 1544  
 Midyear Clinical Meeting; call for student posters, 528; call for submissions, 138; program, 2197  
 officers, directors, councils, and committees, directory of, 1769  
 Omnibus Budget Reconciliation Act of 1990; monitoring, 114  
 pharmaceutical services; community hospitals, definition, survey, 1668  
 policy recommendations—invitation to comment, 767  
 Practitioner Recognition Program—1991 fellows, 994  
 President and Chairman of the Board; report of, 1749  
 President-elect and Vice Chairman of the Board; report of, 1754  
 publications; *AJHP*, CP, paper submission, conflict-of-interest information, 1168; computers, benefits, 950; continuing education, pharmacy students, 2102; handbooks, drug information, reliability, 421  
 recipients of 1991 ASHP Student Leadership Awards, 2252  
 role; sterile products, manufacturing, repackaging, 386  
 roster of residents completing ASHP-accredited programs in calendar year 1991, 1002  
 strategic planning; reports, 1991-92, 1776  
 Treasurer; report of, 1757, 1776
- American Society of Parenteral and Enteral Nutrition**; guidelines; DUE, adult TPN, 1442
- Amikacin sulfate**; i.compatibilities; ciprofloxacin, vehicles, temperature, 2166
- Amino acids**  
 incompatibilities; ceftazidime, parenteral nutrition, stability, 1515  
 nutrition; parenteral, incompatibilities, ganciclovir, 1538  
 TrophAmine; incompatibilities, indomethacin, stability, 2442
- Aminoglycosides**  
 gentamicin; order forms, pharmacists' monitoring, 681  
 gentamicin sulfate; ophthalmic solutions, stability, storage, 507  
 incompatibilities; ciprofloxacin, stability, storage, lack, 2166  
 tobramycin sulfate; interactions, cephalosporins, blood levels, lack, 520; ophthalmic solutions, stability, storage, 507
- Aminophylline**; incompatibilities; ciprofloxacin, stability, storage, 2166
- Amphotericin B**; incompatibilities; dextrose, concentration, injections, stability, 1681; dextrose, concentration, stability, 2430; dextrose, polyvinyl chloride containers, storage, 2635; dextrose, stability, high concentration, 283; fluconazole, injections, stability, 744  
**Ampicillin**; combination, sulbactam; prescribing, use, formulary inclusion, 1492; substitution for cefoxitin, hospital pharmacy programs, 2150
- Amrinone lactate**; incompatibilities; cardiac drugs, stability, i.v. admixtures, 1245
- Analgesics and antipyretics**  
 administration routes; epidural, therapy, 2460  
 antipyrine; incompatibilities, caffeine, stability, storage, 1267  
 controlled substances; injections, refractometry, tampering detection, 1488  
 hydromorphone hydrochloride; incompatibilities, dexamethasone, stability, 2161  
 ketorolac tromethamine; vs. opiates, hospitals, cost savings, 2128  
 meperidine hydrochloride; incompatibilities, i.v. injections, patient-controlled analgesia, 123  
 methadone hydrochloride; stability, storage, admixtures, 515  
 morphine sulfate; incompatibilities, i.v. injections, patient-controlled analgesia, 123; sustained-action tablets, comparison, solution, costs, 101  
 snakebites; therapy, 2190
- Anesthetics**  
 propofol; incompatibilities, PVC, 2627  
 tetracaine hydrochloride; incompatibilities, hydromorphone, injections, stability, efficacy, 1682
- Anesthetics, local**; administration routes; epidural, therapy, 2460
- Antiarhythmic drugs**, see **Cardiac drugs**
- Antibiotics**  
 bacitracin; pseudomembranous enterocolitis therapy, decision analysis, 1477  
 cefmetazole, comparison, cefotetan, cefoxitin; decision analysis, formularies, 2146  
 cefotetan, comparison, cefmetazole, cefoxitin; decision analysis, formularies, 2146  
 cefoxitin; substitution, ampicillin-sulbactam, hospital pharmacy programs, 2150; therapeutic interchange, ceftizoxime, 2655  
 cefoxitin, comparison, cefmetazole, cefotetan; decision analysis, formularies, 2146  
 clindamycin phosphate; incompatibilities, ciprofloxacin, stability, storage, 2166; incompatibilities, polyolefin containers, lack, 2184  
 drug use; effects, restriction policies, 1220  
 imipenem, combination, clastatin sodium; incompatibilities, opiates, i.v. injections, patient-controlled analgesia, 123  
 incompatibilities; fluconazole, injections, stability, 744  
 medication orders; automatic stop orders, hospital policies, 2602  
 sterility; tests, injections, hospital pharmacy, 2414  
 vancomycin; pseudomembranous enterocolitis therapy, decision analysis, 1477  
 vancomycin hydrochloride; incompatibilities, ceftriaxone, injections, precipitation, 77
- Antibodies**; monoclonal; biotechnology, pharmacy practice effects, Oct suppl 54
- Anticonvulsants**  
 carbamazepine; stability, tablets, effects, moisture, temperature, 2130  
 phenytoin sodium; pH variations, stability, admixtures, 510
- Antiemetics**; ondansetron hydrochloride; incompatibilities, i.v. admixtures, 988
- Antifungals**  
 amphotericin B; incompatibilities, dextrose, concentration, injections, 1681; incompatibilities, dextrose, concentration, stability, 2430; incompatibilities, dextrose, stability, high concentration, 283; incompatibilities, dextrose, stability, storage, 2635  
 fluconazole; incompatibilities, injections, stability, 744  
 miconazole; incompatibilities, polyvinyl chloride, stability, storage, 286
- Antihemophilic factor**; toxicity, environmental; HIV transmission, hospital pharmacists' experiences, 148
- Antihistamines**; diphenhydramine hydrochloride; allergies therapy, muromonab-CD3 adverse reactions, 1442; incompatibilities, dexamethasone, stability, 2161
- Anti-infective agents**  
 incompatibilities; fludarabine, injections, stability, 2186  
 metronidazole; ciprofloxacin, stability, storage, lack, 2166; incompatibilities, ceftazidime, i.v. admixtures, stability, 2638; pseudomembranous enterocolitis therapy, decision analysis, 1477  
 nitrofurazone; dressings, effects, dilutions, in vitro,

- 1496  
 pentamidine; *P. carinii*, prophylaxis, hospital protocols, forms, 2440  
 pentamidine isethionate; environmental toxicity, aerosols, health professions, 557; toxicity, aerosols, asthma, AIDS, 556  
 sterility; tests, injections, hospital pharmacy, 2414  
**Anti-inflammatory agents**; indomethacin sodium trihydrate; incompatibilities, injection, stability, 2442  
**Antimanic agents**; lithium; blood levels, laboratory tests, protocols, 1536  
**Antineoplastic agents**  
 cisplatin; stability, decomposition products, effects, containers, pH, light, 1500  
 doxorubicin hydrochloride; stability, storage, infusion pump reservoirs, 1976  
 fludarabine phosphate; incompatibilities, injections, 2186  
 fluorouracil; incompatibilities, mannitol, injections, lack, 2158  
 handling; safety, hospital pharmacists, Kentucky, 119  
 idarubicin hydrochloride; incompatibilities, injections, stability, pH, 2181  
 incompatibilities; fludarabine, injections, stability, 2186  
 medication orders; standardized forms, compounding, dispensing, control, 1683  
 taxol; incompatibilities, vehicles, containers, 1520  
 toxicity, environmental; chromosomal damage, pharmacists, nurses, patients, 1199  
**Antipyretic**; incompatibilities; caffeine, stability, storage, 1267  
**Antituberculars**; rifampin; injections, reconstitution, precipitation, 2127  
**Antivenoms**; snakebites; therapy, 2190  
**Antivirals**  
 acyclovir; incompatibilities, opiates, i.v. injections, patient-controlled analgesia, 123  
 didanosine; AIDS therapy, clinical studies, 1298; protocols, treatment IND, AIDS therapy, 1299  
 foscarnet sodium, comparison, ganciclovir sodium; cytomegalic inclusion disease therapy, AIDS, 2478  
 ganciclovir sodium; incompatibilities, dextrose, stability, storage, 2641; incompatibilities, TPN, concentration, 1538  
 ganciclovir sodium, comparison, foscarnet sodium; cytomegalic inclusion disease therapy, AIDS, 2478  
 naltrexone; AIDS therapy, 2480  
 naloxone; AIDS therapy, 2480  
 research; AIDS, HIV infections, NIH, 2662  
 zidovudine; AIDS therapy, research, 1296; incompatibilities, vehicles, stability, admixtures, storage, 280  
**Anxiolytics, sedatives and hypnotics**; diazepam; snakebites therapy, 2190  
**Apparatus, see Equipment**  
**Arginine**; excipients; cefazidime injections, effects, gas formation, 1727  
**ASHP, see American Society of Hospital Pharmacists**  
**ASHP Affiliates**, 26, 210, 409, 640, 880, 1132, 1401, 1653, 1856, 2082, 2346, 2568  
 Affiliated state chapters share expertise through chapter grants program, 2574  
 Alabama Society of Hospital Pharmacists, 30, 1416, 2590  
 Arizona Society of Hospital Pharmacists, 216, 2587  
 Arkansas Association of Hospital Pharmacists, 216  
 California Society of Hospital Pharmacists, 640, 1406, 1416, 2088, 2364  
 Chapter Briefs, 38, 216, 646, 895, 1144, 1416, 1660, 2088, 2364, 2590  
 Chapter executives convene in Bethesda, 880  
 Chapter survey shows more member involvement, 2574  
 Colorado Society of Hospital Pharmacists, 30, 214, 216, 895, 1416, 2590  
 Conference for state chapter officers precedes ASHP Annual Meeting, 1856  
 Connecticut Society of Hospital Pharmacists, 38, 646, 901, 1148, 1660, 2361, 2590  
 Delaware Society of Hospital Pharmacists, 220, 648, 895, 1864  
 Florida Society of Hospital Pharmacists, 2587  
 Georgia Society of Hospital Pharmacists, 216, 642, 895, 1406, 1413, 1416, 2088  
 Grant applications for technician conferences due December 1, 2082  
 Hawaii Society of Hospital Pharmacists, 1136  
 Idaho Society of Hospital Pharmacists, 1416  
 Illinois Council of Hospital Pharmacists, 1656  
 Indiana Society of Hospital Pharmacists, 38, 895, 1402  
 Iowa Society of Hospital Pharmacists, 1862  
 Kansas Society of Hospital Pharmacists, 33, 646  
 Louisiana Society of Hospital Pharmacists, 1406, 2590  
 Maine Society of Hospital Pharmacists, 220, 895, 901, 1416, 2088  
 Maryland Society of Hospital Pharmacists, 216, 648, 1413, 1421, 2093, 2364, 2590  
 Massachusetts Society of Hospital Pharmacists, 901, 1144, 1660  
 Michigan Society of Hospital Pharmacists, 33, 1136  
 Minnesota Society of Hospital Pharmacists, 412, 1402, 1416  
 Mississippi Society of Hospital Pharmacists, 2088  
 Missouri Society of Hospital Pharmacists, 412, 2361  
 Montana Society of Hospital Pharmacists, 216  
 Nebraska Society of Hospital Pharmacists, 648, 2088  
 Nevada Society of Hospital Pharmacists, 33, 38, 646, 1144, 1416, 2364, 2568  
 New Hampshire Society of Hospital Pharmacists, 30, 38, 1660  
 New Jersey Society of Hospital Pharmacists, 646, 888, 2361  
 New Mexico Society of Hospital Pharmacists, 30, 42, 648, 1148, 1866, 2364  
 New York State Council of Hospital Pharmacists, 642, 1660, 2590  
 North Carolina Society of Hospital Pharmacists, 220, 895, 2364  
 Ohio Society of Hospital Pharmacists, 33, 409, 1132, 1416, 1660, 2088, 2590  
 Oklahoma Society of Hospital Pharmacists, 1148, 2364  
 Oregon Society of Hospital Pharmacists, 220, 1148, 1864, 2364  
 Pennsylvania Society of Hospital Pharmacists, 26, 210, 646, 648, 1136, 1401, 1666, 2082, 2587  
 Pharmacists must participate in political process, Congressman tells state officers, 1856  
 Project grants awarded to three affiliated state chapters, 888  
 Rhode Island Society of Hospital Pharmacists, 216, 888, 901, 1666  
 South Carolina Society of Hospital Pharmacists, 220, 901, 1148, 1653, 2590  
 South Dakota Society of Hospital Pharmacists, 1656  
 State societies make headway in formalizing technician role, 2346  
 Tennessee Society of Hospital Pharmacists, 1136  
 Texas Society of Hospital Pharmacists, 895, 1656  
 Upcoming Meetings, 42, 220, 412, 648, 904, 1148, 1421, 1666, 1866, 2093, 2364, 2590  
 Utah Society of Hospital Pharmacists, 42, 220, 648, 901, 904, 1144, 1402  
 Vermont Society of Hospital Pharmacists, 220  
 Virginia Society of Hospital Pharmacists, 33, 1416, 2364  
 Washington State Society of Hospital Pharmacists, 646, 1402, 1416, 2364, 2588  
 West Virginia Society of Hospital Pharmacists, 888  
 Wisconsin Society of Hospital Pharmacists, 42, 648, 895, 1148, 1656, 2588  
 Wyoming Society of Hospital Pharmacists, 409  
**ASHP Foundation Reports**, 46, 1158, 2097, 2592  
 Applications due for Foundation Fellowships Program preceptorships, 1162  
 Amgen funds development phase of renal dialysis traineeship, 46  
 Burroughs Wellcome funds development phase of AIDS traineeship, 46  
 Burroughs Wellcome sponsors new critical-care drug therapy fellowship, 46  
 Cardiovascular Drug Therapy Fellowship awarded, 2097  
 Foundation announces 1991 Demonstration Projects Grants, 2097  
 Foundation awards two grants for new pharmacy practice researchers, 2097  
 Foundation literature awards to be presented at Mid-year meeting, 2592  
 Foundation selects participants for anticoagulation clinic traineeships, 2594  
 Selection of Foundation fellowship recipients and preceptors announced, 1158  
 Tennessee Wholesale Drug funds pain management program, 2594  
**Asthma**; pentamidine isethionate; aerosols, toxicity, AIDS, 556  
**Athletes**; drugs; banned, USOC, NCAA, list, 76  
**Atropine sulfate**; therapy; pediatrics, nurse education, 97  
**Authorship**  
 journals; paper submission, *AJHP*, *CP*, conflict-of-interest information, 1168  
 manuscripts; seminars, publication, *Clinical Pharmacy*, guidelines, 442  
 pharmacists; publications, guidelines, 687  
 publications; *AJHP*, *CP*, manuscripts, editorial processing system, 2388; *AJHP*, manuscripts, editorial processing system, 909  
**Authorships**; manuscripts; peer-reviewed journals, benefits, 1424  
**Automation**; dispensing; hospital pharmacy, technology impact, review, Oct suppl S24  
**Availability, drugs, see Drugs, availability**  
**AZT, see Zidovudine**
- B**
- Bacitracin**; enterocolitis; pseudomembranous, therapy, decision analysis, 1477  
**Benzo-diazepines**; toxicity; patient counseling, pharmacists, regulations, 1291  
**Beverages**; incompatibilities; methadone, oral, stability, 1252  
**Bid contracting, see Purchasing**  
**Binding**; CD-4; HIV, inhibition, 1300  
**Bioavailability, see Drugs, availability**  
**Biologicals**; approvals; FDA, 1990, 390  
**Biotechnology**; research; pharmacy practice effects, Oct suppl S4  
**Blood**  
 effects; nitrofurazone dressings, antibacterial activity, in vitro, 1496  
 infusion pumps; effects, lack, in vitro, 1970  
 transfusions; infusion pumps, 92; vs. perfluoramine-perflunolene dispensing, pharmacists ethics, 2176  
**Blood derivatives**  
 cardioplegic solutions; formulations, therapy, review, 2444  
 infusion pumps; effects, lack, in vitro, 1970  
**Blood levels**; lithium; laboratory tests, protocols, hospital pharmacy, 1536  
**Blood substitutes**; perfluoramine, combination, perflunolene; pharmacists, dispensing, vs. blood transfusions, ethics, 2176  
**Board of Pharmaceutical Specialties**  
 administration; pharmacist certification, 480  
 certification; nutrition support specialties, 2064  
 psychopharmacy; petition, 1284  
**Book Reviews**, 175, 373, 592, 838, 1103, 1359, 1614, 1822, 2032, 2322, 2530, 2710  
*The Caregiver's Guide to Medication Management*, 175  
*Clinical Laboratory Tests: Values and Implications*, 2032  
*Concise Guide to Parenteral Medications*, 2530  
*Consultation Skills for Health Care Professionals: How to Be an Effective Consultant within Your Organization*, 592  
*Criteria for Drug Use Evaluation, Volume 2*, 838  
*Drugs Available Abroad: A Guide to Therapeutic Drugs Available and Approved Outside the U.S.*, 2041  
*Drug Evaluations Annual, 1991: Drug Evaluations Subscription*, 1991, 2035  
*Enteral Feeding in Long Term Care*, 1614  
*The Essentials of Homeopathic Therapeutics*, 2025  
*European Drug Index*, 2532  
*Financial Management: A Self-instructional Course, ACCRUE Level II*, 594  
*Financial Management for Pharmacists: A Decision-Making Approach*, 373  
*Handbook of Nonprescription Drugs*, 9th Edition, 1822  
*Handbook of Ocular Drug Therapy and Ocular Side Effects of Systemic Drugs*, 1103  
*Handbook of Purchasing and Materials Management: An In-depth Hands-on Reference*, 2041  
*Human Drug Kinetics: A Course of Simulated Experiments*, 2532  
*Human Resources Management: A Self-instructional Course, ACCRUE Level II*, 2045  
*Infectious Diseases: Prophylaxis & Chemotherapy*, 843  
*International Reporting of Adverse Drug Reactions. Final Report of CIOMS Working Group*, 1103  
*Microcomputers in Health Care Management: Strategies and Applications for the 1990s, Second Edition*, 2045  
*Pharmaceutical Calculations, Ninth Edition*, 2532  
*Pharmacy Review*, 374  
*Pill Peddlers: Essays on the History of the Pharmaceutical Industry*, 847  
*Pocket Guide to Injectable Drugs*, 1831  
*Principles of Drug Action: The Basis of Pharmacology, Third Edition*, 175  
*Principles of Pharmacoeconomics*, 1359  
*Prohibit, Provide, Protect—Balancing the Response to Prescription Drug Abuse: Report of a National Symposium on Medicine and Public Policy*, 2534  
*Purchasing and Inventory Control: A Self-instructional Course, ACCRUE Level II*, 1359  
*Quality Assessment and Assurance for Long Term Care Facilities*, 1364  
*Remington's Pharmaceutical Sciences, Eighteenth Edition*, 596

## Annual Index

*Research Proposals: A Guide to Success*, 2710

*Strauss's Pharmacy Law Examination Review, Second Edition*, 2537

*Treating Drug Problems, Volume 1: A Study of the Evolution, Effectiveness, and Financing of Public and Private Drug Treatment Systems*, 1104

*Understanding Scientific Reasoning, Third Edition*, 2711

*USP DI, 11th Edition*, 2537

**Books Received**, 181, 374, 597, 853, 1105, 1365, 1831, 2053, 2325, 2541

**Budgets**; drug abuse; treatment programs, recommendations, 13

## C

**Cachexia**; megestrol acetate; therapy, AIDS, 2479

**Caffeine**; incompatibilities; antipyrine, stability, storage, 1267

**Calcium antagonists**; formularies; selection models, multiattribute utility theory, 301

**Calcium chloride**; therapy; pediatrics, nurse education, 97

**Calcium gluconate**

incompatibilities; indomethacin, injections, stability, 2442

therapy; pediatrics, nurse education, 97

### Calculations

costs; daily drug therapy, 236

emergency drugs; pediatrics, nurse education, 97

pharmacokinetics; drug administration systems, pharmacists' role, review, Oct suppl S14

**Caloric agents**; dextrose; complexes, procainamide, dissociation, in vitro, 2426; incompatibilities, amphotericin B, concentration, stability, 2430; incompatibilities, indomethacin, stability, 2442

**Cancer**, see **Antineoplastic agents**

**Cancer drugs**, see **Antineoplastic agents**

**Carbamazepine**; stability; tablets, effects, moisture, temperature, 2130

**Carbamazepine dihydrate**; decomposition products; carbamazepine tablets, stability, 2130

**Carbon dioxide**; release; cefazolin injections, formulations comparison, 1727

**Carbonic anhydrase inhibitors**; acetazolamide; suspensions, stability, temperature, 1241

### Cardiac drugs

amrinone lactate; incompatibilities, i.v. admixtures, 1245

incompatibilities; amrinone, stability, i.v. admixtures, 1245; fluconazole, injections, stability, 744

procainamide hydrochloride; complexes, dextrose, dissociation, in vitro, 2426

sodium nitroprusside; incompatibilities, haloperidol, stability, 1539

**Cardioplegic solutions**; review, 2444

**Cardiovascular drugs**; incompatibilities; haloperidol, injections, stability, 1539

**Career Opportunities**, 153, 330, 559, 794, 1042, 1304, 1563, 1785, 2001, 2258, 2486, 2671

### Careers

clinical pharmacists; specialties, changes, 1998

pharmacists; hospital; clinical pharmacy, staff development programs, 1704; staff development, clinical services, 1956

**Case Law**, 309, 747, 1281, 1542, 1989

**CD4**; binding; HIV, inhibition, 1300

**Cefadroxil**; stability; suspensions, temperature, 992

**Cefazolin sodium**; incompatibilities; dextrose, stability, peritoneal dialysis solutions, 291

**Cefmetazole**; comparison, cefotetan, cefoxitin; decision analysis, formularies, 2146

### Cefoperazone sodium

incompatibilities; cimetidine hydrochloride, stability, 111; furosemide, stability, storage, 108

interactions; tobramycin, blood levels, lack, 520

**Cefotaxime**; incompatibilities; fluconazole, injections, stability, 744

### Cefotaxime sodium

incompatibilities; metronidazole, i.v. admixtures, stability, storage, 2638

interactions; tobramycin, blood levels, lack, 520

**Cefotetan**; comparison, cefmetazole, cefoxitin; decision analysis, formularies, 2146

### Cefoxitin

comparison, cefotetan, cefmetazole; decision analysis, formularies, 2146

substitution; ampicillin-sulbactam, hospital pharmacy programs, 2150; therapeutic, ceftizoxime, programs, 2655

### Ceftazidime

incompatibilities; amino acids, parenteral nutrition, stability, 1515; fluconazole, injections, stability, 744

injections; formulations comparison, storage, gas formation, 1727

interactions; tobramycin, blood levels, lack, 520

use; effects, restriction policies, 1220

**Ceftizoxime**; substitution; therapeutic, for cefoxitin, programs, 2655

**Ceftriaxone**; incompatibilities; fluconazole, injections, stability, 744

**Ceftriaxone sodium**; incompatibilities; vancomycin, injections, precipitation, 77

**Cefuroxime**; incompatibilities; fluconazole, injections, stability, 744

**Central nervous system stimulants**; caffeine; incompatibilities, antipyrine, stability, storage, 1267

### Cephalosporins

cefadroxil; suspensions, stability, temperature, 992

cefazolin sodium; incompatibilities, dextrose, stability, dialysis solutions, 291

cefoperazone sodium; incompatibilities, cimetidine, stability, 111; incompatibilities, furosemide, stability, storage, 108; interactions, tobramycin, blood levels, lack, 520

cefotaxime sodium; incompatibilities, metronidazole, i.v. admixtures, stability, 2638; interactions, tobramycin, blood levels, lack, 520

ceftazidime; incompatibilities, parenteral nutrition, stability, 1515; injections, formulations comparison, storage, gas formation, 1727; interactions, tobramycin, blood levels, lack, 520

ceftizoxime; therapeutic interchange, for cefoxitin, 2655

ceftriaxone sodium; incompatibilities, vancomycin, injections, precipitation, 77

costs; daily dose therapy, 236

### Certification

administration; pharmacy, ASHP programs, AC-CRUE, 1992

health professions; specialties, administration, 476

laminar airflow; hoods, standards, 654

pharmacists; nutrition support specialties, 2064; specialties, BPS, 480

pharmacy; specialties, conferences, 469

technicians; hospital pharmacists' attitudes, Ohio, survey, 1228; pharmacy, NABP actions, 1640

**Chemicals**; tests, laboratory; sales, marketing predictions, 194

**Chicago College of Pharmacy**; education, pharmaceutical, establishment, 2562

**Chloramphenicol**; incompatibilities; fluconazole, injections, stability, 744

**Chromatography, liquid**; succinylcholine chloride; stability, storage, 501

**Chromatography, thin layer**; succinylcholine chloride; stability, storage, 501

**Cigarettes**; smoking; students, U.S., survey, 622

### Cilastatin

combination, imipenem; incompatibilities, fluconazole, injections, 744

imipenem; use, effects, restriction policies, 1220

**Cilastatin sodium**; combination, imipenem; incompatibilities, meperidine, i.v. injections, patient-controlled analgesia, 123

**Cimetidine**; incompatibilities; indomethacin, injections, stability, 2442

**Cimetidine hydrochloride**; incompatibilities; cefoperazone sodium, stability, 111; enteral nutrition, stability, 1681; methylprednisolone admixtures, stability, 1237

### Ciprofloxacin

incompatibilities; i.v. admixtures, vehicles, temperature, 2166

resistance; hospitals, recommendations, 1892

**Cisplatin**; stability; decomposition products, pH, light, containers, 1500

**Classification**; new drugs; therapeutic, FDA system, 2659

**Cindamycin**; incompatibilities; fluconazole, injections, stability, 744

**Cindamycin phosphate**; incompatibilities; ciprofloxacin, stability, storage, 2166; polyolefin containers, stability, storage, 2184

### Clinical pharmacists

ambulatory care; services, nurses and physicians' attitudes, 1189

careers; specialties, changes, 1998

drug information; programs, geriatrics, personal-care homes, 1530

hospitals; intensive-care units, costs, position, 2154; satellite pharmacy, neonates, obstetrics, 1533; workload, documentation, cost-benefit analysis, 1467

manpower; hospitals, neonatal intensive-care unit, 1708

monitoring; dosage, kidney failure, 1962

rational therapy; medication profile review, physician prescribing, 265

role; nurse education, pediatric emergency drugs, 97

salaries; U.S. teaching hospitals, survey, 249

staff development; administration, hospitals, services, 1956

time studies; hospitals, services, methodology, 1211

### Clinical Pharmacy

guidelines; manuscripts, seminars, publication, 442

manuscripts; editorial processing system, 2388

policies and procedures; paper submission, conflict-of-interest information, 1168

### Clinical pharmacy

hospitals; administration, technology impact, review, Oct suppl S24; documentation, forms, medication order clarification, 2649; dosage monitoring, computers, kidney failure, 1965; services, documentation, applications, 2647

patient-care standards, Missouri, 1257; pediatrics, administration, services, guidelines, 2475; services, documentation, cost-benefit analysis, 1467; services, quality assurance, peer review, 1531; staff development programs, 1704

practice; New Zealand, hospitals, 553

psychiatric facilities; U.S. survey, 967

services; drug information, geriatrics, personal-care homes, 1530; hospitals, contracts, pharmacy schools, clerkships, 1994; hospitals, neonates, obstetrics, 1533; neonatal intensive-care unit, staff development, 1708; nurses, physicians, attitudes, survey, 1189; pharmacists, time studies, methodology, 1211; pharmacy directors, attitudes, survey, 1948; program development, hospital pharmacists' role, 680; psychiatric facilities, survey, 974; staff development, administration, hospitals, 1956

### Clinical studies

didanosine; AIDS therapy, 1298; treatment IND, physician reports, AIDS, 1299

drugs, investigational; handling, material safety data sheets, 1679; unapproved use, marketing, FDA regulations, 16

informed consent; forms, readability, Institutional Review Boards, 2651; investigational drugs, military personnel, ethics, 1525

methodology; therapeutic drug monitoring, analysis, 1553

misuse; drugs, pharmacists' role, 949

publications; peer-reviewed journals, benefits, 1424

research; pharmacists' involvement, ASHP guidelines, 1781

**Closures**; rubber; antipyrine-caffeine incompatibilities, stability, storage, 1267

### Clozapine

distribution; treatment systems, problems, 2336

schizophrenia; therapy, 1271

**Coatings**; enteric; magnesium tablets, stability, unit dose packaging, 1266

**Cocaine**; abuse; students, U.S., survey, 622

**Codes**; bar; technology, hospital pharmacy, impact, review, Oct suppl S24; unit dose distribution systems, hospitals, 953; vs. manual method, inventory control, hospital pharmacy, 1259

**Color**; sodium ascorbate; incompatibilities, stainless steel filters, 1191

### Combined therapy

antivirals and didanosine; AIDS, clinical studies, 1298

didanosine and antivirals; AIDS, clinical studies, 1298

**Commentaries**, 326, 536, 1291, 1550, 1994

### Committees

Blue Ribbon Committee on Generic Medicines; generic drugs, approvals, recommended changes, 188

clinical pharmacy; program development, hospital pharmacists' role, 680

Food and Drug Administration; advisory, administration changes, recommendations, 1632

health care; 102nd Congress, 1991-92 list, 862

National Academy of Sciences; recommendations, drug abuse programs, budgets, 13

### Communication

pharmacists; guidelines, oral presentations, 1730

pharmacists; hospital; administrators, unfair criticism, 1884; interventions, medication order clarification, documentation, 2649; directors, hospital administrators' attitudes, survey, 1948

**Community service**; poison prevention; programs, pharmacists' role, 13, 2657

### Complexes

dextrose and procainamide hydrochloride; dissociation, in vitro, 2426

procainamide hydrochloride and dextrose; dissociation, in vitro, 2426

**Compliance**; patients; consultation, pharmacists, interventions, 1453; drug labeling, deception, ethics, 296; factors, improvement guidelines, 1978



**Compounding**

acetazolamide; suspensions, stability, storage, 1241  
 antibiotics; injections, sterility tests, 2414  
 antineoplastic agents; control, medication orders, standardized forms, 1683  
 cardioplegic solutions; formulations, review, 2444  
 dosage forms; information needs, pharmacists, survey, 1205  
 drugs; handbooks, ASHP publications, reliability, 421  
 gentamicin sulfate; ophthalmic solutions, stability, concentration, 507  
 muromonab-CD3; infusions, adverse reactions, topical exposure, 1442  
 nutrition; parenteral, sterility tests, Septi-Chek, 2419  
 ophthalmic preparations; sterility, guidelines, 2438  
 opiates; epidural injections, 2460  
 pharmaceutical services; NABP actions, 1640  
 sterile products; ASHP role, quality assurance, 386;  
 hospital pharmacy, ASHP conferences, 2391; hospital pharmacy, U.S., survey, 2398; quality assurance, improvement, hospital pharmacy, 2387  
 terbutaline sulfate; suspensions, stability, sucrose vehicles, 293  
 tobramycin sulfate; ophthalmic solutions, stability, concentration, 507

**Computers**

American Society of Hospital Pharmacists; publications, benefits, 950  
 databases; i.v. therapy, home-health-care pharmacy, 1535  
 hospital pharmacy; inventory control, bar codes vs. manual method, 1259; issues, U.S., 1990, review, 720; monitoring, dosage, kidney failure, 1965; services, establishment, 1463  
 libraries; personal, pharmacists, guidelines, 230  
 pharmacists; information sharing, adverse drug reactions, monitoring, 16  
 PharmNet; ASHP electronic bulletin boards, access information, advantages, 1174  
 programs; controlled-substances monitoring, hospital pharmacy, 1262; investigational drug records, hospital pharmacy, 2616; spreadsheets, translations from mainframe, hospital pharmacy, 2619; TPN compounding, hospital pharmacy, 270  
 reports; medication errors, hospitals, quality assurance, 2611  
 technology; impact, hospital pharmacy, review, Oct suppl 524

**Concentration**

amino acids; incompatibilities, ceftazidime, storage, 1515  
 amphotericin B; high, incompatibilities, dextrose, i.v. admixtures, stability, 283; incompatibilities, dextrose, injections, stability, 1681; incompatibilities, dextrose, stability, storage, 2635  
 antipyrine; incompatibilities, caffeine, stability, storage, 1267  
 caffeine; incompatibilities, antipyrine, stability, storage, 1267  
 ceftazidime; incompatibilities, parenteral nutrition, storage, 1515  
 cimetidine; incompatibilities, methylprednisolone, 1237  
 dexamethasone sodium phosphate; incompatibilities, diphenhydramine or hydromorphone, 2161  
 dextrose; incompatibilities, amphotericin B, stability, 2430; incompatibilities, cefazolin, stability, dialysis solutions, 291; incompatibilities, indomethacin, injections, stability, 2442; stability, dobutamine, peritoneal dialysis solutions, 1234  
 diphenhydramine hydrochloride; incompatibilities, dexamethasone, precipitation, 2161  
 dobutamine hydrochloride; stability, dextrose, peritoneal dialysis solutions, 1234  
 drugs; sterile product compounding, hospital pharmacy survey, 2398  
 fluorouracil; incompatibilities, mannitol, injections, lack, 2158  
 ganciclovir sodium; incompatibilities, dextrose, stability, storage, 2641; incompatibilities, TPN, 1538  
 gentamicin sulfate; ophthalmic solutions, stability, storage, 507  
 haloperidol lactate; incompatibilities, sodium chloride, stability, 1539  
 hydromorphone hydrochloride; incompatibilities, dexamethasone, precipitation, 2161  
 methadone hydrochloride; incompatibilities, beverages, stability, storage, 1252; stability, storage, admixtures, 515  
 methylprednisolone; incompatibilities, cimetidine, admixtures, 1237  
 nafcillin; incompatibilities, 125  
 phenytoin sodium; interlot variability, 510  
 procainamide hydrochloride; complexes, dextrose,

dissociation, in vitro, 2426  
 rifampin; injections, precipitation, 2127  
 taxol; incompatibilities, vehicles, containers, 1520  
 tobramycin; stability, human serum, 520  
 tobramycin sulfate; ophthalmic solutions, stability, compounding, 507  
 TrophAmine; incompatibilities, indomethacin, injections, stability, 2442  
 urokinase; incompatibilities, vehicles, containers, 1511

**Containers**

acetazolamide; suspensions, stability, storage, 1241  
 glass; incompatibilities, taxol, stability, storage, 1520  
 infusion pumps; reservoirs, ceftazidime storage, gas formation, 1727; reservoirs, doxorubicin stability, storage, 1976  
 magnesium chloride; unit dose packaging, stability, 1266  
 ophthalmic preparations; sterility, compounding guidelines, 2438  
 plastics; methadone stability, storage, admixtures, 515  
 polyolefin; incompatibilities, injections, stability, 2184; incompatibilities, taxol, stability, storage, 1520  
 polypropylene; unit dose packaging, oxybutynin syringes, stability, 1265  
 polyvinyl chloride; amphotericin B-dextrose admixtures, stability, storage, 2635; cisplatin, effects, pH, light, 1500; incompatibilities, miconazole, stability, storage, 286; incompatibilities, taxol, stability, storage, 1520; incompatibilities, urokinase, container adsorption, 1511

**Contamination**

diethylhexyl phthalate; taxol, polyvinyl chloride containers, 1520  
 levothyroxine sodium; tablets, diethyl phthalate desiccants, 735  
 microbiological; antibiotics injections, sterility tests, hospital pharmacy, 2414; human insulin, plastic syringes, storage, 2631; ophthalmic preparations, compounding guidelines, 2438; sodium benzoate effects, methadone solutions, 1252; sterile product compounding, hospital pharmacy survey, 2398; terbutaline suspensions, storage, 293; TPN, tests, Septi-Chek, 2419

**Content uniformity;** phenytoin sodium; interlot variability, 510

**Contracts**

employment; pharmacists, drug abuse, recovery, considerations, 326  
 hospitals; clerkships, pharmacy schools, 1994

**Control**

antineoplastic agents; compounding, dispensing, medication orders, standardized forms, 1683  
 drug distribution systems; pharmacists' role, ASHP guidelines, 1782  
 drugs, investigational; distribution, storage, hospital pharmacists' responsibilities, 61; records, computer programs, hospital pharmacy, 2616  
 errors, medication; dispensing, management, pharmacists, 1675; pharmacists' role, 949  
 inventory; hospital pharmacy, bar codes vs. manual method, 1259  
 theft; controlled substances, VA pharmacies, 2062

**Control, quality**

cardioplegic solutions; pharmacists' role, review, 2444  
 gloves; surgical, FDA standards, 392  
 hospital pharmacy; unit dose cassette checking, technicians, Minnesota, 1952  
 sterile products; compounding, hospital pharmacy, 2387; compounding, hospital pharmacy, ASHP conferences, 2391; compounding, hospital pharmacy, U.S. survey, 2398

**Controlled substances**

crime; theft, control, VA pharmacies, 2062  
 hospital pharmacy; monitoring, computer programs, 1262  
 injections; refractometry, tampering detection, 1488  
 pharmaceutical services; surgery and anesthesiology satellite, ASHP guidelines, 319  
 refractometry; solutions, screening diversion, 2129  
 storage; refrigeration, JCAHO standards, 2368

**Correction Notices**, 1191, 1690, 2131, 2384

Activity of octreotide acetate in a total nutrient admixture (Oct 1991, Reports), 2384  
 Satisfaction of physicians and nurses with clinical pharmacy services (Jun 1991, Letters) 1690  
 Stability of nizatidine in total nutrient admixtures (Jul 1991, Reports), 2131  
 Table of Contents, May 1991, 1191

**Cost-effectiveness see Economics; cost-benefit analysis**

**Costs**

ampicillin, combination, sulbactam; prescribing, use, formulary inclusion, 1492  
 antibiotics; use, effects, restriction policies, 1220  
 biotechnology; products, pharmacy practice effects, Oct suppl 54  
 calculations; daily drug therapy, 236  
 clinical pharmacists; position, hospitals, intensive-care units, 2154  
 clinical pharmacy; services, hospitals, forms, documentation, 1467  
 clozapine; distribution, problems, 2336  
 drug distribution systems; unit dose, bar codes, satellite pharmacy, 953  
 drugs; cost-benefit analysis, methodology, review, 2622  
 drugs; dosage monitoring, hospital pharmacy computer, 1965  
 drugs; effects, hospital pharmacists' participation, medical team, 1457  
 drugs; physician prescribing, clinical pharmacists' impact, 265  
 education, pharmaceutical; continuing, ASHP programs, administration, ACCRUE, 1992  
 enalapril maleate, comparison, lisinopril; dosage, hypertension therapy, 276  
 equipment; fax, hospital pharmacy, medication orders, time studies, 2653  
 generic drugs; approvals, recommended changes, pharmaceutical industry, 188  
 histamine H<sub>2</sub> antagonists; administration routes, hospital pharmacists' monitoring, 1722  
 hospital pharmacy; dosage monitoring, kidney failure, 1962; issues, U.S., 1990, review, 720  
 lisinopril, comparison, enalapril maleate; dosage, hypertension therapy, 276  
 megestrol acetate; cachexia therapy, AIDS, 2479  
 morphine sulfate; sustained-action, comparison, solutions, 101  
 opiates; physician prescribing, hospital pharmacists' role, 1484  
 transplantation; heart, patient's suitability, ethics, pharmacist's role, 740  
 waste disposal; hospital pharmacy recycling programs, 6  
**CP Digest**, 168, 354, 579, 827, 1067, 1332, 1593, 1800, 2021, 2300, 2514, 2698  
**Crack, see Cocaine**  
**Creatinine;** blood levels; pharmacist monitoring, drug dosage recommendations, 1962  
**m-Cresol;** preservatives; human insulin, incompatibilities, plastic syringes, 2631

**Crime**

fraud; Medicare regulations, exceptions, definitions, 2434  
 marketing; unapproved, cases, 747  
 theft; VA pharmacies, controlled substances, security, 2062

**Crystals;** carbamazepine dihydrate; carbamazepine tablets, stability, 2130

**Current Literature**, 172, 370, 591, 836, 1099, 1356, 1611, 1818, 2025, 2320, 2525, 2710

**Curriculum**

education; health professions, programs, future health-care needs, 1639  
 education, pharmaceutical; continuing, ASHP programs, administration, ACCRUE, 1992; infusion pumps, technology, need survey, Oct suppl 552

**Cytomegalic inclusion disease**

foscarnet sodium, comparison, ganciclovir sodium; therapy, AIDS, 2478  
 ganciclovir sodium, comparison, foscarnet sodium; therapy, AIDS, 2478

**Cytotoxic agents, see Antineoplastic agents**

**D****Databases**

errors, medication; hospitals, quality assurance, 2611  
 health care; home, i.v. therapy, pharmacy, 1535  
 manpower; Pharmacy Manpower Database Project, U.S., development, 50

**Data collection**

administrators; hospitals, attitudes, pharmacy directors, survey, 1846; hospitals, attitudes, pharmacy directors, survey, 1948  
 drug abuse; students, U.S., survey, 622  
 hospital pharmacy; controlled substances, security, VA hospitals, 2062; pharmacists' interventions, forms, 2649; psychiatric, services, U.S., 967; sterile products compounding, U.S., 2398  
 hospitals; personnel, manpower shortages, survey,

- 1114  
nurses; attitudes, clinical pharmacy services, 1189  
pharmaceutical services; community hospitals, definition, ASHP survey, 1668; psychopharmacy specialties, need, 1185  
pharmacists; compounding, drug information, needs, survey, 1205; drug selection, effects, decision analysis models, 1477; knowledge, infusion pumps, survey, Oct suppl 552  
pharmacists, hospital; antineoplastic agents, handling, survey, Kentucky, 119; attitudes, postgraduate education, VA survey, 732; attitudes, technicians' role, survey, 1228  
physicians; attitudes, clinical pharmacy services, 1189; survey, histamine H<sub>1</sub> antagonists, knowledge, pharmacists' monitoring, 1722  
salaries; hospital pharmacists, U.S., 249  
**ddl**, see **Didanosine**  
**Decision analysis**; formularies; methodology, antibiotics, 2146  
**Decision making**  
formularies; drug selection models, multiattribute utility theory, 301  
models; drug selection, effects, pharmacists' choices, 1477  
**Degrees**  
administrators; hospital pharmacy, requirements, 1680  
Doctor of Pharmacy; clerkships, contracts, schools, hospitals, 1994  
pharmacists, hospital; postgraduate education, attitudes, VA survey, 732  
**Dentistry**  
drug information; Dental Precaution Listing, USP DI, reliability, 1447  
specialties; history, certification, 476  
**Department of Veterans Affairs**  
hospital pharmacy; controlled substances, security, survey, 2062  
pharmacists, hospital; attitudes, postgraduate education, survey, 732  
**Dependence**; benzodiazepines; patient counseling, pharmacists, regulations, 1291  
**Desiccants**; diethyl phthalate; contamination, levothyroxine tablets, 735  
**Devices**  
compliance; patients, factors, improvement guidelines, 1978  
drug administration; rate, i.v. injections, posture effects, 2422; technology, review, Oct suppl 514  
health care; home, vendor exclusivity, legal cases, 1542  
infusion pumps; blood transfusions, 92; cefazidime injections, gas formation, 1727; effects, blood products, lack, in vitro, 1970; injections, pharmacists' knowledge, survey, Oct suppl 552; opiates, incompatibilities, i.v. injections, patient-controlled analgesia, 123; portable, doxorubicin stability, reservoirs, 1976  
syringe pumps; administration systems, fat emulsions, costs, neonates, 1972  
**Dexamethasone disodium phosphate**, see **Dexamethasone sodium phosphate**  
**Dexamethasone sodium phosphate**; incompatibilities; diphenhydramine or hydromorphone, concentration, stability, 2161  
**Dextrose**  
complexes; procainamide, dissociation, in vitro, 2426  
incompatibilities; amphotericin B, concentration, injections, stability, 1681; amphotericin B, concentration, stability, 2430; amphotericin B, stability, high concentration, 283; amphotericin B, stability, storage, 2635; cefazolin sodium, stability, peritoneal dialysis solutions, 291; dobutamine, peritoneal dialysis solutions, 1234; ganciclovir, stability, storage, 2641; indomethacin, injections, stability, 2442; taxol, stability, storage, 1520; urokinase, PVC container adsorption, 1511; zidovudine stability, storage, 280  
injections; i.v., administration rate, devices, 2422; methylprednisolone-cimetidine incompatibilities, 1237  
nutrition; parenteral ganciclovir, incompatibilities, 1538; parenteral, cefazidime incompatibilities, 1515  
vehicles; amrinone incompatibilities, i.v. admixtures, 1245; cefoperazone-cimetidine incompatibilities, 111; cefoperazone sodium, incompatibilities, furosemide, stability, 108; ciprofloxacin incompatibilities, stability, storage, 2166; fluorouracil, incompatibilities, mannitol, 2158; ondansetron incompatibilities, i.v. admixtures, 988  
**Dialysis**; peritoneal; solutions, cefazolin stability, 291; solutions, containers, miconazole incompatibilities, 286; solutions, dextrose-dobutamine incompatibilities, 1234  
**Diazepam**  
incompatibilities; fluconazole, injections, stability, 744  
snakebites; therapy, 2190  
**Didanosine**  
acquired immunodeficiency syndrome; therapy, clinical studies, 1298  
protocols; treatment IND, AIDS therapy, 1299  
**Dideoxyinosine**, see **Didanosine**  
**Diethylhexyl phthalate**; contamination; taxol, polyvinyl chloride containers, 1520  
**Diethyl phthalate**; desiccants; contamination, levothyroxine tablets, 735  
**Digoxin**; incompatibilities; amrinone lactate, stability, i.v. admixtures, 1245; fluconazole, injections, stability, 744  
**Diltiazem**; formularies; selection models, multiattribute utility theory, 301  
**Diphenhydramine hydrochloride**  
allergies; therapy, muromonab-CD3 adverse reactions, 1442  
incompatibilities; dexamethasone, concentration, stability, 2161  
**Directories**; committees; health care, 102nd Congress, 1991-92 list, 862  
**Discrimination**; pharmacists, hospital; HIV infections, employment, 606  
**Disintegration**; carbamazepine; tablets, effects, moisture, temperature, 2130  
**Dispensing**  
antineoplastic agents; control, medication orders, standardized forms, 1683  
clinical pharmacists; hospitals, time studies, methodology, 1211; services, neonatal intensive-care unit, 1708  
controlled substances; computer programs, hospital pharmacy, monitoring, 1262  
drugs, investigational; handling, material safety data sheets, 1679; military personnel, informed consent, ethics, 1525  
errors, medication; control, management, pharmacists, 1675; hospital pharmacy, effects, lighting, 2137  
hospital pharmacy; drug allergy documentation policies, 260; technology impact, review, Oct suppl 524  
hospitals; development, medication-use indicators, JCAHO guidelines, 1925  
perflumamine, combination, perflunafene; vs. blood transfusions, ethics, Jehovah's Witness, 2176  
pharmacists; ambulatory care, ASHP guidelines, 311; role, control, ASHP guidelines, 1782  
**Dissociation**; procainamide hydrochloride; complexes, dextrose, in vitro, 2426  
**Dissolution rates**; carbamazepine; tablets, effects, moisture, temperature, 2130  
**Diuretics**  
furosemide; incompatibilities, cefoperazone, stability, storage, 108; incompatibilities, opiates, i.v. injections, patient-controlled analgesia, 123  
mannitol; incompatibilities, fluorouracil, injections, lack, 2158  
**Dobutamine**; incompatibilities; indomethacin, injections, stability, 2442  
**Dobutamine hydrochloride**  
incompatibilities; dobutamine, peritoneal dialysis solutions, 1234  
therapy; pediatrics, nurse education, 97  
**Documentation**  
allergies; drugs, hospital policies, 260  
clinical pharmacy; services, cost-benefit analysis, 1467; services, hospitals, applications, 2647  
hospital pharmacy; pharmacists' interventions, forms, 2649  
pharmaceutical services; quality assurance, guidelines, 1901  
quality assurance; hospital pharmacy, administration, patient outcomes, 1908; hospital pharmacy, indicators, patient care, 1931  
**Dopamine**; incompatibilities; indomethacin, injections, stability, 2442  
**Dopamine hydrochloride**; therapy; pediatrics, nurse education, 97  
**Dosage**  
ampicillin, combination, sulbactam; prescribing, formulary inclusion, 1492  
cardioplegic solutions; therapy, administration, review, 2444  
didanosine; AIDS therapy, clinical studies, 1298  
drugs; kidney failure, medication order monitoring, hospital pharmacy, 1965; monitoring, clinical pharmacists, kidney failure, 1962  
emergency drugs; pediatrics, nurse education, 97  
enalapril maleate, comparison, lisinopril; costs, hypertension therapy, 276  
gentamicin; order forms, pharmacists' monitoring, 681  
lisinopril, comparison, enalapril maleate; costs, hypertension therapy, 276  
megestrol acetate, 2479  
ranitidine; administration, parenteral nutrition, 104  
**Dosage forms**  
morphine sulfate; sustained-action, comparison, solutions, costs, 101  
tranquilizers; schizophrenia therapy, 1271  
unapproved; i.v., marketing, criminal convictions, 747  
**Dosage schedules**  
antibiotics; automatic stop orders, hospital policies, 2502  
morphine sulfate; sustained-action, comparison, solutions, costs, 101  
zidovudine; AIDS therapy, 1296  
**Doxorubicin hydrochloride**; stability; storage, infusion pump reservoirs, 1976  
**Dressings**; nitrofurazone; dilutions, effects, antibacterial activity, in vitro, 1496  
**Drug abuse**  
pharmacists; employment, recovery, considerations, 326  
students; U.S., survey, 622  
therapy; programs, increased budget, recommendations, 13  
**Drug administration**  
cardioplegic solutions; therapy, formulations, review, 2444  
controlled substances; computer programs, hospital pharmacy, monitoring, 1262  
didanosine; AIDS therapy, clinical studies, 1298  
hospitals; development, medication-use indicators, JCAHO guidelines, 1925  
laws; cases, prisoner consent, 309  
omeprazole; labeling, hospital pharmacy programs, 2380  
ophthalmic preparations; nonprescription, manufacturers' instructions, 987  
perflumamine, combination, perflunafene; toxicity, blood substitutes, pharmacists, ethics, 2176  
posture; effects, i.v. administration rate, devices, 2422  
**Drug administration rate**  
blood; transfusions, infusion pumps, 92  
infusion pumps; effects, blood products, lack, 1970  
injections; i.v. devices, posture effects, 2422  
propofol; incompatibilities, PVC, 2627  
**Drug administration routes**  
emergency drugs; pediatrics, nurse education, 97  
epidural; hydromorphone and tetracaine injections, stability, efficacy, 1682; pain therapy, 2460  
histamine H<sub>1</sub> antagonists; hospital pharmacist monitoring, physicians' attitude, 1722  
penicillin G benzathine; errors, toxicity, pediatrics, litigation, 1989  
pentamidine; aerosols, *P. carinii*, prophylaxis, hospital protocols, forms, 2440  
pentamidine isethionate; nebulized aerosols, toxicity, asthma, AIDS, 556  
ranitidine; parenteral nutrition, dosage, 104  
technology; research, review, Oct suppl 514  
**Drug administration systems**  
syringe pumps; fat emulsions, cost-benefit analysis, neonates, 1972  
technology; research, review, Oct suppl 514  
**Drug delivery systems**; cardioplegic solutions; single pass, recirculating, review, 2444  
**Drug distribution**; clozapine; treatment systems, problems, 2336  
**Drug distribution systems**  
pharmacists; role, control, ASHP guidelines, 1782  
psychiatric facilities; pharmaceutical services, U.S. survey, 967  
unit dose; bar codes, satellite pharmacy, 953; cassette checking, technician training, Minnesota, 1952; hospital pharmacy, establishment, 1463; hospital pharmacy, regulations, New York, 1374; psychiatric facilities, survey, 974  
**Drug diversion**; controlled substances; screening, refractometry, 2129  
**Drug histories**, see **Patient information; drug histories**  
**Drug information**  
acquired immunodeficiency syndrome; pharmacists' role, NIH, 2662  
adverse reactions; pharmacists' role, 16  
clinical pharmacists; geriatrics, programs, personal-care homes, 1530; hospitals, time studies, methodology, 1211; services, neonatal intensive-care unit, 1708  
drugs, investigational; records, computer programs,

hospital pharmacy, 2616  
libraries; personal, guidelines, 230  
pharmacists; compounding, needs, survey, 1205; patients, public, ASHP guidelines, 1780  
pharmacy; practice, theoretical base, 536  
reference books; ASHP publications, reliability, 421; Dental Precaution Listing, *USP DI*, reliability, 1447  
**Drug information centers;** hospital pharmacy; services, establishment, 1463  
**Drug interactions**  
cefepazone sodium and tobramycin sulfate; blood levels, lack, 520  
cefotaxime sodium and tobramycin sulfate; blood levels, lack, 520  
ceftazidime and tobramycin sulfate; blood levels, lack, 520  
monitoring; programs, pharmacists' and physicians' role, 16  
tobramycin sulfate and cephalosporins; blood levels, lack, 520  
**Drugs**  
cost-benefit analysis; definitions, methodology, review, 2622  
emergency; pediatrics, nurse education, 97  
generic approvals, recommended changes, 188; selection, formularies, methodology, 301  
list; banned, USOC, NCAA, 76  
most used; top 200, prescriptions, 1990, 1122  
new; marketing, FDA approvals, 1990, 390; therapeutic classification, FDA system, 2659  
recalls; FDA, pharmacists, role, 2595  
reconstitution; cefadroxil, suspensions, stability, 992; doxorubicin, injections, stability, storage, 1976; rifampin injections, precipitation, 2127  
selection; decision analysis models, effects, pharmacists' choices, 1477; formularies, methodology, 301; purchasing, manufacturers, suppliers, ASHP guidelines, 523; tranquilizers, schizophrenia therapy, 1271  
unapproved use; FDA regulations, criminal convictions, 747; marketing regulations, FDA, 16  
**Drugs, adverse reactions**  
see also Toxicity  
algorithms; correlation analysis, methodology, 121  
documentation; hospital policies, 260  
monitoring; programs, pharmacists' and physicians' role, 16  
muromonab-CD3; allergies, topical exposure, 1442  
patient information; consultation, pharmacists, Medic Alert, 236  
quality assurance; indicators, hospital pharmacy, 1937  
reports; ASHP, JCAHO standards, 1428; concurrent vs. retrospective review, hospitals, 1974; programs, research, quality assurance, 72  
**Drugs, availability;** didanosine; AIDS therapy, clinical studies, 1298  
**Drugs, clinical effectiveness;** psychotherapeutic agents; schizophrenia therapy, review, 1271  
**Drugs, investigational**  
abbreviated new-drug applications; generic, approvals, recommendations, 188  
acquired immunodeficiency syndrome; therapy, research, 1296  
classification; therapeutic, FDA system, 2659  
control; community hospitals, pharmacists' responsibilities, 61  
guidelines; ASHP, institutional use, 315  
hospital pharmacy; JCAHO standards, pharmacist attitude, 1550  
new-drug applications; didanosine, protocols, AIDS therapy, 1299  
pharmacists; dispensing, military personnel, informed consent, ethics, 1525  
records; computer programs, hospital pharmacy, 2616  
toxicity, environmental; material safety data sheets, handling, 1679  
**Drugs, nonprescription;** ophthalmic preparations; patient information, manufacturers' instructions, 987  
**Drug use**  
ampicillin, combination, sulbactam; prescribing, formulary inclusion, 1492  
antibiotics; costs, effects, restriction policies, 1220  
cefotaxime; therapeutic interchange, ceftiozime, 2655  
evaluation; ciprofloxacin, resistance, hospitals, 1892; omepazole, criteria, hospital pharmacy programs, 2380  
pentamidine; *P. carinii*, prophylaxis, hospital protocols, forms, 2440  
pharmacists, hospital; clinical services, staff development, 1704  
review; adult TPN, ASPEN guidelines, 1442; clinical pharmacists' impact, medication profiles, 265; con-

current vs. retrospective, adverse reactions, hospitals, 1974; development, medication-use indicators, JCAHO guidelines, 1925; hospital pharmacy, implementation, 518; hospital pharmacy internships, 1260; hospital pharmacy, JCAHO standards, pharmacist attitude, 1550; omepazole, criteria, hospital pharmacy programs, 2382; pharmacists' role, HMO, 1712; programs, principles, APHA, AMA, FMA, 2062; programs, research, quality assurance, 72; quality assurance, hospital pharmacy, patient outcomes, 1908; ranitidine, parenteral nutrition administration, 104

## E

### Economics

cost-benefit analysis; antibiotics, formularies, methodology, 2146; bar codes, unit dose distribution, hospitals, 953; clinical pharmacist position, intensive-care units, 2154; clinical pharmacy services, 1457; clinical pharmacy, services, documentation, 1467; community pharmacists' interventions, prescribing errors, 1376; definitions, methodology, review, 2622; dosage monitoring, kidney failure, clinical pharmacists, 1962; home health care, need, regulations, 2548; ketorolac vs. opiates, hospitals, savings, 2128; lisinopril vs. enalapril, therapeutic substitution, 276; syringe pumps, fat emulsions, neonates, 1972; technology, hospital pharmacy, review, Oct suppl S24; therapeutic substitution, hospital pharmacy programs, 1471; unit dose distribution, regulations, hospitals, New York, 1374  
health care; reform, need, U.S., 2133  
hospital pharmacy; effects, Omnibus Budget Reconciliation Act of 1990, 678; practice, New Zealand, 553  
managed-care systems; HMO, PPO, marketing, 2341  
pharmacy; specialties, certification, 480; specialties, manpower effects, future, 691  
prescription drugs; pricing, U.S., 1990, 1122  
research; chemical reagent sales, market predictions, 194  
transplantation; heart, patient's suitability, ethics, pharmacist's role, 740  
waste disposal; recycling, pharmacy, savings, 118  
**Editorials,** 81, 245, 467, 687, 949, 1195, 1453, 1693, 1897, 2133, 2387, 2607  
Advice on writing for the beginner, 687  
Assuming responsibility for improving quality, 1898  
Counseling patients about drug use, 1196  
Degrees of equity, 2607  
Expressing the mission of pharmacy practice, 1195  
Gaining external support for pharmacy's new mission, 949  
Goals for health-care reform, 2133  
Measuring and improving quality, 1897  
The mission of *AJHP*, 81  
A model for ambulatory-care pharmaceutical services, 245  
Pharmaceutical promotion and pharmacist probity, 1693  
Reassessing patient counseling, 1453  
Stability papers and equal publishing opportunities, 1454  
Tracking manuscripts and reviewers electronically, 950  
Upgrading quality assurance for pharmacy-prepared sterile products, 2387  
War, 467  
What have you done to my manuscript!? 2388  
**Education**  
clinical pharmacists; drug information, programs, personal-care homes, 1530; role, satellite pharmacy, neonates, obstetrics, 1533  
health professions; programs, future health-care needs, 1639  
inservice; influenza vaccines, hospital pharmacists' role, 256; nurses, residents, clinical pharmacists, 1708  
nurses; pediatric emergency drugs, 97  
physicians; effects, postoperative opiate prescribing, hospital pharmacists, 1484; guidelines, drug-use review, 518; therapeutic interchange programs, 2655; therapeutic substitution, antibiotics, newsletter, 2150  
**Education, pharmaceutical**  
administrators; hospital pharmacy, employment, qualifications, 1680  
antineoplastic agents; handling, safety, hospital pharmacists, Kentucky, 119  
Chicago College of Pharmacy; establishment, 2562

clerkships; contracts, schools, hospitals, 1994; hospital pharmacy, students, expectations, 1671  
clinical pharmacists; hospitals, time studies, methodology, 1211  
continuing; ASHP programs, administrative, AC-CRUE, 1992; ASHP publications, pharmacy students, 2102; hospital pharmacists, therapeutic substitution, 2150; licensure, state regulations, 2560  
curriculum; programs, future health-care needs, 1639  
internships; hospitals, DUE, 1260  
Lithuania; history, politics, 1035  
New Zealand; undergraduate and graduate programs, 553  
nutrition; parenteral, hospital pharmacists, 980  
pharmacists; biotechnology, need, Oct suppl S4; infusion pumps, need, survey, Oct suppl S52; pediatrics, specialties, guidelines, 2475; psychopharmacy specialty, 1284; WHO recommendations, health-care team, 391  
pharmacists, community; training, hospital setting, 666  
pharmacists, hospital; clinical services, staff development programs, 1704; sterile products, compounding, U.S., survey, 2398  
postgraduate; hospital pharmacists attitudes, VA survey, 732  
professionalism; role, leadership, development, 1559  
residencies; advantages, 1878; hospital pharmacy, opportunities, December graduate, 54; student information, programs, 1717  
seminars; manuscripts, publication, *Clinical Pharmacy*, guidelines, 442  
specialties; conference recommendations, 712; conferences, summary, 469; future, effects, U.S., 700  
technicians; certification, pharmacists' attitudes, Ohio, survey, 1228; hospital pharmacy, unit dose cassette checking, Minnesota, 1952  
**Educators;** pharmacy; role, professionalism, leadership, development, 1559  
**E-Ferol,** see *D,L-α-tocopheryl acetate*  
**Electrolytes;** magnesium chloride; tablets, stability, unit dose packaging, 1266  
**Electronic bulletin boards;** PharmNet; access information, advantages, 1174  
**Elimination,** see *Metabolism*  
**Employment**  
administrators; hospital pharmacy, requirements, adversities, 1680  
personnel, pharmacy; interviews, guidelines, 670  
pharmacists; December graduate, opportunities, hospital pharmacy residencies, 54; interviews, guidelines, 1180; licensure information, NABP Disciplinary Clearinghouse, 199  
pharmacists, hospital; discrimination, HIV infections, 606; salaries, U.S. survey, 249; training program, community pharmacists, 666; VA policies, postgraduate education, 732  
**Enalapril maleate;** comparison, lisinopril; dosage, costs, hypertension therapy, 276  
**Enterocolitis;** therapy; pseudomembranous, decision analysis, 1477  
**Environment;** hospital pharmacy; recycling programs, 6  
**Enzyme inhibitors**  
cilastatin sodium, combination, imipenem; incompatibilities, meperidine, injections, patient-controlled analgesia, 123  
sulbactam, combination, ampicillin; prescribing, use, formulary inclusion, 1492; substitution for cefoxitin, hospital pharmacy programs, 2150  
**Epinephrine hydrochloride;** therapy; pediatrics, nurse education, 97  
**Equations;** costs; calculations, daily drug therapy, 236  
**Equipment**  
ambulatory care; pharmaceutical services, ASHP guidelines, 311  
compounding; ophthalmic preparations, sterility, guidelines, 2438  
fax; costs, time studies, medication orders, hospital pharmacy, 2653  
hospital pharmacy; Navy ships, Persian Gulf, 530; U.S. Army, Saudi Arabia, 533  
laminar airflow; hoods, certification, standards, 654  
medical; home health care, vendor exclusivity, legal cases, 1542  
refractometry; controlled-substances tampering detection, 1488  
refrigerators; storage, JCAHO standards, 2368  
regulations; Medicare reimbursement, institutional pharmacy, 2434  
**Equipment and Supplies,** 1584  
**Equivalency, generic;** phenytoin sodium; injections, pH variations, stability, 510  
**Equivalency, therapeutic**

cefoxitin; substitution, cefprozime, 2655  
 cefprozime; substitution, cefoxitin, 2655  
 enalapril maleate, comparison, lisinopril; cost savings, 276  
 ketorolac tromethamine; vs. opiates, hospitals, cost savings, 2128  
 lisinopril, comparison, enalapril maleate; cost savings, 276  
 opiates; vs. ketorolac, hospitals, cost savings, 2128  
**Errors; inventory; control, hospital pharmacy, bar codes vs. manual method, 1259**  
**Errors, medication**  
 dispensing; control, management, pharmacists, 1675; hospital pharmacy, effects, lighting, 2137  
 drug distribution systems; unit dose, effects, regulations, New York, 1374  
 hospital pharmacy; reduction, bar codes, drug distribution systems, 953; technology, impact, review, Oct suppl 524  
 misuse; pharmacists' role, control, 949  
 penicillin G benzathine; toxicity, pediatrics, litigation, 1989  
 pharmacists, hospital; interventions, drug therapy, clinical impact, 2644  
 prescriptions; community pharmacists' interventions, cost-benefit analysis, 1376  
 quality assurance; hospital pharmacy, administration, patient outcomes, 1908; indicators, hospital pharmacy, 1937  
 reports; hospitals, computers, quality assurance, 2611; Medication Errors Reporting Program, USP role, 2559; programs, research, quality assurance, 72  
 technicians; unit dose cassette checking, training, Minnesota, 1952  
**Erythromycin; incompatibilities; fluconazole, injections, stability, 744**  
**Ethics**  
 authorship; honoraria acceptance, pharmaceutical industry, disclosure, 1168  
 biotechnology; therapy, costs, Oct suppl S4  
 discrimination; hospital pharmacists, HIV infections, 606  
 drug administration; prisoner consent, legal issues, 309  
 health professions; drug labeling, patient deception, 296  
 HIV infections; hospital pharmacists' experiences, 148; pharmacists' experiences, 938  
 hospital pharmacy; issues, U.S., 1990, review, 720  
 industry, pharmaceutical; symposia sponsorship, FDA attitudes, 16  
 pharmacists; conflict of interest, pharmaceutical industry marketing, 551; investigational drugs, dispensing, military personnel, 1525; patient consultation, 1196; relation, pharmaceutical industry, patient-care decisions, 1693  
 pharmacists, hospital; perfluorinated-perfluorinated dispensing, vs. blood transfusions, 2176  
 transplantation; heart, patient's suitability, pharmacist's role, 740  
**Ethylene oxide; incompatibilities; cisplatin, stability, storage, 1500**  
**Examinations; pharmacists; nutrition support specialties, 2064**  
**Excipients; cefazidime; injections, effects, gas formation, 1727**  
**Excretion; drugs; renal, dosage monitoring, hospital pharmacy, computers, 1965**

## F

**Fat emulsions**  
 administration systems; syringe pumps, cost-benefit analysis, neonates, 1972  
 safflower oil, combination, soybean oil; incompatibilities, nizatidine, 1507  
 soybean oil; alone and with safflower oil, incompatibilities, nizatidine, 1507  
 sterility; TPN, tests, Septi-Chek, 2419  
**Fax; medication orders; time studies, hospital pharmacy, 2653**  
**Fentanyl; injections; refractometry, tampering detection, 1488**  
**Fentanyl citrate; injections; refractometry, tampering detection, 1488**  
**Filters**  
 needles; incompatibilities, propofol, lack, 2627  
 ophthalmic preparations; compounding guidelines, 2438  
 stainless steel; incompatibilities, sodium ascorbate, 1191

**Filtration; injections; sterile product compounding, hospital pharmacy survey, 2398**  
**Floor stock; hospitals; controlled-substances storage, refrigeration, 2368**  
**Florida; cases; quality assurance, peer review, hospitals, 1989**  
**Fluconazole; incompatibilities; injections, stability, 744**  
**Fludarabine phosphate; incompatibilities; injections, stability, 2186**  
**Fluorouracil; incompatibilities; mannitol, injections, lack, 2158**  
**Food and Drug Administration (U.S.)**  
 Advisory Committee on the Food and Drug Administration; administration changes, recommendations, 1632  
 approvals; generic drugs, recommended changes, 188; new drugs and biologicals, 1990, 390  
 classification; therapeutic, investigational drugs, 2659  
 recalls; role, 2595  
 regulations; marketing, drugs, unapproved use, 16; new drug approvals, i.v. E-Ferol marketing cases, 747; surgical gloves, quality control, 392  
**Forms**  
 antineoplastic agents; standardized, medication orders, control, dispensing, 1683  
 clinical pharmacy; hospitals, services, documentation, cost-benefit analysis, 1467  
 controlled substances; hospital pharmacy, computer programs, monitoring, 1262  
 drug use; review, hospital pharmacy, implementation, 518  
 hospital pharmacy; documentation, pharmacists' interventions, 2649  
 informed consent; clinical studies, readability, Institutional Review Boards, 2651  
 medication orders; gentamicin, pharmacists' monitoring, 681; pentamidine, *P. carinii*, prophylaxis, hospital protocols, 2440  
**Formuleries**  
 ampicillin, combination, subcutaneous; inclusion, use, hospitals, 1492  
 antibiotics; decision analysis, methodology, 2146  
 calcium antagonists; selection, multiattribute utility theory, 301  
 costs; calculations, daily drug therapy, 236  
 hospital pharmacy; development, ASHP guidelines, 791; services, establishment, 1463; therapeutic substitution programs, 1471  
 hospitals; therapeutic substitution, antibiotics, 2150  
**Formulary system; hospital pharmacy; development, ASHP guidelines, 791**  
**Formulations**  
 cardioplegic solutions; compounding, review, 2444  
 cefazidime; comparison, injections, gas formation, 1727  
**Foscarnet sodium; comparison, ganciclovir sodium; cytomegalic inclusion disease therapy, AIDS, 2478**  
**Fraud; Medicare; regulations, exceptions, definitions, 2434**  
**Freezing; injections; polyolefin containers, stability, 2184**  
**Furosemide; incompatibilities; cefoperazone sodium, stability, storage, 108; fluconazole, injections, stability, 744; morphine, meperidine, i.v. injections, patient-controlled analgesia, 123**

## G

**Ganciclovir sodium**  
 comparison, foscarnet sodium; cytomegalic inclusion disease therapy, AIDS, 2478  
 incompatibilities; dextrose, stability, storage, 2641; total parenteral nutrition, concentration, 1538  
**Gases; carbon dioxide; formation, cefazidime, formulation comparison, 1727**  
**Gastrointestinal drugs**  
 cimetidine; incompatibilities, indomethacin, stability, 2442  
 cimetidine hydrochloride; incompatibilities, cefoperazone, stability, 111; incompatibilities, enteral nutrition, stability, 1681; incompatibilities, methylprednisolone admixtures, 1237  
 histamine  $H_2$  antagonists; administration routes, pharmacist monitoring, physicians' attitude, 1722  
 incompatibilities; haloperidol, injections, stability, 1539  
 nizatidine; incompatibilities, fat emulsions, stability, 1507  
 octreotide acetate; incompatibilities, TPN, stability, storage, 2172  
 omeprazole; DUE criteria, hospital pharmacy programs, 2382; DUE criteria, labeling, hospital pharmacy programs, 2380;  
 ranitidine; use, parenteral nutrition, dosage, 104  
 ranitidine hydrochloride; incompatibilities, polyolefin containers, lack, 2184  
**Genetic engineering**  
 research; biotechnology, pharmacy practice effects, Oct suppl S4  
 technology; drug administration systems, review, Oct suppl S14  
**Genitourinary smooth-muscle relaxants; oxybutynin chloride; stability, unit dose packaging, 1265**  
**Gentamicin; dosage; order forms, pharmacists' monitoring, 681**  
**Gentamicin sulfate**  
 incompatibilities; ciprofloxacin, stability, storage, lack, 2166  
 solutions, ophthalmic; stability, concentration, storage, 507  
**Geography; hospital pharmacy; limitations, New Zealand, 553**  
**Geriatrics**  
 influenza vaccines; immunization, outpatients, hospital pharmacists' role, 256  
 pharmacy, institutional; programs, pharmacists, personal-care homes, 1530  
 rational therapy; polypharmacy, ANA recommendations, 862  
**Glass**  
 containers; amber vs. clear, cisplatin stability, decomposition products, 1500  
 incompatibilities; taxol, containers, stability, storage, 1520; urokinase, containers, syringes, lack, 1511  
**Gloves; control, quality; surgical, FDA standards, 392**  
**Glycoproteins; CD-4; binding HIV, inhibition, 1300**  
**Good Samaritan Hospital, Inc.; litigation; American Home Products, quality assurance, hospitals, 1989**  
**Good Samaritan Hospital, Inc. v. American Home Products; litigation; quality assurance, P&T committee, Florida, 1989**  
**Graft vs. host disease; immunosuppressive agents; therapy, bone marrow transplantation, 127**  
**Greater Kansas City Society of Hospital Pharmacists; patient care; standards, clinical pharmacy, 1257**  
**Guidelines**  
 administration; pharmacy managers, exit interviews, 1433  
 American Society of Hospital Pharmacists; ambulatory care, pharmaceutical services, 311; drug distribution, control, pharmacists' role, 1782; drugs, purchasing, manufacturers, suppliers selection, 523; formulary system, development, 791; investigational drugs, institutional use, 315; manuscripts, seminars, publication, *Clinical Pharmacy*, 442; patient education, programs, pharmacists' role, 1780; pharmaceutical research, pharmacists' involvement, 1781; pharmaceutical services, surgery and anesthesiology, 319  
 American Society for Parenteral and Enteral Nutrition; DUE, adult TPN, 1442  
 communication; pharmacists, oral presentations, 1730  
 compliance; patients, factors, 1978  
 compounding; ophthalmic preparations, sterility, 2438  
 drug use; review, APhA, AMA, PMA, 2062  
 employment; pharmacists, interviews, 1180  
 ethics; pharmacists, relations, pharmaceutical industry, 551  
 Joint Commission on Accreditation of Healthcare Organizations; development, medication-use indicators, 1925  
 libraries; personal, building and maintenance, pharmacists, 230  
 newsletters; publications, hospital pharmacy, 2121  
 pediatrics; hospital pharmacy services, administration, 2475  
 personnel, pharmacy; managers, employment interviews, 670; managers, performance appraisal, 2600  
 pharmaceutical services; quality assurance, administration, 1917; quality assurance, ASHP, 1941  
 pharmacy; mission statements, 1195; practice, JCPP mission statements, 1847  
 prescribing; drug-use review, hospital pharmacy, 518  
 publications; authorship, pharmacists, 687  
 quality assurance; pharmaceutical services, development, 1901  
**Guidelines, treatment, see Protocols**

**H**  
**Haloperidol; incompatibilities; fluconazole, injections, stability, 744**



**Haloperidol lactate**; incompatibilities; sodium chloride, sodium nitroprusside, stability, 1539

**Harper, W.**; litigation; Washington, drug administration, prisoner consent, 309

**Harvey A. K. Whitney Lecture Award**; American Society of Hospital Pharmacists; 1991, pharmaceutical care, 1697

**Health-benefit programs**  
 drug use; review, guidelines, APhA, AMA, PMA, 2062  
 insurance; heart transplantation, patient's suitability, ethics, 740  
 managed-care systems; marketing, HMO vs. PPO, 2341  
 Medicaid; rebates, laws, effects, hospital pharmacy economics, 678; rebates, pharmaceutical industry, laws, 114; regulations, purchasing, reimbursement, 2434  
 Medicare; regulations, purchasing, reimbursement, 2434

**Health care**  
 administration; New Zealand, hospital pharmacy practice, 553  
 home; administrators, infusion pumps, attitudes, survey, Oct suppl 552; cost-effectiveness, need, regulations, 2548; intravenous therapy, pharmacy, databases, 1535; medical equipment, vendor exclusivity, legal issues, 1542; pharmacy recycling programs, 118; Specialty Practice Group, ASHP, need, 75  
 legislation; committees, 102nd Congress, list, 862; pharmacists, role, 1840  
 pharmacists; role, drug therapy, 1195  
 pharmacy; specialties, 487  
 quality assurance; hospitals, administration, patient outcomes, 1908  
 regulations; Medicare, purchasing, institutional pharmacy, 2434  
 services; quality improvement, pharmacists' role, 1897; quality improvement, pharmacists' role, 1898  
 team; pharmacists' role, WHO report, 391  
 United States; future, health professions, educational programs, 1639; problems, need for reform, 2133

**Health maintenance organizations**  
 drug-use; review, administration, 1712  
 economics; vs. PPO, health-benefits marketing, 2341

**Health professions**  
 education; pediatrics, patient care, hospital pharmacy role, 2475; programs, future health-care needs, 1639  
 ethics; drug labeling, 296  
 specialties; certification, administration, 476  
 toxicity, environmental; tuberculosis, pentamidine exposure, AIDS, 557

**Hemophilia**; anti-hemophilic factor; environmental toxicity, HIV transmission, 148

**Hiland**; litigation; cases, unapproved drug marketing, criminal convictions, 747

**History**  
 pharmacy; Lithuania, politics, 1035; specialties, manpower, future, 691; specialties, recognition, 480

**HIV infections**  
 pentamidine; *P. carinii*, prophylaxis, hospital protocols, forms, 2440  
 pharmacists; experiences, ethics, psychology, 938  
 pharmacists, hospital; discrimination, employment, 606; experiences, ethics, psychology, 148  
 therapy; research, NIH, 2662

**HMOs**, see **Health maintenance organizations**

**Home health care**, see **Health care; home**

**Hospital pharmacy**, see **Pharmacy, institutional, hospital**

**Hospitals**  
 accreditation; manuals, revision, JCAHO standards, 434  
 administration; policies, automatic antibiotic stop orders, 2602  
 administrators; attitudes, pharmacy directors, survey, 1846; attitudes, pharmacy directors, survey, 1948; new, problems, guidelines, pharmacy directors, 2372  
 clinical pharmacy; services, documentation, cost-benefit analysis, 1467  
 contracts; pharmacy schools, clinical services, clerkships, 1994  
 documentation; clinical pharmacy services, 2647  
 drugs, adverse reactions; reports, concurrent vs. retrospective review, 1974  
 drugs, investigational; pharmacists' responsibilities, 61  
 drug use; effects, restriction policies, 1220  
 economics; ketorolac vs. opiates, cost savings, 2128  
 formularies; therapeutic substitution programs, administration, 1471  
 Institutional Review Boards; informed consent forms,

readability, 2651  
 intensive-care units; costs, clinical pharmacist position, 2154; fat emulsions, administration systems, neonates, 1972; neonates, clinical pharmacy services, 1708  
 length of stay; effects, hospital pharmacists' participation, medical team, 1457  
 liability; medical equipment, home care, vendor exclusivity, legal issues, 1542; research, quality assurance regulations, 72  
 medication orders; i.v. admixtures, fax, time studies, pharmacy, 2653  
 personnel; manpower shortages, survey, 1114  
 personnel, pharmacy; job description, revisions, suggestions, 2118  
 pharmaceutical services; community, definition, ASHP survey, 1668; government, private, U.S. survey, 967  
 policies and procedures; allergy documentation, 260  
 protocols; forms, pentamidine, *P. carinii*, prophylaxis, 2440  
 psychiatric facilities; pharmaceutical services, survey, 974  
 purchasing; chemical reagents, market predictions, 194  
 quality assurance; consultants, effects, pharmacy department, 1891; development, use indicators, JCAHO guidelines, 1925  
 ranitidine; parenteral nutrition administration, 104  
 records; P&T committee, confidentiality, cases, Florida, 1989  
 teaching; pharmacists' salaries, U.S. survey, 249  
 technicians; role, pharmacists' attitudes, Ohio, survey, 1228

**Hours**  
 clinical pharmacy; hospitals, neonatal intensive-care unit, 1708  
 part-time; women pharmacists, 85  
 psychiatric facilities; pharmaceutical services, survey, 974

**How To**, 230, 670, 1180, 2121, 2600  
 How to be interviewed for a job, 1180  
 How to build and organize a personal reference library, 230  
 How to conduct a job interview, 670  
 How to do a performance appraisal, 2600  
 How to publish a pharmacy newsletter, 2121

**Human immunodeficiency virus**; binding; CD4 proteins, inhibition, 1300

**Hydrogen ion concentration**  
 acetazolamide; suspensions, stability, storage, 1241  
 cimetidine hydrochloride; incompatibilities, methylprednisolone admixtures, 1237  
 cisplatin; effects, decomposition products, containers, storage, 1500  
 idarubicin hydrochloride; incompatibilities, injections, pH, stability, 2181  
 indomethacin sodium trihydrate; incompatibilities, injections, stability, 2442  
 methylprednisolone sodium succinate; incompatibilities, cimetidine admixtures, 1237  
 ondansetron hydrochloride; incompatibilities, i.v. admixtures, 988  
 phenytoin sodium; interlot variability, injections, 510  
 succinylcholine chloride; stability, sterilization, storage, 501

**Hydromorphone hydrochloride**  
 incompatibilities; dexamethasone, concentration, stability, 2161; tetracaine, injections, stability, efficacy, 1682  
 injections; refractometry, tampering detection, 1488

**Hyperalimentation**, see **Nutrition; parenteral**

**Hypertension**  
 enalapril maleate, comparison, lisinopril; therapy, costs, dosage, 276  
 lisinopril, comparison, enalapril maleate; therapy, costs, dosage, 276

**Hypotensive agents**  
 enalapril maleate, comparison, lisinopril; dosage, costs, hypertension therapy, 276  
 lisinopril, comparison, enalapril maleate; dosage, costs, hypertension therapy, 276

**I**

**Iatrogenic diseases**, see **Drugs, adverse reactions**

**Idarubicin hydrochloride**; incompatibilities; injections, stability, pH, 2181

**Illinois**; Chicago College of Pharmacy; establishment, 2562

**Imipenem**  
 combination, cistatin; incompatibilities, flucon-

azole, injections, 744; use, effects, restriction policies, 1220  
 combination, cistatin sodium; incompatibilities, meperidine, i.v. injections, patient-controlled analgesia, 123

**Immunization**; influenza; vaccines, geriatric outpatients, hospital pharmacists' role, 256

**Immunosuppressive agents**  
 muromonab-CD3; adverse reactions, allergies, topical exposure, 1442  
 transplantation; bone marrow, therapy, 127

**Incompatibilities**  
 acyclovir and meperidine hydrochloride or morphine sulfate; i.v. injections, stability, patient-controlled analgesia, 123  
 amikacin sulfate and ciprofloxacin; stability, storage, 2166  
 amino acids and cefazidime; parenteral nutrition, stability, storage, 1515  
 aminophylline and ciprofloxacin; stability, storage, 2166  
 amphotericin B and dextrose; concentration, injections, stability, lack, 1681; concentration, stability, 2430; stability, i.v. admixtures, high concentration, 283; stability, storage, 2635  
 amrinone lactate and cardiac drugs; stability, vehicles, 1245  
 antibiotics and fluconazole; injections, stability, 744  
 anti-infective agents and fludarabine phosphate; injections, stability, 2186  
 antineoplastic agents and fludarabine phosphate; injections, stability, 2186  
 antipyrine and caffeine; injections, stability, storage, 1267  
 beverages and methadone hydrochloride; preservatives, temperature, stability, 1252  
 caffeine and antipyrine; injections, stability, storage, 1267  
 calcium gluconate and indomethacin sodium trihydrate; injections, stability, 2442  
 cardiac drugs and fluconazole; injections, stability, 744  
 cefazolin sodium and dextrose; stability, peritoneal dialysis solutions, 291  
 cefoperazone sodium and cimetidine hydrochloride; stability, 111  
 cefoperazone sodium and furosemide; stability, storage, 108  
 cefotaxime sodium and metronidazole; i.v. admixtures, stability, storage, 2638  
 ceftazidime and nutrition; parenteral, stability, storage, 1515  
 ceftriaxone sodium and vancomycin hydrochloride; injections, precipitation, 77  
 cephalosporins and tobramycin sulfate; human serum, storage, lack, 520  
 cistatin sodium, combination, imipenem and opiates; i.v. injections, stability, patient-controlled analgesia, 123  
 cimetidine and indomethacin sodium trihydrate; injections, stability, 2442  
 cimetidine hydrochloride and cefoperazone sodium; stability, 111  
 cimetidine hydrochloride and methylprednisolone sodium succinate; admixtures, stability, 1237  
 cimetidine hydrochloride and nutrition; enteral, lack, 1681  
 ciprofloxacin; injections, stability, storage, 2166  
 cisplatin and containers, vehicles; stability, storage, 1500  
 clindamycin phosphate and ciprofloxacin; stability, storage, 2166  
 dexamethasone sodium phosphate and diphenhydramine hydrochloride; precipitation, concentration, 2161  
 dexamethasone sodium phosphate and hydromorphone hydrochloride; precipitation, concentration, 2161  
 dextrose and amphotericin B; concentration, injections, stability, lack, 1681; concentration, stability, 2430; stability, i.v. admixtures, high concentration, 283; stability, storage, 2635  
 dextrose and cefazolin sodium; stability, peritoneal dialysis solutions, 291  
 dextrose and dobutamine hydrochloride; stability, peritoneal dialysis solutions, 1234  
 dextrose and ganciclovir sodium; stability, storage, 2641  
 dextrose and indomethacin sodium trihydrate; injections, stability, 2442  
 dextrose and urokinase; container adsorption, 1511  
 dextrose and zidovudine; stability, storage, 280  
 digoxin and amrinone lactate; stability, i.v. admixtures, 1245

diphenhydramine hydrochloride and dexamethasone sodium phosphate; precipitation, concentration, 2161  
 dobutamine and indomethacin sodium trihydrate; injections, stability, 2442  
 dobutamine hydrochloride and dextrose; stability, peritoneal dialysis solutions, 1234  
 dopamine and indomethacin sodium trihydrate; injections, stability, 2442  
 doxorubicin hydrochloride; infusion pump reservoirs, stability, storage, 1976  
 drugs; handbooks, ASHP publications, reliability, 421  
 ethylene oxide and cisplatin; stability, storage, 1500  
 fat emulsions and nizatidine; stability, storage, 1507  
 filters and sodium ascorbate; stainless steel, 1191  
 fluconazole; injections, stability, 744  
 fludarabine phosphate; injections, stability, 2186  
 fluorouracil and mannitol; injections, lack, 2158  
 furosemide and cefoperazone sodium; stability, storage, 108  
 furosemide and meperidine hydrochloride or morphine sulfate; i.v. injections, stability, patient-controlled analgesia, 123  
 ganciclovir sodium and dextrose; stability, storage, 2641  
 ganciclovir sodium and nutrition; parenteral, concentration, 1538  
 gentamicin sulfate and ciprofloxacin; stability, storage, lack, 2166  
 glass and cisplatin; containers, stability, storage, 1500  
 haloperidol lactate and sodium chloride or sodium nitroprusside; stability, 1539  
 human insulin and plastics; syringes, stability, storage, 2631  
 hydromorphone hydrochloride and dexamethasone sodium phosphate; precipitation, concentration, 2161  
 hydromorphone hydrochloride and tetracaine hydrochloride; stability, storage, efficacy, 1682  
 idarubicin hydrochloride; injections, stability, pH, 2181  
 indomethacin sodium trihydrate; injections, stability, 2442  
 injections; polyolefin containers, stability, storage, 2184  
 insulin human; i.v. drugs, admixtures, stability, 125  
 mannitol and fluorouracil; injections, lack, 2158  
 meperidine hydrochloride; i.v. injections, patient-controlled analgesia, 123  
 methadone hydrochloride and beverages; preservatives, temperature, stability, 1252  
 methadone hydrochloride and sodium chloride; admixtures, stability, 515  
 methylprednisolone sodium succinate and cimetidine hydrochloride; admixtures, stability, 1237  
 metronidazole and cefotaxime sodium; i.v. admixtures, stability, storage, 2638  
 metronidazole and ciprofloxacin; stability, storage, lack, 2166  
 miconazole and polyvinyl chloride; stability, storage, 286  
 morphine sulfate; i.v. injections, patient-controlled analgesia, 123  
 nafcillin and insulin human; stability, 125  
 nizatidine and nutrition; parenteral, stability, storage, 1507  
 nutrition and ceftazidime; parenteral, stability, storage, 1515  
 nutrition and cimetidine hydrochloride; enteral, lack, 1681  
 nutrition and ganciclovir sodium; parenteral, concentration, 1538  
 nutrition and nizatidine; parenteral, stability, storage, 1507  
 nutrition and octreotide acetate; parenteral, stability, storage, 2172  
 octreotide acetate and nutrition; parenteral, stability, storage, 2172  
 ondansetron hydrochloride; stability, i.v. admixtures, 988  
 phenytoin sodium and sodium chloride; admixtures, interlot variability, 510  
 plastics and cisplatin; syringes, stability, storage, 1500  
 plastics and human insulin; syringes, stability, storage, 2631  
 polyethylene and taxol; administration sets, stability, 1520  
 polyolefin; containers, injections, stability, storage, 2184  
 polyolefin and taxol; containers, administration sets, stability, 1520  
 polyvinyl chloride and cisplatin; containers, stability, storage, 1500  
 polyvinyl chloride and miconazole; stability, storage,

286  
 polyvinyl chloride and propofol; administration sets, 2627  
 polyvinyl chloride and taxol; contamination, plasticizers, storage, 1520  
 polyvinyl chloride and urokinase; container adsorption, vehicles, 1511  
 potassium chloride and amrinone lactate; stability, i.v. admixtures, 1245  
 procainamide hydrochloride and amrinone lactate; stability, i.v. admixtures, 1245  
 propranolol hydrochloride and amrinone lactate; stability, i.v. admixtures, 1245  
 propofol and polyvinyl chloride; administration sets, 2627  
 sodium ascorbate and filters; stainless steel, 1191  
 sodium bicarbonate and amrinone lactate; stability, i.v. admixtures, 1245  
 sodium chloride and cisplatin; stability, storage, 1500  
 sodium chloride and haloperidol lactate; stability, concentration, 1539  
 sodium chloride and methadone hydrochloride; admixtures, stability, 515  
 sodium chloride and phenytoin sodium; admixtures, interlot variability, 510  
 sodium chloride and urokinase; stability, 1511  
 sodium chloride and zidovudine; stability, storage, 280  
 sodium nitroprusside and haloperidol lactate; stability, 1539  
 sucrose and terbutaline sulfate; stability, compounding, 293  
 taxol and containers or vehicles; stability, storage, 1520  
 terbutaline sulfate and sucrose; stability, compounding, 293  
 tetracaine hydrochloride and hydromorphone hydrochloride; stability, storage, efficacy, 1682  
 tobramycin sulfate and cephalosporins; human serum, storage, lack, 520  
 tobramycin sulfate and ciprofloxacin; stability, storage, lack, 2166  
 tranquilizers and fluconazole; injections, stability, 744  
 TrophAmine and indomethacin sodium trihydrate; injections, stability, 2442  
 urokinase and containers or vehicles; adsorption, stability, 1511  
 vancomycin hydrochloride and ceftriaxone sodium; injections, precipitation, 77  
 verapamil hydrochloride; stability, i.v. admixtures, 1245  
 zidovudine and dextrose or sodium chloride; stability, storage, 280  
**Indomethacin sodium trihydrate;** incompatibilities; injections, stability, 2442  
**Industry, pharmaceutical**  
 drugs, investigational; institutional use, ASHP guidelines, 315  
 ethics; authors, honoraria acceptance, 1168  
 generic drugs; approvals, recommended changes, 188  
 marketing; drugs, unapproved use, FDA regulations, 16; techniques, pharmacists' conflict of interest, 551  
 prescription drugs; rebates, Medicaid, laws, 114  
 pricing; Medicaid rebates, laws, effects, hospitals, 678; prescription drugs, U.S., 1990, 1122  
 purchasing; drugs, selection, ASHP guidelines, 523  
 recalls; drugs, FDA, pharmacists, roles, 2595  
 relation; pharmacists, patient-care decisions, commercial influence, 1693  
 research; publications, peer-reviewed journals, benefits, 1424  
 Sandoz; clozapine distribution, problems, 2336  
**Influenza vaccines;** immunization; geriatric outpatients, hospital pharmacists' role, 256  
**Information**  
 acquired immunodeficiency syndrome; research, NIH, 2662  
 computers; PharmNet access, ASHP electronic bulletin boards, 1174  
 licensure; pharmacists, NABP Disciplinary Clearinghouse, 199  
 pharmacists; Pharmacy Manpower Database Project, development, U.S., 50  
 residencies; pharmacy students, programs, 1717  
**Infusion devices, see Devices; infusion pumps**  
**Inhalers, see Aerosols**  
**Injections**  
 additives; methadone, stability, storage, 515  
 amphotericin B; high concentration, stability, dextrose, 283; incompatibilities, dextrose, concentration, stability, 2430; incompatibilities, dextrose, lack, concentration, 1681; incompatibilities, dextrose, stability, storage, 2635  
 amrinone lactate; incompatibilities, cardiac drugs, sta-

bility, 1245  
 antibiotics; sterility tests, hospital pharmacy, 2414  
 antipyrine; incompatibilities, caffeine, i.v., storage, 1267  
 caffeine; incompatibilities, antipyrine, i.v., storage, 1267  
 cefazolin sodium; incompatibilities, dextrose, peritoneal dialysis solutions, 291  
 cefoperazone; incompatibilities, furosemide, 108  
 cefotaxime sodium; incompatibilities, metronidazole, i.v. admixtures, 2638  
 ceftazidime; formulations comparison, storage, gas formation, 1727; incompatibilities, parenteral nutrition, stability, 1515  
 ceftriaxone sodium; incompatibilities, vancomycin, precipitation, 77  
 cimetidine hydrochloride; incompatibilities, enteral nutrition, lack, 1681; incompatibilities, methylprednisolone, 1237  
 ciprofloxacin; incompatibilities, stability, storage, 2166  
 cisplatin; stability, effects, containers, pH, light, 1500  
 compounding; stability, incompatibilities, ASHP publications, reliability, 421  
 controlled substances; refractometry, tampering detection, 1488  
 dexamethasone sodium phosphate; incompatibilities, diphenhydramine or hydromorphone, concentration, 2161  
 dextrose; incompatibilities, amphotericin B, concentration, stability, 2430; stability, dobutamine, peritoneal dialysis solutions, 1234  
 diphenhydramine hydrochloride; incompatibilities, dexamethasone, concentration, 2161  
 dobutamine hydrochloride; stability, dextrose, peritoneal dialysis solutions, 1234  
 doxorubicin hydrochloride; stability, storage, infusion pump reservoirs, 1976  
 fluconazole; incompatibilities, stability, storage, 744  
 fludarabine phosphate; incompatibilities, antineoplastic agents, anti-infective agents, 2186  
 fluorouracil; incompatibilities, mannitol, lack, 2158  
 furosemide; incompatibilities, cefoperazone, 108  
 ganciclovir sodium; incompatibilities, dextrose, stability, storage, 2641; incompatibilities, TPN, 1538  
 haloperidol lactate; incompatibilities, vehicles, emergency drugs, 1539  
 histamine H<sub>2</sub> antagonists; administration routes, hospital pharmacists' monitoring, 1722  
 human insulin; incompatibilities, plastic syringes, stability, storage, 2631  
 hydromorphone hydrochloride; incompatibilities, dexamethasone, concentration, 2161; incompatibilities, tetracaine, stability, efficacy, 1682  
 idarubicin hydrochloride; incompatibilities, stability, pH, 2181  
 incompatibilities; polyolefin containers, 2184  
 indomethacin sodium trihydrate; infusions, incompatibilities, stability, 2442  
 infusion pumps; pharmacists' knowledge, survey, Oct suppl 552  
 insulin human; incompatibilities, i.v. drugs, 125  
 intravenous; compounding, hospital pharmacy, ASHP conferences, 2391; compounding, hospital pharmacy, U.S., survey, 2398; devices, administration rate, posture effects, 2422; medication orders, fax, hospitals, 2653  
 methylprednisolone sodium succinate; incompatibilities, cimetidine, 1237  
 metronidazole; incompatibilities, cefotaxime sodium, i.v. admixtures, 2638  
 muromonab-CD3; adverse reactions, allergies, topical exposure, compounding, 1442  
 nizatidine; incompatibilities, fat emulsions, parenteral nutrition, 1507  
 nutrition; parenteral, sterility tests, Septi-Chek, 2419  
 octreotide acetate; incompatibilities, TPN, stability, storage, 2172  
 ondansetron hydrochloride; incompatibilities, i.v. admixtures, 988  
 opiates; epidural, compounding, pain therapy, 2460; incompatibilities, patient-controlled analgesia, 123  
 phenytoin sodium; pH variations, stability, admixtures, 510  
 propofol; incompatibilities, PVC, 2627  
 rifampin; reconstitution, precipitation, 2127  
 sodium ascorbate; incompatibilities, stainless steel filters, 1191  
 sodium nitroprusside; incompatibilities, haloperidol, stability, 1539  
 succinylcholine chloride; stability, sterilization, storage, 501  
 taxol; incompatibilities, vehicles, containers, 1520  
 tetracaine hydrochloride; incompatibilities, hydro-

morphone, stability, efficacy, 1682  
 D,L- $\alpha$ -tocopheryl acetate; i.v., unapproved marketing, criminal conviction, 747  
 urokinase; incompatibilities, vehicles, containers, 1511  
 vancomycin hydrochloride; incompatibilities, ceftriaxone, precipitation, 77  
 zidovudine; incompatibilities, vehicles, stability, 280  
**Inspections;** hospital pharmacy; JCAHO standards, 914  
**Institutional Review Boards**  
 hospitals; informed consent forms, readability, 2651  
 research; quality assurance regulations, 72  
**Insulin human;** incompatibilities; i.v. drugs, stability, 125; plastics, syringes, storage, temperature, 2631  
**Insulin human isophane;** incompatibilities; plastics, syringes, storage, temperature, 2631  
**International Union, U.A.W.;** litigation; Johnson Controls, Inc., sex discrimination, environmental toxicity, 1281  
**International Union, U.A.W. v. Johnson Controls, Inc.** litigation; women, sex discrimination, environmental toxicity, 1281  
**Interviews**  
 personnel, pharmacy; employment, guidelines, 670; exit, guidelines, managers, 1433  
 pharmacists; employment, guidelines, 1180  
**Intravenous therapy**  
 health care; home, databases, pharmacy, 1535  
 pharmacy; waste disposal, recycling, 118  
**Inventory**  
 control; hospital pharmacy, bar codes vs. manual method, 1259  
 controlled substances; hospital pharmacy, computer programs, monitoring, 1262  
 psychiatric facilities; pharmaceutical services, survey, 974  
**Investigational drugs, see Drugs, investigational**  
**Investments;** regulations; Medicare reimbursement, institutional pharmacy, 2434  
**Invitational Conference on Pharmacy Specialization**  
 meetings; proceedings, 469; recommendations, 712  
**Isoproterenol hydrochloride;** therapy; pediatrics, nurse education, 97

## J

**Job description**  
 clinical pharmacists; time studies, hospitals, methodology, 1211  
 internships; hospitals, DUE, 1260  
 personnel, pharmacy; hospitals, revisions, suggestions, 2118  
 pharmacists; women, part-time, administration, 85  
 pharmacists, hospital; VA policies, postgraduate education, 732; salaries, U.S., survey, 249; satellite pharmacy, Navy ships, Persian Gulf, 730; staff development, administration, clinical services, 1956  
 technicians; hospital pharmacists' attitudes, Ohio, survey, 1228; satellite pharmacy, Navy ships, Persian Gulf, 730  
**Job satisfaction**  
 personnel, pharmacy; exit interviews, guidelines, 1433  
 pharmacists, hospital; clinical pharmacy, staff development programs, 1704; effects, clinical services documentation, 2647; VA, postgraduate education, VA survey, 732  
**Johnson Controls, Inc.;** litigation; International Union, U.A.W., sex discrimination, environmental toxicity, 1281  
**Joint Commission Dialogue,** 434, 914, 1428  
 Frequency of JCAHO-mandated medication inspections, 914  
 Joint Commission begins shrinking accreditation manual, 434  
 Working toward uniformity in evaluation of ADR-reporting programs, 1428  
**Joint Commission of Pharmacy Practitioners**  
 guidelines; mission statements, 1847; pharmacy mission statements, 1195  
 role; implementation, pharmaceutical care, 1697  
**Joint Commission on Accreditation of Healthcare Organizations**  
 drugs, adverse reactions; standards, monitoring, reporting, 1428  
 guidelines; development, medication-use indicators, 1925  
 standards; clinical services, hospital pharmacy, quality assurance, 1531; controlled substances, storage, refrigeration, 2368; dosage monitoring, clinical pharmacists, 1962; hospital pharmacy, pharmacist

attitude, 1550; investigational drugs, hospitals, pharmacists' role, 61; pharmacy inspections, ASHP attitudes, 914; policies and procedures, hospital pharmacy, 926; revision, Accreditation Manual for Hospitals, 434  
**Journal References,** 172, 370, 591, 836, 1099, 1356, 1611, 1818, 2029, 2320, 2525, 2710  
**Journals**  
*American Journal of Hospital Pharmacy;* manuscripts, editorial processing system, 909, 2388; manuscripts, reviewers, computers, 950; policies, conflict of interest information, authors, 1168; publications, stability studies, criteria, 1454; role, pharmacists, practice, 81  
*Clinical Pharmacy;* manuscripts, editorial processing system, 2388; manuscripts, reviewers, computers, 950; manuscripts, seminars, publication, guidelines, 442; policies, conflict of interest information, authors, 1168  
 guidelines; publications, authorship, pharmacists, 687  
 peer review; publications, research, benefits, 1424  
**Juices;** apples; incompatibilities, methadone, stability, 1252

## K

**Kentucky;** pharmacists, hospital; antineoplastic agents, handling, safety, survey, 119  
**Ketorolac tromethamine;** cost-benefit analysis; vs. opiates, hospitals, savings, 2128  
**Kidney failure;** drugs; dosage, medication order monitoring, hospital pharmacy, 1965; monitoring, clinical pharmacists, 1962

## L

**Labeling**  
 omeprazole; administration, DUE criteria, hospital pharmacy programs, 2380  
 ophthalmic preparations; compounding, sterility, guidelines, 2438  
 psychotherapeutic agents; compliance, ethics, patient deception, 296  
**Laboratories;** reagents; chemical, purchasing, market predictions, 194  
**Laminar airflow;** hoods; certification, standards, 654; compounding, sterile products, U.S., survey, 2398  
**Law Notes,** 114, 2434  
**Laws**  
 cases; *Advanced Health Care Services v. Radford Community Hospital*, 1542; employment, discrimination, HIV infections, pharmacists, 606; *Good Samaritan Hospital, Inc. v. American Home Products*, 1989; *International Union, U.A.W. v. Johnson Controls, Inc.*, U.S. Supreme Court, 1281; patient consultation, benzodiazepine toxicity, pharmacists, 1291; unapproved drug marketing, criminal convictions, 747; *Washington v. Harper*, drug administration, prisoner consent, 309  
 hospital pharmacy; issues, U.S., 1990, review, 720  
 labeling; drugs, patient deception, ethics, 296  
 Medicare and Medicaid Patient Protection Act of 1987; regulations, purchasing, reimbursement, institutional pharmacy, 2434  
 Omnibus Budget Reconciliation Act of 1990; effects, economics, hospital pharmacy, 678; effects, pharmacy, 114  
 pharmacists; patient consultation, legal issues, 1196  
 Prescription Drug Marketing Act; wholesaler licensure, states, activities, 2560  
**Leaching;** diethyl phthalate; contamination, levothyroxine tablets, 735  
**Lead;** toxicity, environmental; cases, sex discrimination, women, 1281  
**Legislation**  
 health care; committees, 102nd Congress, list, 862; pharmacists, role, 1840  
 patient information; consultation, pharmacists, benzodiazepine toxicity, 1291  
 wholesalers; licensure, state activities, 2560  
**Letters,** 71, 235, 457, 678, 937, 1185, 1441, 1679, 1891, 2127, 2380, 2602  
 Adverse reaction from topical exposure to mupirocin-CD3, 1442  
 Affordability of cimetidine, 943  
 Alternative term for intervention needed, 2605  
 Animal research is necessary, 2606  
 Antineoplastic admixtures, 945

Applying business principles to pharmaceutical care, 78  
 Automatic stop-order procedure for antibiotics needs evaluation, 2602  
 Avoid Las Vegas as a meeting site for ASHP, 939  
 Banned drugs in amateur athletics, 76  
 Benefits of training Pharm.D. students, 240  
 Calling all former NPC interns, 78  
 Caution advised with quality assurance consultants, 1891  
 Cephalosporin confusion—one simple solution? 236  
 Change needed for i.v. rifampin preparation instructions, 2127  
 Clarifications to *Pediatric Drug Formulations*, 682  
 Clinical pharmacy for all, 239  
 Clinical pharmacy term is outdated, 1443  
 Comment on stability of ranitidine hydrochloride in total nutrient admixtures, 2384  
 Comments on levels of pharmaceutical care, 1689  
 Comments on "War" editorial, 1449  
 Compatibility of hydromorphone hydrochloride and tetracaine hydrochloride, 1682  
 Competition in the home infusion industry, 1441  
 Correction to *AHFS Drug Information* 91, 2606  
 Dental precaution listing needs improvement, 1447  
 Diethyl phthalate not dangerous, 1448  
 Disturbing susceptibility pattern for ciprofloxacin, 1892  
 Do not forget medical staff education, 1684  
 Do we know what we are really looking for? 2383  
 Drug information services provided by pharmaceutical manufacturers, 1683  
 Drug-use evaluation of adult total parenteral nutrition using modified ASPEN guidelines, 1442  
 Educational qualifications of hospital pharmacy managers, 1680  
 Error in January note, 946  
 Ethics of cardiac transplantation, 1690  
 Ethics of war, 463  
 Extended-release niacin not problem free, 237  
 Further update on stability of thrombin topical powder at room temperature, 464  
 Gentamicin dosing services in the absence of 24-hour pharmaceutical services, 681  
 Growth of psychopharmacy, 1185  
 Home-care group needed within ASHP, 75  
 H<sub>2</sub>-receptor antagonists and acute intermittent porphyria, 1190  
 Idarubicin hydrochloride dosing guidelines might cause confusion, 72  
 Incompatibility of ceftriaxone with vancomycin, 77  
 Institutional review boards and quality assurance activities, 72  
 Interaction of sodium ascorbate with stainless steel particulate-filter needles, 1191  
 Is ketorolac more cost-effective? 2128  
 I, too, am an HIV-positive pharmacist, 938  
 Keep Las Vegas as a meeting site for ASHP, 1895  
 Labeling of nonprescription quinine needs revision, 1892  
 Lest we forget, 1689  
 Material safety data sheets for investigational drugs, 1679  
 Methylphenidate use in Michigan, 2129  
 More information on hardening of carbamazepine tablets, 2130  
 More to the E-Ferol case than presented, 1894  
 Negative financial impact of Medicaid legislation, 680  
 New ruling unfair to nuclear pharmacists, 235  
 No more animal research, 1684  
 Notifying patients of adverse drug reactions, 236  
 Personal shampoos and safety considerations, 937  
 Pharmacists and animal research, 76  
 Pharmacists and drug company gifts, 457  
 Pharmacists should initiate as well as prevent, 2383  
 Pharmacists stationed in the Persian Gulf, 458  
 Pharmacy manager need not be a pharmacist, 2384  
 Pharmacy needs a computer-rating group, 938  
 Potential economic impact of changes in Medicaid drug program purchasing, 678  
 Providing medication information as a professional obligation, 77  
 Reactions to Lake Mindbogene, 682  
 Refractometry of controlled substances, 2129  
 Reserve-duty pharmacist proud to serve, 2131  
 Resolving problems in the use of omeprazole, 2380  
 Rethinking the term "intervention," 1679  
 Room-temperature stability of allergenic extracts, 682  
 Satisfaction of physicians and nurses with clinical pharmacy services, 1189  
 Stability of amphotericin B in 5% dextrose injection at 25°C, 1681  
 Stability of cimetidine hydrochloride in Sondalis Iso enteral nutrition formula, 1681

Staff pharmacist-driven clinical pharmacy program, 680  
 Standardized cancer chemotherapy order form, 1683  
 Sterility of extemporaneously compounded preservative-free injections, 71  
 Switching from enalapril to lisinopril, 2605  
 Thanks for the complimentary subscriptions, 463  
 Thanks for the educational opportunity, 2131  
 Thanks from Persian Gulf pharmacist, 1449  
 The theory of ADD-MORE, 2383  
 Time clocks in health-care institutions, 464  
 Understanding physician prescribing behavior, 463  
 Which bottom line? 2130  
**Levothyroxine sodium**; tablets; contamination, diethyl phthalate, desiccants, 735  
**Liability**  
 hospitals; medical equipment, home care, vendor exclusivity, legal issues, 1542; research, quality assurance regulations, 72  
 prisons; drug administration, prisoner consent, 309  
**Libraries**; pharmacists; personal, guidelines, 230  
**Licensure**  
 pharmacists; regulations, continuing education, 2560; states, listing, NABP Disciplinary Clearinghouse, 199  
 wholesalers; legislation, state activities, 2560  
**Lidocaine hydrochloride**; therapy; pediatrics, nurse education, 97  
**Lighting**; hospital pharmacy; effects, medication errors, 2137  
**Lisinopril**; comparison, enalapril maleate; dosage, costs, hypertension therapy, 276  
**Lithium**; blood levels; laboratory tests, protocols, hospital pharmacy, 1536  
**Lithuania**; pharmacy; history, politics, 1035  
**Lobbying**; pharmacists; health-care issues, role, 1840

## M

**Magnesium chloride**; tablets; stability, unit dose packaging, 1266  
**Managed-care systems**  
 marketing; HMO, PPO, economics, 2341  
 pharmacy; manpower, specialties, future, 691  
**Management**; see **Administration**  
**Management Consultation**, 61, 444, 666, 926, 1433, 1675, 1884, 2118, 2372, 2598  
 Controlling investigational drug use in community hospitals, 61  
 Coping with administrative turnover, 2372  
 Counseling a staff member after errors in dispensing, 1675  
 Dealing with unfair criticism from a superior, 1884  
 Easing tension through flexible leadership style, 2598  
 Inspiring staff to invest time in professional organizations, 444  
 Making job descriptions functional, 2118  
 Pharmacy participation in exit interviews, 1433  
 Training community pharmacists to fill hospital vacancies, 666  
 Transforming policies and procedures from burden to boon, 926  
**Mannitol**; incompatibilities; fluorouracil, injections, lack, 2158  
**Manpower**  
 clinical pharmacists; services, neonatal intensive-care unit, 1708  
 drug distribution systems; unit dose, bar codes, satellite pharmacy, 953  
 hospital pharmacy; inventory control, bar codes vs. manual method, 1259; Navy ships, Persian Gulf, 530, 730; pharmacists, U.S., 1990, 1868; services, establishment, 1463; staffing levels, U.S., survey, 249; staff turnover, exit interviews, guidelines, 1433; TPN compounding, computer programs, time studies, 270; U.S. Army, Saudi Arabia, 533  
 pharmacists; WHO recommendations, health-care team, 391; specialties, future, 691  
 pharmacists, hospital; shortages, survey, 1114  
 pharmacy; Pharmacy Manpower Database Project, development, U.S., 50; specialties, conferences, 469; specialties, conference recommendations, 712  
 psychiatric facilities; pharmaceutical services, survey, 974  
**Manuals**; hospitals; accreditation, revision, JCAHO standards, 434  
**Manufacturers**; ophthalmic preparations; nonprescription, patient information, 987  
**Manufacturing**  
 generic drugs; approvals, recommended changes, 188  
 sterile products; ASHP role, 386  
**Marketing**

drugs; unapproved use, regulations, FDA, 16  
 health care; HMO vs. PPO, 2341  
 industry, pharmaceutical; techniques, pharmacists' conflict of interest, 551  
 new drugs; and biologicals, FDA approvals, 1990, 390  
 D,L- $\alpha$ -tocopheryl acetate; i.v., unapproved, criminal convictions, 747  
**Mechanism of action**  
 analgesics and antipyretics; epidural injections, 2460  
 cardiopulmonary solutions; review, 2444  
 pentamidine isethionate; toxicity, aerosols, asthma, AIDS, 556  
 tranquilizers; schizophrenia therapy, 1271  
**Medic Alert**; patient information; adverse drug reactions, pharmacists' role, 236  
**Medicare and Medicaid Patient Protection Act of 1987**; regulations; reimbursement, institutional pharmacy, 2434  
**Medication Errors Reporting Program**; United States Pharmacopoeial Convention; role, 2559  
**Medication orders**  
 antibiotics; automatic stop orders, hospital policies, 2602  
 antineoplastic agents; standardized forms, compounding, dispensing, control, 1683  
 clinical pharmacy; hospitals, staff development programs, 1704  
 computers; monitoring, dosage, kidney failure, hospital pharmacy, 1965  
 documentation; forms, hospital pharmacists' interventions, 2649  
 fax; hospital pharmacy, 2653  
 gentamicin; forms, pharmacists' monitoring, 681  
**Medicine**; specialties; history, certification, 476  
**Meetings**  
 hospital pharmacy; sterile products compounding, ASHP, 2391  
 industry, pharmaceutical; symposia sponsorship, ethics, FDA attitudes, 16  
 pharmacy; specialties, conference recommendations, 712; specialties, conferences, summary, 469  
**Megestrol acetate**; cachexia; therapy, AIDS, 2479  
**Membership**  
 committees; health care, 102nd Congress, 862  
 pharmacists, hospital; professional organizations, involvement, 444  
**Meperidine hydrochloride**  
 incompatibilities; i.v. injections, patient-controlled analgesia, 123  
 injections; refractometry, tampering detection, 1488  
**Metabolism**; didanosine; AIDS therapy, clinical studies, 1298  
**Methadone**; maintenance; programs, increased budget, recommendations, 13  
**Methadone hydrochloride**  
 incompatibilities; vehicles, oral, stability, 1252  
 stability; storage, photodecomposition, 515  
**Methodology**  
 clinical studies; therapeutic drug monitoring, analysis, 1553; unapproved use, marketing, industry ethics, 16  
 cost-benefit analysis; review, 2622  
 costs; calculations, daily drug therapy, 236  
 data collection; ASHP surveys, community hospital definition, 1668  
 decision analysis; antibiotics, formularies, 2146  
 decision making; drug selection models, formularies, 301; drug therapy, models, 1477  
 drugs, adverse reactions; correlation analysis, algorithms, 121; reports, concurrent vs. retrospective review, 1974  
 meta-analysis; didanosine, clinical studies, 1298  
 patient care; algorithms, outcome, pharmacists' role, 1912  
 pharmacy; practice, drug information, theoretical base, 536; practice, models, patient needs, 547; practice, theoretical models, 540  
 quality assurance; indicator selection, 1931  
 workload; clinical pharmacists, services, hospitals, 1211  
**Methylprednisolone sodium succinate**; incompatibilities; cimetidine admixtures, stability, 1237  
**Metronidazole**  
 enterocolitis; pseudomembranous, therapy, decision analysis, 1477  
 incompatibilities; cefotaxime, i.v. admixtures, stability, storage, 2638; ciprofloxacin, stability, storage, lack, 2166  
**Miconazole**; incompatibilities; polyvinyl chloride, stability, storage, 286  
**Military**  
 hospital pharmacy; Navy ships, Persian Gulf, 530, 730; U.S. Army, Saudi Arabia, 533  
 personnel; ethics, investigational drugs, informed

consent, 1525  
 pharmacists; role, Operation Desert Storm, 467  
 pharmacists, hospital; U.S., mailing addresses, Operation Desert Storm, 458  
**Missouri**; hospital pharmacy; patient-care standards, 1257  
**Missouri Society of Hospital Pharmacists**; patient care; standards, clinical pharmacy, 1257  
**Models**  
 decision making; drug selection, effects, pharmacists' choices, 1477  
 formularies; calcium antagonist selection, decision theory, 301  
 pharmaceutical services; ambulatory care, 245  
 pharmacy; practice, patient needs, 547; practice, theoretical, 540; practice, theoretical base, 536  
**Moisture**  
 absorption; magnesium tablets, unit dose packaging, 1266  
 carbamazepine; tablets, stability, 2130  
**Morphine sulfate**  
 dosage forms; sustained-action tablets, comparison, solution, costs, 101  
 incompatibilities; i.v. injections, patient-controlled analgesia, 123  
 injections; refractometry, tampering detection, 1488  
**Murmonab-CD3**; adverse reactions; allergies, topical exposure, 1442  
**Mutagenicity**; antineoplastic agents; pharmacists, nurses, patients, tests, 1199

## N

**Nafcillin**; incompatibilities; insulin human, injections, stability, 125  
**Naloxone**; acquired immunodeficiency syndrome; therapy, 2480  
**Naltrexone**; acquired immunodeficiency syndrome; therapy, 2480  
**National Academy of Sciences**; reports; drug abuse programs, increased budget, recommendations, 13  
**National Association of Boards of Pharmacy**  
 meetings; resolutions, pharmacy technicians, certification, compounding, 1640  
 pharmacists; licensure information, states, listing, 199  
**National Collegiate Athletic Association**; drugs; banned, list, 76  
**National Institutes of Health**; research; AIDS, HIV infections, 2662  
**Needles**; filters; incompatibilities, propofol, lack, 2627  
**New Periodicals**, 379, 853, 2541  
**News**, 6, 188, 386, 606, 860, 1112, 1374, 1632, 1840, 2060, 2336, 2548  
 Adverse events involved in 3.7% of hospitalizations in New York in 1984, study finds, 860  
 AMA issues guidelines on gifts from industry, 610  
 American Nurses Association adopts position on polypharmacy, 862  
 APhA house of delegates adopts broad range of new policies, 1114  
 Appointments and Promotions, 19, 199, 392, 630, 874, 1129, 1390, 1642, 1849, 2068, 2342, 2562  
 ASHP gears up multistep action plan regarding sterile drug products, 386  
 BPS sets requirements for nutrition support certification, schedules exam for January, 2064  
 CDC issues guidelines on HIV transmission by health-care workers, 2060  
 Committee recommends changes in generic drug industry and drug approval process, 188  
 Community pharmacists more likely to consider severity of illness than cost in selecting alternative drug therapies, study shows, 1112  
 Community practice study shows pharmacist interventions add economic value to patient care, 1376  
 Employers given limited access to NABP disciplinary clearinghouse, 199  
 FDA targets illegal drug promotion in industry-sponsored activities, 2339  
 FDA upgrades glove-testing requirements, 392  
 Fifth supplement to USP XXII-NF XVII published, 2562  
 Finding common ground: two pharmacists on Capitol Hill, 1840  
 Health devices agency reviews needle-stick prevention products, 1642  
 Health-related committee assignments in the 102nd Congress, 862  
 Hospital discriminated against HIV-positive pharmacist, New York ruling says, 606  
 Hospital executives give pharmacy directors high marks, 1846



Hospital medication histories not accurate in elderly patients, study shows, 391

Iatrogenic contamination of multidose vials can lead to patient infection, study finds, 1120

International pharmacy groups meet in Washington, D.C., for Pharmacy World Congress, 2340

ION committee recommends increased funds for drug treatment programs, 13

JCPP calls for pharmacists to comment on provisional draft mission statement for pharmacy practice, 1847

Limits on future cuts in hospital admissions, patient stays suggest hospital costs will rise, 1380

Many hospitals find pharmacists difficult to recruit, AHA study finds, 1114

Medication errors, toxic effects most common causes of preventable iatrogenic cardiac arrests, 2065

Meetings and Continuing Education, 24, 199, 393, 630, 874, 1129, 1391, 1642, 1849, 2068, 2342, 2563

Melvin W. Green, ACPE director emeritus, dies, 2561

NABP approves resolutions on technicians, compounding, 1640

New college of pharmacy to open in Illinois, 2562

News Briefs, 24, 199, 402, 630, 875, 1129, 1391, 1643, 1849, 2077, 2343, 2563

1990 rise in prescription drug prices averages nearly 8%, 1122

9000 "treatment systems" register for new clozapine distribution plan; dissatisfaction remains with high cost, paperwork, 2336

Nosocomial bacteremias attributed to narcotic tampering in pharmacy, 1117

Open-label studies for unapproved uses, symposia to be scrutinized by FDA, 16

Panel recommends independence, more resources for FDA, 1632

Paying the price for home care: Costs are lower than at hospitals, but lack of regulation raises concerns, 2548

Pew Commission moves to help health professional schools prepare for changing health-care needs, 1639

Pfizer offers patient-counseling program, 1122

Pharmacies recycle, 6

Pharmacists challenged to routinely screen for adverse drug reactions, 16

Pharmacists in New York say mandatory unit dose law will upgrade practice, patient care despite temporary challenges, 1374

Pharmacists urged to participate in poison prevention efforts, 13

Principles of drug-use review approved by APhA, AMA, and PMA, 2062

Quality of care for hospitalized Medicare patients improves despite prospective-pricing system, 190

Regional conferences for residents and preceptors held, 1641

Report predicts growth for clinical chemistry reagents market, 194

Residents' conferences set for 1991, 19

Resources on training pharmacy preceptors available from AACP, 1122

76 million now enrolled in HMOs and PPOs, but reforms and competition may influence market, 2341

Smoking-related deaths top 434,000 in 1988, 611

State pharmacy boards adopting topic-specific CE requirements, 2560

States on track for licensing wholesalers, as 1992 deadline looms, 2560

Students' use of cocaine drops, but cigarette and alcohol use remains high, 622

Theophylline toxicity associated with errors in drug therapy management, study shows, 1390

USP issues fourth supplement to USP XXII-NF XVII, 873

USP to coordinate medication errors reporting program, 2559

VA pharmacies' controls over addictive drugs are inadequate, government study finds, 2062

Washington, D.C., to host Pharmacy World Congress '91, 191

Washington State project studies effects of expanded technician role, 2342

World Health Organization report cites pharmacists' essential role on health-care team, 391

Year-end review shows 23 new drugs approved, 14 important biologic licensing actions taken by FDA, 390

**Newsletters**

hospital pharmacy; publications, guidelines, 2121

pharmaceutical services; hospital pharmacists, staff development programs, 1704

**New York**; regulations; unit dose distribution, hospital pharmacy, 1374

**New Zealand**; hospital pharmacy; practice, education, 553

**Nicardipine**; formularies; selection models, multiattributed utility theory, 301

**Nifedipine**; formularies; selection models, multiattributed utility theory, 301

**Nitrofurazone**; dressings; dilutions, effects, antibacterial activity, in vitro, 1496

**Nizatidine**; incompatibilities; fat emulsions, stability, storage, 1507

**Norepinephrine bitartrate**; therapy; pediatrics, nurse education, 97

**NSC-312887**, see **Fludarabine phosphate**

**Nurses**

antineoplastic agents; environmental toxicity, chromosomal damage, tests, 1199

attitudes; clinical pharmacy services, survey, 1189

communication; hospital pharmacists, hospital administrators' attitudes, survey, 1948

documentation; drug allergies, hospital policies, 260

medication orders; fax, i.v. admixtures, time studies, 2653

workload; forms, controlled substances, monitoring, 1262

**Nursing**

administration; medication errors, reports, quality assurance, 2611

specialties; history, certification, 476

standards; comparison, JCAHO standards, hospital pharmacy, 1550

workload; morphine sustained-action tablets, comparison, solutions, 101

**Nutrition**

enteral; incompatibilities, cimetidine injections, stability, 1681

parenteral; compounding, hospital pharmacy computer programs, 270; DUE, adults, ASPEN guidelines, 1442; incompatibilities, ceftazidime, storage, stability, 1515; monitoring, staff development programs, 980; ranitidine administration, dosage, 104; sterility tests, Septi-Chek, 2419; total, incompatibilities, ganciclovir, concentration, 1538; total, incompatibilities, nizatidine, stability, 1507; total, incompatibilities, octreotide, stability, storage, 2172; total, quality assurance indicators, hospital pharmacy, 1937

support; specialties, certification, 2064

## O

**Obstetrics**; hospital pharmacy; satellite, clinical services, 1533

**Octreotide acetate**; incompatibilities; parenteral nutrition, stability, storage, 2172

**Omeprazole**; use; evaluation, labeling, hospital pharmacy programs, 2380; review, criteria, hospital pharmacy programs, 2382

**Omnibus Budget Reconciliation Act of 1990**

effects; economics, hospital pharmacy, 678

Medicaid; rebates, pharmaceutical industry, 114

**Oncology**; clinical pharmacists; specialties, career changes, 1998

**Ondansetron hydrochloride**; incompatibilities; i.v. admixtures, stability, 988

**Ophthalmic preparations**

compounding, drug information needs, pharmacists, survey, 1205; sterility, guidelines, 2438

patient information; nonprescription, manufacturers' instructions, 987

**Opiates**

administration routes; epidural therapy, 2460

cost-benefit analysis; vs. ketorolac, hospitals, savings, 2128

hydromorphone hydrochloride; incompatibilities, tetracaine, injections, stability, efficacy, 1682

pain; postoperative, effects, education, physician prescribing, 1484

**Organizations**

American Society of Hospital Pharmacists; strategic planning, reports, 1991-92, 1776

Board of Pharmaceutical Specialties; administration, pharmacist certification, 480

Greater Kansas City Society of Hospital Pharmacists; patient-care standards, clinical pharmacy, 1257

health care; home, Specialty Practice Group, need, 75

Missouri Society of Hospital Pharmacists; patient-care standards, clinical pharmacy, 1257

pharmacy; conference, specialties, summary, 469; membership, hospital pharmacists, involvement, 444; mission statements, 1195; regulations, patient consultation, benzodiazepine toxicity, 1291; role,

implementation, pharmaceutical care, 1697

**Oxybutynin chloride**; stability; unit dose packaging, storage, 1265

## P

**Package inserts**; rifampin; injections, reconstitution, instructions, 2127

**Packaging**

drugs; patient compliance, improvement guidelines, 1978

fat emulsions; administration systems, costs, neonates, 1972

levothyroxine sodium; tablets, contamination, diethyl phthalate desiccants, 735

sterile products; ASHP role, 386

unit dose; magnesium tablets, stability, 1266; oxybutynin syrup, stability, 1265

**Pain**

hydromorphone hydrochloride and tetracaine hydrochloride; mixtures, stability, efficacy, 1682

opiates; postoperative, physician prescribing, hospital pharmacists, 1484

tetracaine hydrochloride and hydromorphone hydrochloride; mixtures, stability, efficacy, 1682

**Parenterals**, see **Injections**

**Particle size**; emulsions; TPN, incompatibilities, octreotide, storage, 2172

**Patient care**

algorithms; outcome, pharmacists' role, 1912

clinical pharmacists; geriatrics, personal-care homes, rational therapy, 1530

clinical pharmacy; services, quality assurance, peer review, 1531

hospital pharmacy; standards, Missouri, 1257; unit dose distribution, effects, regulations, New York, 1374

pediatrics; hospital pharmacy, services, guidelines, 2475

pharmaceutical services; practice, theoretical models, 540; practice, theoretical models, 547

pharmacists; role, consultation, drug therapy, 1196; role, drug therapy, 949

pharmacists, community; prescriptions, interventions, cost-benefit analysis, 1376

pharmacists, hospital; JCAHO standards, attitude, 1550

pharmacists, institutional; decisions, relation, commercial influence, 1693

**Patient-controlled analgesia**; opiates; incompatibilities, i.v. injections, 123

**Patient education**

ambulatory care; pharmaceutical services, ASHP guidelines, 311

compliance; factors, improvement guidelines, 1978

pharmacists; role, ASHP guidelines, 1780

poison prevention; pharmacists' role, 13; programs, pharmacists' role, 2657

**Patient information**

clinical studies; informed consent forms, readability, 2651

consultation; adverse drug reactions, pharmacists, Medic Alert, 236; drug administration systems, pharmacists' role, review, Oct suppl S14; hospital administrators' attitudes, survey, 1948; hospital pharmacists, neonates, obstetrics, 1533; influenza immunization, geriatric outpatients, hospital pharmacists' role, 256; pharmacists, benzodiazepine toxicity, regulations, 1291; pharmacists, interventions, 1453; pharmacists' role, drug therapy, 1196

drug histories; allergy documentation, hospital policies, 260

ophthalmic preparations; nonprescription, manufacturers' instructions, 987

profile; drug allergy documentation, hospital pharmacists, 260; physician prescribing, monitoring, 265

**Patients**

acquired immunodeficiency syndrome; didanosine protocols, requirements, 1299

antineoplastic agents; toxicity, chromosomal damage, tests, 1199

attitudes; generic drugs, approvals, recommended changes, 188

compliance; factors, improvement guidelines, 1978

drugs, personal; psychiatric facilities, medicated shampoos; toxicity, 937

geriatrics; personal-care homes, rational therapy, clinical pharmacists, 1530

HIV infections; experiences, sociology, psychology, 148

inpatients; hospital pharmacy, U.S., 1990, review, 720

rights; military personnel, informed consent, ethics,

## Annual Index

- 1525; research, protection, regulations, 72  
transplantation; heart, suitability, ethics, pharmacist's role, 740
- Pediatrics**  
clinical pharmacists; specialties, career changes, 1998  
clinical pharmacy; neonatal intensive care, services, 1708  
dosage forms; compounding, information needs, pharmacists, survey, 1205  
emergency drugs; nurse education, 97  
fat emulsions; neonates, syringe pumps, cost-benefit analysis, 1972  
hospital pharmacy; patient care, services, guidelines, 2475; satellite, neonates, clinical services, 1533; services, establishment, 1463  
penicillin G benzathine; toxicity, medication errors, litigation, 1989  
poisoning; prevention, programs, pharmacists' role, 13  
poison prevention; programs, pharmacists' role, 2657
- Peer review**  
hospitals; quality assurance, records, confidentiality, cases, Florida, 1989  
journals; publications, research, benefits, 1424; reviewer tracking, computers, 950  
pharmaceutical services; quality assurance, standards, development, 1901  
pharmacists, hospital; clinical services, quality assurance, 1531
- Penicillin G benzathine**; toxicity; medication errors, pediatrics, litigation, 1989
- Penicillins**  
ampicillin, combination, sulbactam; prescribing, use, formulary inclusion, 1492; substitution for cefoxitin, hospital pharmacy programs, 2150  
nafcillin; incompatibilities, insulin human, stability, 125  
penicillin G benzathine; toxicity, errors, pediatrics, litigation, 1989  
piperacillin sodium; incompatibilities, polyolefin containers, lack, 2184
- Pennsylvania**; Committee for the Impaired Pharmacist; role, pharmacist employment, drug abuse recovery, 326
- Pentamidine**; pneumonia; *P. carinii*, prophylaxis, hospital protocols, forms, 2440
- Pentamidine isethionate**  
toxicity; aerosols, asthma, AIDS, 556  
toxicity, environmental; aerosols, health professions, 557
- Perflumamine**; combination, perflunafene; pharmacists, dispensing, vs. blood transfusions, ethics, 2176
- Perflunafene**; combination, perflumamine; pharmacists, dispensing, vs. blood transfusions, ethics, 2176
- Personnel**  
health care; risks, pentamidine, tuberculosis exposure, AIDS, 557  
hospitals; manpower shortages, survey, 1114  
military; ethics, investigational drugs, informed consent, 1525
- Personnel, pharmacy**  
administration; employment interviews, guidelines, 670; exit interviews, guidelines, 1433; management, supervisors, interaction techniques, 2598; performance appraisal, guidelines, 2600  
compounding; sterile products, ASHP conferences, 2391; sterile products, U.S. survey, 2398; sterile products, quality assurance, improvement, 2387  
employment; hospital pharmacists, training program, 666  
hospitals; handling, investigational drugs, material safety data sheets, 1679; issues, U.S., 1990, review, 720; recycling programs, 6  
job description; hospitals, revisions, suggestions, 2118  
pharmacists, hospital; manpower shortages, survey, 1114; staff development, clinical career ladders, 1956  
reimbursement; Medicare regulations, 2434  
supportive; education, unit dose cassette checking, Minnesota, 1952; satellite pharmacy, Navy ships, Persian Gulf, 730; staffing levels, teaching hospitals, U.S., 249; technicians, certification, NABP actions, 1640; technicians, muromonab-CD3 adverse reactions, 1442; technicians, pharmacists' attitudes, Ohio, survey, 1228; technicians' role, surgery and anesthesiology satellite, guidelines, 319; time studies, fax, medication orders, hospitals, 2653; TPN, time studies, computer programs, 270
- Pew Health Professions Commission**; education; health professions, programs, future health-care needs, 1639
- Pharmaceutical education**, see **Education, pharmaceutical**
- Pharmaceutical Manufacturers Association**; drug use; review, principles, 2062
- Pharmaceutical services**  
ambulatory care; ASHP guidelines, 311; models, 245  
clinical; dosage monitoring, kidney failure, 1962; hospitals, contracts, pharmacy schools, clerkships, 1994; hospitals, documentation, applications, 2647; hospitals, neonatal intensive-care units, 1708; hospitals, staff development programs, 1704; nurses, physicians, attitudes, survey, 1189; pharmacist's position, intensive-care units, costs, 2154; program development, hospital pharmacists' role, 680; staff development, hospitals, administration, 1956  
compounding; NABP actions, 1640  
cost-benefit analysis; definitions, methodology, review, 2622  
guidelines; quality assurance, ASHP, 1941  
hospitals; clinical, documentation, cost-benefit analysis, 1467; community, definition, ASHP survey, 1668; effects, pharmacists' participation, medical team, 1457; establishment, 1463; gentamicin, order forms, pharmacists' monitoring, 681; psychiatric facilities, survey, 974; satellite, neonates, obstetrics, clinical pharmacists, 1533; surgery and anesthesiology, ASHP guidelines, 319; therapeutic drug monitoring, analysis, review, 1553; unit dose distribution, regulations, New York, 1374; models; practice, theoretical, 540; practice, theoretical, 547  
nutrition; parenteral, monitoring, staff development programs, 980  
organizations; role, implementation, pharmaceutical-care concept, 1697  
patient education; pharmacists' role, ASHP guidelines, 1780  
patient information; consultation, pharmacists, interventions, 1453  
pharmacists; military, role, Operation Desert Storm, 467; role, drug therapy, 1195; role, patient care, development, 1559; role, patient consultation, drug therapy, 1196  
psychiatric facilities; U.S. survey, 967  
quality assurance; guidelines, development, hospital pharmacy, 1901; indicators, patient care, hospital pharmacy, 1931  
reimbursement; Medicare regulations, 2434  
United States Army; hospital facilities, Saudi Arabia, 533  
United States Navy; hospital ships, Persian Gulf, 530, 730
- Pharmacists**  
acquired immunodeficiency syndrome; role, therapy, research, 1296  
administration; employment interviews, guidelines, 670  
ambulatory care; pharmaceutical services, ASHP guidelines, 311  
authorship; publications, guidelines, 687  
certification; nutrition support specialties, 2064  
communication; oral presentations, guidelines, 1730  
databases; Pharmacy Manpower Database Project, development, U.S., 50  
decision making; drug selection, models, effects, 1477  
drug administration systems; technology, role, review, Oct suppl 514  
drug distribution; role, control, ASHP guidelines, 1782  
education, pharmaceutical; infusion pumps, survey, Oct suppl 552; psychopharmacy specialties, 1284  
employment; interviews, guidelines, 1180  
ethics; conflict of interest, pharmaceutical industry marketing, 551; drug labeling, patient deception, 296; investigational drugs, dispensing, military personnel, 1525; role, patient's suitability, heart transplantation, 740  
guidelines; ambulatory-care services, 245  
health care; home, Specialty Practice Group, ASHP, need, 75; team role, WHO report, 391  
HIV infections; experiences, ethics, psychology, 938  
libraries; personal, guidelines, 230  
licensure; regulations, continuing education, 2560; states, listing, NABP Disciplinary Clearinghouse, 199  
military; role, Operation Desert Storm, 467  
patient care; role, outcome, algorithms, 1912  
patient education; compliance, improvement guidelines, 1978; role, programs, ASHP guidelines, 1780  
patient information; consultation, interventions, 1453  
poison prevention; programs, role, 2657  
politics; role, 1840  
practice; models, patient needs, 547; theoretical models, 540  
professionalism; leadership, development, 1559  
purchasing; drugs, manufacturers, suppliers selection, ASHP guidelines, 523  
recruitment; psychiatric facilities, need, 1185  
research; AIDS, NIH, 2662  
role; adverse drug reactions, monitoring programs, 16; cardioplegic solutions, review, 2444; drug recalls, 2595; drug therapy, 1195; drug therapy, control, medication errors, 949; health-care services, quality improvement, 1897, 1898; JCPP mission statements, 1847; patient consultation, drug therapy, 1196; poison prevention programs, 13  
specialties; manpower, future, 691; psychopharmacy, petition, 1284  
workload; home health care, i.v. therapy, databases, 1535
- Pharmacists, clinical**, see **Clinical pharmacists**
- Pharmacists, community**  
compounding; drug information needs, survey, 1205  
education, pharmaceutical; training, hospital setting, 666  
patient information; consultation, benzodiazepine toxicity, regulations, 1291  
prescriptions; interventions, cost-benefit analysis, 1376
- Pharmacists, hospital**  
administration; administrators' turnover, problems, 2372; exit interviews, guidelines, 1433; management, supervisors, interaction techniques, 2598; performance appraisal, guidelines, 2600  
administrators; employment requirements, advertisements, 1680; hospital administrators' attitudes, survey, 1846; hospital administrators' attitudes, survey, 1948  
antineoplastic agents; control, dispensing, compounding, standardized forms, 1683; environmental toxicity, chromosomal damage, tests, 1199; handling, safety, training, attitudes, 119  
attitudes; postgraduate education, VA survey, 732; technicians, Ohio, survey, 1228  
clinical pharmacy; administration, technology impact, review, Oct suppl 524; program development, role, 680; services, neonates, obstetrics, 1533  
compounding; drug information needs, survey, 1205; sterile products, education, U.S., survey, 2398; TPN, time studies, computer programs, 270  
dispensing; medication errors, effects, lighting, 2137  
documentation; clinical services, 2647; drug allergies, hospital policies, 260; interventions, forms, 2649  
drug abuse; employment, recovery, considerations, 326  
drugs, adverse reactions; patient consultation, Medic Alert, 236  
education; influenza vaccines, immunization, geriatric outpatients, 256; physicians, effects, postoperative opiate prescribing, 1484  
education, pharmaceutical; continuing, therapeutic substitution, antibiotics, 2150  
employment; discrimination, HIV infections, 606; training program, community pharmacists, 666  
ethics; perflumamine-perflunafene dispensing, vs. blood transfusions, 2176  
formulary system; development, ASHP guidelines, 791  
health care; team, participation, effects, hospital costs, 1457  
HIV infections; experiences, ethics, psychology, 148  
interventions; drug therapy, clinical impact, 2644  
job description; revisions, suggestions, 2118; satellite pharmacy, Navy ships, Persian Gulf, 730  
manpower; U.S., 1990, 1868; shortages, survey, 1114  
medication orders; computer monitoring, drug dosage, kidney failure, 1965  
military; U.S., mailing addresses, Operation Desert Storm, 458  
monitoring; histamine H<sub>1</sub> antagonists, physicians' attitudes, 1722  
patient care; pediatrics, services, guidelines, 2475  
patient information; consultation, benzodiazepine toxicity, regulations, 1291  
peer review; quality assurance, clinical services, 1531  
pharmaceutical services; surgery and anesthesiology, ASHP guidelines, 319  
practice; JCAHO standards, attitude, 1550  
professionalism; membership, pharmacy organizations, involvement, 444  
professional relations; administrators' unfair criticism, 1884  
quality assurance; pharmaceutical services, guidelines, role, 1901; services, role, administration, 1917; unapproved drug marketing, 747  
role; investigational drugs, community hospitals, 61; restructured QA programs, consultants, effects, 1891  
safety; laminar-airflow hoods, certification, standards, 654  
salaries; U.S., survey, 249

services; gentamicin, order forms, monitoring, 681  
staff development; administration, clinical services, 1956; clinical pharmacy, programs, 1704; TPN monitoring programs, 980

women; drugs, environmental toxicity, pregnant employees, 1281; hours, part-time, administration, 85

#### Pharmacists, institutional

administration; ASHP programs, ACCRUE, 1992; drug-use review, HMO, 1712  
drugs, investigational; ASHP guidelines, 315  
errors, medication; dispensing, control, management, 1675

practice; role, *AJHP*, 81

relation; pharmaceutical industry, patient-care decisions, commercial influence, 1693

research; involvement, ASHP guidelines, 1781

#### Pharmacokinetics

analgesics and antipyretics; epidural therapy, 2460  
drugs; monitoring, analysis, review, 1553  
hospital pharmacy; services, satellite, neonates, obstetrics, 1533

megestrol acetate, 2479

quality assurance; indicators, hospital pharmacy, 1937

**Pharmacology**; emergency drugs; pediatrics, nurse education, 97

#### Pharmacy

degrees; December graduate, opportunities, hospital pharmacy residencies, 54

health care; home, i.v. therapy, databases, 1535  
intravenous therapy; waste disposal, recycling, 118

manpower; effects, specialties, economics, future, 691; *Pharmacy Manpower Database Project*, development, U.S., 50

pediatrics; hospitals, administration, guidelines, 2475  
practice; biotechnology, impact, Oct suppl 54; drug information, theoretical base, 536; effects, specialties, education, U.S., 700; history, Lithuania, 1035

hospitals, JCAHO standards, pharmacist attitude, 1550; hospitals, patient-care standards, Missouri, 1257; mission statements, JCPP, 1847; models, patient needs, 547; nutrition support specialties, certification, 2064; organizations' role, implementation, pharmaceutical care, 1697; pharmacists' role, drug therapy, 1195; professionalism, leadership, development, 1559; research, ASHP guidelines, 1781

specialties, certification, 480; specialties, conference recommendations, 712; specialties, development, 706; specialties, future, 469; specialties, politics, 487; theoretical models, 540

specialties; psychopharmacy, need, 1185; psychopharmacy, petition, 1284

state boards; regulations, continuing education, 2560  
students; biotechnology, pharmaceutical education, need, Oct suppl 54; continuing education, ASHP publications, 2102; hospital pharmacy, clerkships, expectations, 1671; hospital residencies, advantages, 1878; hospitals, nontraditional internships, 1260; residencies, information, programs, 1717

**Pharmacy Abroad**, 553, 1035

#### Pharmacy and therapeutics committee

communication; pharmacy directors, hospital administrators' attitudes, survey, 1948

drugs, adverse reactions; patient consultation, *Medic Alert*, 236

drug use; review, pharmacists' role, HMO, 1712  
hospitals; role, therapeutic substitution programs, 1471

protocols; lithium blood levels, laboratory tests, 1536  
records; confidentiality, hospitals, Florida, 1989

#### Pharmacy, clinical, see Clinical pharmacy

**Pharmacy, community**; laws; Medicaid rebates, effects, 114

**Pharmacy, education**, see *Education, pharmaceutical*

**Pharmacy Ethics**, 296, 740, 1525, 2176

#### Pharmacy, institutional

administration; ASHP programs, ACCRUE, 1992; technicians' certification, compounding, NABP actions, 1640

clinical services; drug information, geriatrics, personal-care homes, 1530

clinics; medication profile review, clinical pharmacists' role, 265

controlled substances; screening, refractometry, 2129  
drugs, investigational; ASHP guidelines, 315

errors, medication; dispensing, pharmacists, control, management, 1675

health maintenance organizations; drug-use review, 1712

purchasing; reimbursement, Medicare regulations, 2434

research; pharmacists' involvement, ASHP guidelines, 1781

#### Pharmacy, institutional, hospital

administration; employment interviews, guidelines, 670; exit interviews, guidelines, 1433; formulary system, development, ASHP guidelines, 791; inventory control, bar codes vs. manual method, 1259; medication errors, reports, quality assurance, 2611; performance appraisal, guidelines, 2600; personnel, involvement, professional organizations, 444; pharmacists' interventions, drug therapy, clinical impact, 2644; role, *AJHP*, 81; staff development, clinical services, 1956; training program, community pharmacists, 666

administrators; employment, requirements, advertisements, 1680; infusion pumps, attitudes, survey, Oct suppl 552; management, supervisors, interaction techniques, 2596; problems, guidelines, pharmacy directors, 2372; professional relations, unfair criticism, 1884

clinical pharmacists; intensive-care units, costs, 2154  
clinical pharmacy; patient-care standards, Missouri, 1257; program development, pharmacists' role, 680

compounding; antibiotics, injections, sterility tests, 2414; sterile products, ASHP conferences, 2391; sterile products, quality assurance, improvement, 2387; sterile products, U.S., survey, 2398; TPN, computer programs, 270

computers; medication order monitoring, dosage, kidney failure, 1965; spreadsheet programs, translations from mainframe, 2619

controlled substances; floor stock, storage, refrigeration, 2368; monitoring, computer programs, 1262  
costs; effects, pharmacists' participation, medical team, 1457

decentralized; clinical pharmacists, time studies, methodology, 1211; clinical services, neonatal intensive-care units, 1708; obstetrics, neonates, clinical services, 1533; satellite, surgery and anesthesiology, ASHP guidelines, 319; services, establishment, 1463; unit dose distribution systems, bar codes, 953; U.S. Navy ships, Persian Gulf, 730

Department of Veterans Affairs; controlled substances, security, survey, 2062

documentation; drug allergies, dispensing policies, 260; pharmacists' interventions, forms, 2649

drug distribution systems; technology, impact, review, Oct suppl 524; unit dose, regulations, New York, 1374

drugs, adverse reactions; monitoring, vs. retrospective record review, 1974

drugs, investigational; material safety data sheets, handling, 1679

drug use; evaluation, ciprofloxacin resistance, 1892; review, implementation, 518

drug-use review; students, nontraditional internships, 1260

economics; effects, laws, Medicaid rebates, 678  
education, pharmaceutical; clerkships, students, expectations, 671

employment; pharmacists, drug abuse, recovery, considerations, 326

formularies; ampicillin-sulbactam, use, prescribing, 1492

inspections; JCAHO standards, 914  
laws; Medicaid rebates, effects, 114

lighting; effects, medication errors, dispensing, 2137  
medication orders; fax, i.v. admixtures, time studies, 2653

manpower; pharmacists, U.S., 1990, 1868  
newsletters; publications, guidelines, 2121

omeprazole; DUE criteria, 2382; DUE criteria, labeling, 2380

pediatrics; administration, services, guidelines, 2475  
pharmaceutical services; quality assurance, guidelines, development, 1901

pharmacists; patient-care decisions, commercial influence, 1693; women, part-time, administration, 85  
policies and procedures; antibiotic-use restrictions, effects, 1220; drugs, teratogenicity, pregnant employees, 1281; JCAHO standards, 926

practice; New Zealand, 553; U.S., 1990, review, 720  
protocols; lithium blood levels, laboratory tests, 1536  
psychiatric facilities; services, survey, 974

quality assurance; administration, indicators, patient care, 1931; administration, patient outcomes, 1908; indicators, development, 1937; JCAHO standards, pharmacist attitude, 1550; programs, consultants, effects, 1891; services, administration, processes, 1917

records; investigational drugs, computer programs, 2616

residencies; advantages, 1878; opportunities, December graduate, 54

services; clinical, contracts, pharmacy schools, clerkships, 1994; clinical, documentation, applications, 2647; clinical, documentation, cost-benefit analysis, 1467; clinical, nurses, physicians' attitudes, 1189; clinical, quality assurance, peer review, 1531; community, definition, ASHP survey, 1668; dosage monitoring, kidney failure, 1962; gentamicin, order forms, pharmacists' monitoring, 681; hospital administrators' attitudes, survey, 1846, 1948; psychiatric, U.S. survey, 967; quality assurance, guidelines, ASHP, 1941; therapeutic drug monitoring, analysis, review, 1553

staff development; pharmacists, clinical services, programs, 1704; TPN monitoring programs, 980

sterile products; manufacturing, repackaging, ASHP role, 386

substitution; therapeutic, ampicillin-sulbactam for cefoxitin, 2150; therapeutic, cefazoxime for cefoxitin, 2655; therapeutic, programs, administration, 1471

technicians; pharmacists' attitudes, Ohio, survey, 1228; unit dose, cassette checking, training, Minnesota, 1952

United States Army; services, Saudi Arabia, 533  
United States Navy; ships, Persian Gulf, 530

waste disposal; recycling programs, 6  
workload; morphine sustained-action tablets, comparison, solutions, 101

#### Pharmacy personnel, see Personnel, pharmacy

**Pharmacy services**, see *Pharmaceutical services*

**PharmNet**; electronic bulletin boards; access information, advantages, 1174

**Phenol**; preservatives; human insulin, incompatibilities, plastic syringes, 2631

**Phenytoin sodium**; injections; pH variations, stability, admixtures, 510

#### Photodecomposition

antipyrine; incompatibilities, caffeine, storage, 1267  
caffeine; incompatibilities, antipyrine, storage, 1267  
cisplatin; effects, decomposition products, containers, storage, 1500

methadone hydrochloride; stability, storage, admixtures, 515

sodium ascorbate; incompatibilities, stainless steel filters, 1191

succinylcholine chloride; injections, stability, storage, 501

#### Physicians

attitudes; clinical pharmacy services, survey, 1189; dosage monitoring, clinical pharmacists, 1962; histamine H<sub>2</sub> antagonists, pharmacists' monitoring, 1722; TPN pharmacists, staff development, 980

documentation; drug allergies, hospital policies, 260  
drug administration; didanosine treatment IND protocols, AIDS therapy, 1299

drug use; review, role, 518  
education; therapeutic interchange programs, 2655; therapeutic substitution, antibiotics, newsletter, 2150

ethics; drug labeling, patient deception, 296  
formularies; role, therapeutic substitution, hospital pharmacy, 1471

medication orders; hospital pharmacist dosage monitoring, kidney failure, 1965

prescribing; antineoplastic agents, standardized forms, 1683; gentamicin order forms, pharmacists' monitoring, 681; pentamidine, *P. carinii*, prophylaxis, hospital protocols, forms, 2440; pharmacists' interventions, documentation, forms, 2649; pharmacists' role, medication profile review, 265; post-operative opiates, effects, education, hospital pharmacists, 1484

protocols; lithium blood levels, laboratory tests, 1536  
role; adverse drug reactions, monitoring programs, 16

**Piperacillin**; incompatibilities; fluconazole, injections, stability, 744

**Piperacillin sodium**; incompatibilities; polyolefin containers, stability, storage, 2184

#### Planning and design

hospital pharmacy; compounding, sterile products, 2387; compounding, sterile products, U.S., survey, 2398; lighting, effects, medication errors, 2137; psychiatric facilities, survey, 974; services, establishment, 1463

#### Plasticizers

diethylhexyl phthalate; contamination, taxol, containers, 1520

diethyl phthalate; desiccants, contamination, levothyroxine tablets, 735

#### Plastics

gloves; surgical, quality control, FDA standards, 392  
polypropylene; alone and with polyethylene, syringes, incompatibilities, human insulin, 2631

polyethylene and polypropylene; syringes, incompatibilities, human insulin, storage, 2631

**Platelets**; infusion pumps; effects, lack, in vitro, 1970

## Annual Index

**Pneumonia;** pentamidine; *P. carinii*, prophylaxis, hospital protocols, forms, 2440

**Poisoning**  
prevention; programs, pharmacists' role, 13  
shampoos; medicated, psychiatric facilities policies, 937

**Poison prevention**  
programs; pharmacists' role, 2657; week, pharmacists' role, 13

**Policies and procedures,** see **Administration**

### Politics

health care; committees, 102nd Congress, U.S., 862;  
reform, need, U.S., 2133  
Medicaid; prescription drug rebates, ASHP role, 114  
pharmacists; role, 1840  
pharmacy; Lithuania, history, 1035; specialties, 487

### Polyethylene

incompatibilities; taxol, administration sets, 1520  
and polypropylene; syringes, incompatibilities, human insulin, stability, 2631

### Polyolefin

incompatibilities; injections, containers, storage, 2184;  
taxol, containers, administration sets, 1520

### Polypropylene

alone and with polyethylene; syringes, incompatibilities, human insulin, stability, 2631  
containers; unit dose, oxybutynin stability, 1265  
incompatibilities; urokinase, syringes, adsorption, lack, 1511

### Polyvinyl chloride

containers; amphotericin B-dextrose containers, stability, storage, 2635; stability, cisplatin, decomposition products, pH, light, 1500  
incompatibilities; amrinone lactate, stability, i.v. admixtures, 1245; miconazole, stability, storage, 286;  
propofol, administration sets, 2622; taxol, containers, stability, storage, 1520; urokinase, container adsorption, 1511

**Powders;** doxorubicin hydrochloride; reconstitution, stability, storage, pump reservoirs, 1976

### Precipitation

ceftriaxone sodium; incompatibilities, vancomycin, injections, 77  
ciprofloxacin; incompatibilities, injections, stability, storage, 2166  
dexamethasone sodium phosphate; incompatibilities, diphenhydramine or hydromorphone, concentration, 2161  
diphenhydramine hydrochloride; incompatibilities, dexamethasone, concentration, 2161  
fluconazole; incompatibilities, injection, stability, 744  
ganciclovir sodium; incompatibilities, TPN, 1538  
haloperidol lactate; incompatibilities, sodium chloride, concentration, 1539  
hydromorphone hydrochloride; incompatibilities, dexamethasone, concentration, 2161  
indomethacin sodium trihydrate; incompatibilities, injections, stability, 2442  
nutrition; parenteral, incompatibilities, ganciclovir, 1538  
rifampin; injections, reconstitution, 2127  
taxol; incompatibilities, vehicles, containers, 1520  
vancomycin hydrochloride; incompatibilities, ceftriaxone, injections, 77

**Preferred provider organizations;** economics; vs. HMO, health-benefits marketing, 2341

### Prescribing

ampicillin, combination, sulbactam; use, formulary inclusion, 1492  
cefazolin; therapeutic interchange, ceftizoxime, 2655  
ceftizoxime; for cefazolin, therapeutic interchange, 2655  
errors; medication; community pharmacists' interventions, cost-benefit analysis, 1376  
guidelines; drug-use review, hospital pharmacy, 518  
hospitals; development, medication-use indicators, JCAHO guidelines, 1925  
pharmacists, hospital; interventions, clinical impact, 2644; TPN, staff development program, 980  
physicians; pharmacists, medication profile review, 265; postoperative opiates, effects, education, hospital pharmacists, 1484

**Prescription Drug Marketing Act;** licensure; wholesalers, requirements, state activities, 2560

### Prescriptions

benzodiazepines; patient consultation, toxicity, pharmacists, 1291  
dispensing; medication errors, effects, lighting, hospital pharmacy, 2137  
drugs; costs, clinical pharmacists' impact, 265  
errors, medication; community pharmacists' interventions, cost-benefit analysis, 1376  
pricing; U.S., 1990, 1122; laws, Medicaid rebates, 114  
stop orders; automatic, antibiotics, hospital policies,

2602

### Preservatives

m-cresol; human insulin, incompatibilities, plastic syringes, 2631  
ethylene oxide; effects, cisplatin stability, storage, 1500  
phenol; human insulin, incompatibilities, plastic syringes, 2631  
sodium benzoate; effects, microbiological contamination, methadone solutions, 1252

**Pricing;** industry, pharmaceutical; Medicaid rebates, laws, effects, hospitals, 678

**Primers,** 127, 301, 1271, 1730, 1978, 2190, 2444

**Prisons;** liability; drug administration, prisoner consent, 309

### Procainamide hydrochloride

complexes; dextrose, dissociation, in vitro, 2426  
incompatibilities; amrinone lactate, stability, i.v. admixtures, 1245

**Professional advancement;** pharmacists, hospital; clinical career ladders, 1956

### Professionalism

pharmacists; development, educators, 1559  
pharmacists, hospital; membership, pharmacy organizations, involvement, 444

### Professional relations

administrators; hospital pharmacists, unfair criticism, 1884

pharmacists; support, need, expanded role, 949

**Professions;** pharmacy; mission statements, 1195

**Progestins;** megestrol acetate; cachexia therapy, AIDS, 2479

**Propofol;** incompatibilities; PVC, administration sets, 2627

**Propranolol hydrochloride;** incompatibilities; amrinone lactate, stability, i.v. admixtures, 1245

### Protocols

algorithms; adverse reactions correlation analysis, methodology, 121; patient care, outcome, pharmacists' role, 1912  
analgesics; epidural injections, patient monitoring, 2460  
cefoxitin; hospitals, vs. therapeutic substitution, 2150  
didanosine; treatment IND, AIDS therapy, 1299  
drugs, investigational; information, computer programs, hospital pharmacy, 2616  
drug use; review, pharmacists' role, HMO, 1712  
histamine H<sub>2</sub> antagonists; administration routes, hospital pharmacists' monitoring, 1722  
lithium; blood levels, laboratory tests, hospital pharmacy, 1536  
omeprazole; DUE criteria, hospital pharmacy programs, 2380, 2382  
pentamidine; *P. carinii*, prophylaxis, hospitals, forms, 2440

### Psychiatric facilities

pharmaceutical services; government, private, U.S. survey, 967; survey, 974  
pharmacists; psychopharmacy specialties, need, 1185  
policies and procedures; medicated shampoos, toxicity, 937

**Psychiatry;** pharmaceutical services; specialties, need, 1185

### Psychology

HIV infections; hospital pharmacists' experiences, 148; pharmacists' experiences, 938

### Psychotherapeutic agents

administration; prisoner consent, legal issues, 309  
compliance; labeling, patient deception, ethics, 296  
schizophrenia; therapy, review, 1271

### Publications

*American Journal of Hospital Pharmacy*; manuscripts, editorial processing system, 2388; role, pharmacists, practice, 81; stability studies, criteria, 1454  
*American Society of Hospital Pharmacists*; *AJHP*, CP, paper submission, conflict-of-interest information, 1168; computers, benefits, 950; continuing education, pharmacy students, 2102; handbooks, drug information, reliability, 421  
authorship; pharmacists, guidelines, 687  
*Clinical Pharmacy*; manuscripts, editorial processing system, 2388  
drug information; USP DI, Dental Precaution Listing, sources, reliability, 1447  
manuscripts; seminars, *Clinical Pharmacy*, guidelines, 442  
newsletters; hospital pharmacy, guidelines, 2121  
research; peer-reviewed journals, benefits, 1424  
**Public health;** services; Advisory Committee on the FDA, recommended changes, 1632  
**Public relations;** National Poison Prevention Week; pharmacists' role, 13

### Purchasing

drugs; institutional pharmacy, Medicare reimburse-

ment regulations, 2434; manufacturers, suppliers selection, ASHP guidelines, 523

hospital pharmacy; costs, effects, laws, Medicaid rebates, 678  
reagents; chemical, clinics, physician offices, market predictions, 194

**Purity;** tests; sterile product compounding, hospital pharmacy survey, 2398

## Q

### Quality assurance

drug use; review, pharmacists' role, HMO, 1712  
health care; home, i.v. therapy, pharmacy databases, 1535; pharmacists' role, 1897, 1898  
hospital pharmacy; administration, indicators, patient care, 1931; administration, patient outcomes, 1908; clinical services documentation, 2647; clinical services, peer review, 1531; indicators, development, 1937; JCAHO standards, pharmacist attitude, 1550; TPN monitoring programs, staff development, 980  
hospitals; consultants, effects, pharmacy department, 1891; development, medication-use indicators, JCAHO guidelines, 1925; medication errors, reports, computers, 2611; records, confidentiality, cases, Florida, 1989  
pharmaceutical services; administration, processes, 1917; guidelines, development, hospital pharmacy, 1901; surgery and anesthesiology satellite, ASHP guidelines, 319  
pharmacists, hospital; unapproved drug marketing, 747

pharmacy services; guidelines, ASHP, 1941  
research; regulations, hospitals, 72  
sterile products; compounding, ASHP role, 386; compounding, hospital pharmacy, ASHP conferences, 2391; compounding, hospital pharmacy, U.S. survey, 2398; compounding, improvement, hospital pharmacy, 2387

### Quality control, see Control, quality

### Quality of life

health care; services, improvement, 1897  
pharmaceutical services; quality assurance, guidelines, hospital pharmacy, 1901

**Questions and Answers,** 50, 222, 421, 654, 909, 1168, 1424, 1668, 1868, 2102, 2368, 2595

Access to PharmNet, ASHP's electronic bulletin board, 1174

The ASHP national survey's definition of community hospitals, 1668

Authors' acknowledgment of potential conflicts of interest, 1168

Benefits of peer-reviewed publication, 1424

FDA's role in drug product recalls, 2595

How many hospital pharmacists? 1868

Locked storage of refrigerated controlled substances, 2368

Reliability of stability, compatibility, and compounding data in ASHP handbooks, 421

Requirements for certifiers of biological-safety cabinets, 654

Status of the Pharmacy Manpower Database Project, 50

Use of ASHP publications by pharmacy students, 2102

Why authors no longer receive typeset galley proofs, 222

Why journal manuscripts are edited, 909

### Quinolones

ciprofloxacin; incompatibilities, injections, stability, storage, 2166; resistance, DUE, hospitals, 1892

## R

**Radford Community Hospital;** litigation; Advanced Health Care Services, medical equipment, vendor exclusivity, 1542

**Ranitidine;** use; parenteral nutrition, toxicity, dosage, 104

**Ranitidine hydrochloride;** incompatibilities; polyolefin containers, stability, storage, 2184

### Rational therapy

ampicillin, combination, sulbactam; utilization, formulary inclusion, 1492  
antibiotics; prescribing, restriction policies effects, 1220  
clinical pharmacists; medication profile review, 265  
nutrition; parenteral, DUE criteria, ASPEN, 1442



- opiates; postoperative pain, hospital pharmacists' role, 1484
- pharmacists, hospital; interventions, clinical impact, 2644
- polypharmacy; geriatrics, ANA recommendations, 862; programs, pharmacists, personal-care homes, 1530
- ranitidine; parenteral nutrition administration, 104
- Readability**; informed consent; forms, Institutional Review Boards, 2651
- Reagents**; sales; chemical, clinics, physician offices, market predictions, 194
- Reconstitution**, see **Drugs**; **reconstitution**
- Records**
- confidentiality; hospital P&T committee, cases, 1989
- controlled substances; hospital pharmacy, computer programs, monitoring, 1262
- drugs, investigational; computer programs, hospital pharmacy, 2616
- inventory; control, hospital pharmacy, bar codes vs. manual method, 1259
- medical; reports, adverse reactions, vs. concurrent pharmacy review, 1974
- Recruitment**
- personnel; hospitals, manpower shortages, survey, 1114
- pharmacists; psychiatric facilities, need, 1185
- Reference books**
- American Society of Hospital Pharmacists; handbooks, publications, reliability, 421
- drug information; Dental Precaution Listing, *USP DI*, reliability, 1447
- pharmacists; personal libraries, guidelines, 230
- Reflections**, 148, 1039, 1998
- Refractometry**
- controlled substances; injections, tampering detection, 1488; solutions, screening diversion, 2129
- Regulations**
- drugs; banned, athletes, 76
- education, pharmaceutical; continuing, state boards of pharmacy, 2560
- Food and Drug Administration; marketing, drugs, unapproved use, 16; recalls, 2595; surgical gloves, quality, control, 392
- generic drugs; approvals, recommended changes, 158
- health care; home, need, U.S., 2548
- Institutional Review Boards; research, quality assurance, 72
- licensure; wholesalers, state legislative activities, 2560
- Medicare; purchasing, reimbursement, 2434
- National Association of Boards of Pharmacy; resolutions, pharmacy technicians, certification, compounding, 1640
- New York; unit dose distribution, hospital pharmacy, 1374
- patient information; consultation, benzodiazepine toxicity, pharmacists, California, 1291
- Reimbursement**
- ethics; honoraria, authors, disclosure, *AJHP*, CP policies, 1168
- Medicaid; prescription drugs, pharmaceutical industry, laws, 114
- pharmacy, institutional; drug purchasing, Medicare regulations, 2434
- Religion**; patients; perflumamine-perflunafene dispensing vs. blood transfusions, Jehovah's Witness, ethics, 2176
- Replacement solutions**
- perflumamine, combination, perflunafene; pharmacists, dispensing, vs. blood transfusions, ethics, 2176
- snakebites; therapy, 2190
- Reports**
- American Society of Hospital Pharmacists; strategic planning, 1991-92, 1776
- drugs, adverse reactions; ASHP, JCAHO standards, 1428; concurrent vs. retrospective review, hospitals, 1974
- drugs, investigational; computer programs, hospital pharmacy, 2616
- errors, medication; hospitals, quality assurance, 2611; Medication Errors Reporting Program, USP role, 2559
- hospital pharmacy; clinical services documentation, 2647
- National Academy of Sciences; drug abuse programs, increased budget, recommendations, 13
- physicians; didanosine treatment IND protocols, AIDS therapy, 1299
- World Health Organization; pharmacists' role, health-care team, 391
- Research**
- antivirals; AIDS, HIV infections, NIH, 2662
- CD-4; binding, HIV, inhibition, 1300
- clinical pharmacists; hospitals, time studies, methodology, 1211
- clinical pharmacy; hospitals, staff development programs, 1704
- drug administration systems; technology, review, Oct suppl 514
- drugs; stability studies, publications, *AJHP* criteria, 1454
- drugs, investigational; AIDS therapy, 1296
- economics; chemical reagent sales, market predictions, 194
- Institutional Review Boards; quality assurance regulations, 72
- pediatrics; drug therapy, hospital pharmacists' role, guidelines, 2475
- pharmacists, institutional; involvement, ASHP guidelines, 1781
- Residencies**, see **Education**, **pharmaceutical**; **residencies**
- Residential-care facilities**; clinical pharmacists; personal-care homes, drug information, programs, 1530
- Resistance**
- cefotaxim; substitution, ampicillin-sulbactam, hospital pharmacy programs, 2150
- ciprofloxacin; hospitals, recommendations, 1892
- Respiratory smooth-muscle relaxants**; aminophylline; incompatibilities, ciprofloxacin, stability, storage, 2166
- Rifampin**; injections; reconstitution, precipitation, 2127
- Rubber**; gloves; surgical, quality control, FDA standards, 392
- S**
- Safety**
- antineoplastic agents; handling, training, hospital pharmacists, Kentucky, 119
- drugs, investigational; handling, material safety data sheets, 1679
- infusion pumps; effects, blood transfusions, 92
- Safflower oil**; combination, soybean oil; incompatibilities, nizatidine, stability, storage, 1507
- Salaries**; pharmacists, hospital; VA policies, postgraduate education, 732; staff development, administration, clinical services, 1956; survey, 249
- Sales**; reagents; chemical, clinics, physician offices, market predictions, 194
- Saline**, see **Sodium chloride**
- Sandoz**; clozapine; new distribution system, problems, 2336
- Saudi Arabia**; hospital pharmacy; services, U.S. Army, 533
- Schizophrenia**; tranquilizers; therapy, review, 1271
- Schools**
- health professions; educational programs, future health-care needs, 1639
- pharmacy; administrators, infusion pumps, attitudes, survey, Oct suppl 552; Chicago College of Pharmacy, establishment, 2562; contracts, hospitals, clinical services, clerkships, 1994; Lithuania, relationship, U.S., 1035; residencies, student information, programs, 1717
- Security**
- controlled substances; refrigeration, storage, JCAHO standards, 2368
- hospital pharmacy; controlled substances, VA hospitals, 2062
- Sex**; discrimination; women, environmental toxicity, cases, 1281
- Shampoos**; medicated; toxicity, policies, psychiatric facilities, 937
- Skeletal muscle relaxants**; succinylcholine chloride; stability, sterilization, storage, 501
- Smoking**; cigarettes; students, U.S., survey, 622
- Snakebites**; therapy, 2190
- Sociology**
- administrators; leadership effectiveness, interaction techniques, 2598
- drug abuse; pharmacists, employment considerations, 326
- health care; reform, need, U.S., 2133; outcome indicators, quality assurance, 1908
- HIV infections; hospital pharmacists' experiences, 148; pharmacists' experiences, 938
- pharmaceutical services; quality assurance, factors, guidelines, 1901
- pharmacists, hospital; professional relations, administrators, 1884
- pharmacy; specialties, conferences, 469; specialties, effects, manpower, future, 691; specialties, health care, politics, 487
- war; Operation Desert Storm, 467
- Sodium ascorbate**; incompatibilities; stainless steel filters, 1191
- Sodium benzoate**; effects; microbiological contamination, methadone solutions, 1252
- Sodium bicarbonate**
- incompatibilities; amrinone lactate, stability, i.v. admixtures, 1245
- therapy; pediatrics, nurse education, 97
- Sodium carbonate**; excipients; ceftazidime injections, effects, gas formation, 1727
- Sodium chloride**
- incompatibilities; cisplatin, stability, storage, 1500; haloperidol, concentration, stability, 1539; taxol, stability, storage, 1520; urokinase, stability, 1511; zidovudine stability, storage, 280
- vehicles; amrinone incompatibilities, i.v. admixtures, 1245; antipyrine-caffeine incompatibilities, lack, 1267; ciprofloxacin incompatibilities, stability, storage, 2166; doxorubicin injections, stability, storage, 1976; fluorouracil, incompatibilities, mannitol, 2158; methadone stability, storage, 515; ondansetron incompatibilities, i.v. admixtures, 988; phenytoin stability, pH variations, admixtures, 510
- Sodium nitroprusside**
- incompatibilities; haloperidol, stability, 1539
- therapy; pediatrics, nurse education, 97
- Software Reviews**, 596, 847, 1104, 1364, 1622, 2049, 2324
- Arrhythmias, 1364
- Athletic Drug Reference, 596
- Clinical Chemistry Quiz, 2049
- The Evaluator, 2324
- The Johns Hopkins Oncology Center's Narcotic Conversion Program, 1622
- Medicom Kinetics Consultant PC, Version 2.21, 2324
- Stedman's WordPerfect 5.0/5.1 Version, 847
- Therapeutic Drug Monitoring System, 1104
- USP Leaflet Diskette, Version 3.1, 2053
- Solutions**
- controlled substances; refractometry, screening, diversion, 2129
- dialysis; peritoneal, miconazole stability, 286
- dobutamine hydrochloride; peritoneal dialysis, stability, dextrose, 1234
- methadone hydrochloride; vehicles, stability, storage, 1252
- morphine sulfate; comparison, sustained-action tablets, costs, 131
- Solutions, ophthalmic**
- gentamicin sulfate; stability, concentration, storage, 507
- tobramycin sulfate; stability, concentration, storage, 507
- Sondalis Iso**; incompatibilities; cimetidine, stability, enteral nutrition, 1681
- Soybean oil**; alone and with safflower oil; incompatibilities, nizatidine, stability, storage, 1507
- Specialties**
- clinical pharmacists; career changes, 1998
- health professions; certification, administration, 476
- pediatrics; pharmacy guidelines, 2475
- pharmacy; conferences, 469; health care, politics, sociology, 487; history, recognition, 480; manpower, education, administration, conference recommendations, 712; manpower effects, economics, sociology, future, 691; nutrition support, certification, 2064; pharmaceutical education, U.S., 700; structure, development, 706
- psychopharmacy; need, 1185; petition, 1284
- residencies; pharmacy students, information programs, 1717
- Stability**
- amino acids; incompatibilities, ceftazidime, storage, 1515
- amphotericin B; incompatibilities, dextrose, concentration, storage, 2430; incompatibilities, dextrose injections, lack, concentration, 1681; incompatibilities, dextrose, i.v. admixtures, high concentration, 283; incompatibilities, dextrose, storage, 2635
- amrinone lactate; incompatibilities, cardiac drugs, i.v. admixtures, 1245
- antipyrine; incompatibilities, caffeine, storage, 1267
- caffeine; incompatibilities, antipyrine, storage, 1267
- carbamazepine; tablets, effects, moisture, temperature, 2130
- cefadroxil; suspensions, temperature, 992
- cefazolin sodium; incompatibilities, dextrose, peritoneal dialysis solutions, 291
- cefeperazone sodium; incompatibilities, cimetidine, 111; incompatibilities, fursemide, storage, 108
- cefotaxime sodium; incompatibilities, metronidazole, i.v. admixtures, 2638
- ceftazidime; incompatibilities, parenteral nutrition, storage, 1515

ceftriaxone sodium; incompatibilities, vancomycin, injections, precipitation, 77  
 cimetidine hydrochloride; incompatibilities, cefoperazone, 111; incompatibilities, enteral nutrition, lack, 1681; incompatibilities, methylprednisolone, 1237  
 ciprofloxacin; incompatibilities, injections, storage, 2166  
 cisplatin; decomposition products, effects, containers, pH, light, 1500  
 m-cresol; preservatives, human insulin, plastic syringes, storage, 2631  
 dexamethasone sodium phosphate; incompatibilities, diphenhydramine or hydromorphone, 2161  
 dextrose; complexes, procainamide, dissociation, in vitro, 2426; incompatibilities, ganciclovir, storage, 2641  
 diphenhydramine hydrochloride; incompatibilities, dexamethasone, concentration, 2161  
 dobutamine hydrochloride; incompatibilities, dextrose, peritoneal dialysis solutions, 1234  
 doxorubicin hydrochloride; storage, infusion pump reservoirs, 1976  
 drug information; compounding, pharmacists' needs, survey, 1205  
 drugs; handbooks, ASHP publications, reliability, 421; studies, publications, *AJHP* criteria, 1454  
 fat emulsions; incompatibilities, nizatidine, storage, 1507  
 fluconazole; incompatibilities, injections, storage, 744  
 fludarabine phosphate; incompatibilities, injections, 2186  
 fluorouracil; incompatibilities, mannitol, injections, lack, 2158  
 furosemide; incompatibilities, cefoperazone, storage, 108  
 ganciclovir sodium; incompatibilities, dextrose, storage, 2641; incompatibilities, TPN, concentration, 1538  
 gentamicin sulfate; ophthalmic solutions, concentration, storage, 507  
 haloperidol lactate; incompatibilities, vehicles, emergency drugs, 1539  
 human insulin; incompatibilities, plastic syringes, storage, temperature, 2631  
 hydromorphone hydrochloride; incompatibilities, dexamethasone, concentration, 2161; incompatibilities, tetracaine, injections, efficacy, 1682  
 idarubicin hydrochloride; incompatibilities, injections, pH, 2181  
 indomethacin sodium trihydrate; incompatibilities, injections, 2442  
 injections; incompatibilities, polyolefin containers, 2184  
 insulin human; incompatibilities, i.v. drugs, 125  
 magnesium chloride; tablets, unit dose packaging, 1266  
 meperidine hydrochloride; incompatibilities, i.v. injections, patient-controlled analgesia, 123  
 methadone hydrochloride; incompatibilities, beverages, 1 32; storage, photodecomposition, admixtures, 515  
 methylprednisolone sodium succinate; incompatibilities, cimetidine, 1237  
 metronidazole; incompatibilities, cefotaxime, storage, 2638  
 miconazole; incompatibilities, polyvinyl chloride, storage, 286  
 morphine sulfate; incompatibilities, i.v. injections, patient-controlled analgesia, 123  
 nizatidine; incompatibilities, fat emulsions, TPN, 1507  
 nutrition; parenteral, incompatibilities, ganciclovir, concentration, 1538; parenteral, incompatibilities, octreotide, storage, 2172  
 octreotide acetate; incompatibilities, TPN, storage, 2172  
 ondansetron hydrochloride; incompatibilities, i.v. admixtures, 988  
 oxybutynin chloride; syrups, unit dose packaging, 1265  
 phenol; preservatives, human insulin, plastic syringes, storage, 2631  
 phenytoin sodium; injections, pH variations, 510  
 polyolefin; containers, incompatibilities, injections, storage, 2184  
 procainamide hydrochloride; complexes, dextrose, dissociation, in vitro, 2426  
 propofol; incompatibilities, PVC, 2627  
 rifampin; injections, reconstitution, precipitation, 2127  
 sodium ascorbate; incompatibilities, stainless steel filters, 1191  
 sodium chloride; incompatibilities, haloperidol, con-

centration, 1539  
 sodium nitroprusside; incompatibilities, haloperidol, 1539  
 succinylcholine chloride; sterilization, storage, 501  
 taxol; incompatibilities, vehicles, containers, 1520  
 terbutaline sulfate; suspensions, compounding, storage, 293  
 tetracaine hydrochloride; incompatibilities, hydromorphone, injections, efficacy, 1682  
 tobramycin sulfate; human serum, storage, 520; ophthalmic solutions, concentration, storage, 507  
 urokinase; incompatibilities, vehicles, containers, 1511  
 vancomycin hydrochloride; incompatibilities, ceftriaxone, injections, precipitation, 77  
 zidovudine; admixtures, storage, 280  
**Staff development**  
 clinical pharmacy; hospitals, neonatal intensive-care unit, 1708  
 hospital pharmacy; TPN monitoring programs, 980  
 pharmacists, hospital; administration, clinical services, 1956; clinical services, programs, 1704  
**Standards**  
 American Society of Hospital Pharmacists; adverse drug reactions monitoring, reporting, 1428; sterile products, manufacturing, repackaging, 386  
 ambulatory care; services, ASHP guidelines, 311  
 clinical pharmacy; patient care, Missouri, 1257  
 drugs, investigational; institutional use, ASHP guidelines, 315  
 hospital pharmacy; surgery satellites, ASHP guidelines, 319  
 Joint Commission on Accreditation of Healthcare Organizations; adverse drug reactions monitoring, reporting, 1428; controlled substances, storage, refrigeration, 2368; dosage monitoring, clinical pharmacists, 1962; hospital pharmacy, clinical services, quality assurance, 1531; investigational drugs, hospitals, pharmacists' role, 61; pharmacist attitude, 1550; pharmacy inspections, ASHP attitudes, 914; policies and procedures, hospital pharmacy, 926; revision, Accreditation Manual for Hospitals, 434  
 laminar airflow; hoods, certification, 654  
 pharmaceutical services; quality assurance, development, 1901  
**State boards; pharmacy; regulations, patient consultation, pharmacists, 1291**  
**States; licensure; drug wholesalers, 2560**  
**Statistics**  
 pharmacists; Pharmacy Manpower Database Project, development, U.S., 50  
 pharmacists, hospital; U.S., 1990, 1868  
 prescription drugs; pricing, U.S., 1990, 1122  
**Sterile products**  
 compounding; hospital pharmacy, ASHP conferences, 2391; hospital pharmacy, U.S., survey, 2398; quality assurance, improvement, hospital pharmacy, 2387  
 manufacturing; repackaging, ASHP role, 386  
**Sterility**  
 antibiotics; tests, injections, USP methods, 2414  
 human insulin; incompatibilities, plastic syringes, 2631  
 nutrition; parenteral, tests, Septi-Chek, 2419  
 ophthalmic preparations; compounding guidelines, 2438  
 tests; sterile product compounding, hospital pharmacy survey, 2398  
**Sterilization**  
 drugs; sterile product compounding, hospital pharmacy survey, 2398  
 succinylcholine chloride; injections, stability, storage, 501  
**Steroids, cortico-**  
 dexamethasone sodium phosphate; incompatibilities, diphenhydramine or hydromorphone, stability, 2161  
 methylprednisolone sodium succinate; incompatibilities, cimetidine admixtures, 1237  
**Storage**  
 acetazolamide; suspensions, temperature, stability, 1241  
 amphotericin B; incompatibilities, dextrose, concentration, stability, 2430; incompatibilities, dextrose, lack, concentration, 1681; incompatibilities, dextrose, stability, 2635; incompatibilities, dextrose, stability, high concentration, 283  
 antipyrine; incompatibilities, caffeine, stability, 1267  
 caffeine; incompatibilities, antipyrine, stability, 1267  
 carbamazepine; stability, tablets, effects, moisture, temperature, 2130  
 cefadroxil; suspensions, stability temperature, 992  
 cefazolin sodium; incompatibilities, dextrose, peritoneal dialysis solutions, 291

cefoperazone sodium; incompatibilities, cimetidine, temperature, 111; incompatibilities, furosemide, stability, 108  
 cefotaxime sodium; incompatibilities, metronidazole, i.v. admixtures, 2638  
 ceftazidime; incompatibilities, parenteral nutrition, stability, 1515; injections, formulations comparison, gas formation, 1727  
 cephalosporins; serum incompatibilities, tobramycin, lack, 520  
 cimetidine hydrochloride; incompatibilities, cefoperazone, temperature, 111; incompatibilities, enteral nutrition, lack, 1681; incompatibilities, methylprednisolone, stability, 1237  
 ciprofloxacin; incompatibilities, injections, stability, 2166  
 cisplatin; stability, decomposition products, effects, pH, light, 1500  
 controlled substances; refrigeration, JCAHO standards, 2368  
 dextrose; incompatibilities, ganciclovir, stability, 2641; stability, dobutamine, peritoneal dialysis solutions, 1234  
 dobutamine hydrochloride; stability, dextrose, peritoneal dialysis solutions, 1234  
 doxorubicin hydrochloride; infusion pump reservoirs, stability, 1976  
 fat emulsions; incompatibilities, nizatidine, stability, 1507  
 fluconazole; incompatibilities, injections, stability, 744  
 furosemide; incompatibilities, cefoperazone, stability, 108  
 ganciclovir sodium; incompatibilities, dextrose, stability, 2641  
 gentamicin sulfate; temperature, stability, ophthalmic solutions, 507  
 hydromorphone hydrochloride; incompatibilities, tetracaine, injections, stability, efficacy, 1682  
 injections; incompatibilities, polyolefin containers, storage, 2184  
 insulin human; incompatibilities, plastic syringes, stability, sterility, 2631  
 magnesium chloride; tablets, unit dose packaging, stability, 1266  
 methadone hydrochloride; incompatibilities, beverages, stability, 1252; stability, photodecomposition, 515  
 methylprednisolone sodium succinate; incompatibilities, cimetidine, stability, 1237  
 metronidazole; incompatibilities, cefotaxime, i.v. admixtures, 2638  
 miconazole; incompatibilities, polyvinyl chloride, stability, 286  
 nizatidine; incompatibilities, TPN, stability, 1507  
 nutrition; parenteral, incompatibilities, ceftazidime, stability, 1515; parenteral, incompatibilities, nizatidine, stability, 1507  
 octreotide acetate; incompatibilities, TPN, stability, 2172  
 oxybutynin chloride; syrups, unit dose packaging, stability, 1265  
 propofol; incompatibilities, PVC, 2627  
 rifampin; injections, reconstitution, precipitation, 2127  
 sodium ascorbate; incompatibilities, stainless steel filters, 1191  
 succinylcholine chloride; stability, injections, 501  
 taxol; incompatibilities, vehicles, containers, 1520  
 terbutaline sulfate; suspensions, stability, compounding, 293  
 tetracaine hydrochloride; incompatibilities, hydromorphone, injections, stability, efficacy, 1682  
 tobramycin sulfate; serum incompatibilities, cephalosporins, lack, 520; temperature, stability, ophthalmic solutions, 507  
 zidovudine; incompatibilities, vehicles, stability, admixtures, temperature, 280  
**Strategic planning; American Society of Hospital Pharmacists; reports, 1991-92, 1776**  
**Student and Resident Forum, 54, 228, 442, 664, 1671, 1878, 2114**  
 Beginning clinical clerkships, 1671  
 Choices confronting the December graduate in search of residency training, 54  
 Opportunities for pharmacy students at the ASHP Annual Meeting, 664  
 Preparing manuscripts based on clinical seminars, 442  
 Presenting the findings of residency projects in poster sessions or platform sessions, 228  
 Special opportunities for students and residents at the 1991 Midyear Clinical Meeting, 2114  
 Why pursue a residency? 1878

- Students:** drug abuse; U.S., survey, 622
- Substitution:** therapeutic; ampicillin-sulbactam for cefoxitin, hospital pharmacy, 2150; cefixime for cefixitin, programs, 2655; hospital pharmacy programs, 1471
- Succinylcholine chloride:** stability; sterilization, storage, 501
- Sucrose:** vehicles; terbutaline suspensions, stability, compounding, 293
- Sulbactam**  
combination, ampicillin; prescribing, use, formulary inclusion, 1492; substitution for cefixitin, hospital pharmacy programs, 2150
- Sulfamethoxazole:** combination, trimethoprim; incompatibilities, fluconazole, injections, 744
- Surgical supplies**  
administration sets; devices, i.v. rate, posture effects, 2422; incompatibilities, taxol, 1520; polyvinyl chloride, incompatibilities, urokinase, 1511; PVC, incompatibilities, propofol, 2627  
convalescent aids; durable medical equipment, home care, vendor exclusivity, legal issues, 1542  
gloves; quality, control, FDA standards, 392
- Suspensions**  
acetazolamide; stability, temperature, storage, 1241  
cefadroxil; stability, temperature, 992  
compounding; drug information needs, pharmacists, survey, 1205  
terbutaline sulfate; stability, compounding, 293
- Sustained-action medications:** morphine sulfate; comparison, solutions, costs, 101
- Sympathomimetic agents**  
asthma; therapy, pentamidine toxicity, AIDS, 556  
dobutamine; incompatibilities, indomethacin, stability, 2442  
dobutamine hydrochloride; incompatibilities, dextrose, peritoneal dialysis solutions, 1234  
dopamine; incompatibilities, indomethacin, stability, 2442  
incompatibilities; haloperidol, injections, stability, 1539  
terbutaline sulfate; suspensions, stability, compounding, storage, 293
- Syringes**  
glass; incompatibilities, vehicles, containers, 1511  
ophthalmic preparations; compounding, sterility, guidelines, 2438  
plastics; cisplatin stability, effects, pH, light, 1500; incompatibilities, human insulin, stability, storage, 2631  
polypropylene; incompatibilities, urokinase, adsorption, lack, 1511  
prefilled; fat emulsions, cost-benefit analysis, neonates, 1972
- Syrups:** oxybutynin chloride; unit dose packaging, stability, 1265
- T**
- Tablets**  
carbamazepine; stability, effects, moisture, temperature, 2130  
levothyroxine sodium; contamination, diethyl phthalate desiccants, 735  
magnesium chloride; unit dose packaging, stability, 1266
- Tampering**  
controlled substances; injections, detection, refractometry, 1488; screening, refractometry, 2129
- Taxol:** incompatibilities; vehicles, containers, stability, storage, 1520
- Team:** health care; hospital pharmacists' participation, effects, costs, 1457
- Technicians, pharmacy:** see **Personnel, pharmacy; supportive**
- Technology**  
drug administration systems; research, review, Oct suppl 514  
hospital pharmacy; impact, review, Oct suppl 524; issues, U.S., 1990, review, 720  
pharmaceutical services; quality assurance, factors, guidelines, 1901
- Telecommunications:** electronic bulletin boards; PharmNet, access information, advantages, 1174
- Tetanus**  
acetazolamide; suspensions, stability, storage, 1241  
amphotericin B; incompatibilities, dextrose, concentration, storage, 2430; incompatibilities, dextrose, stability, high concentration, 283; incompatibilities, dextrose, stability, storage, 2635  
antipyrine; incompatibilities, caffeine, stability, storage, 1267  
caffeine; incompatibilities, antipyrine, stability, storage, 1267  
carbamazepine; tablets, stability, 2130  
cefadroxil; suspensions, stability, storage, 992  
cefazolin sodium; incompatibilities, dextrose, peritoneal dialysis solutions, 291  
cefoperazone sodium; incompatibilities, cimetidine, stability, 111; incompatibilities, furosemide, stability, storage, 108  
cefotaxime sodium; incompatibilities, metronidazole, storage, 2638  
ceftazidime; formulations comparison, storage, gas formation, 1727; incompatibilities, parenteral nutrition, storage, 1515  
cimetidine hydrochloride; incompatibilities, cefoperazone, stability, 111; stability, injections, enteral nutrition, 1681; stability, methylprednisolone admixtures, 1237  
ciprofloxacin; incompatibilities, injections, stability, storage, 2166  
dextrose, stability, dobutamine, peritoneal dialysis solutions, 1234  
dobutamine hydrochloride; stability, dextrose, peritoneal dialysis solutions, 1234  
doxorubicin hydrochloride; infusion pump reservoirs, stability, storage, 1976  
furosemide; incompatibilities, cefoperazone, stability, storage, 108  
ganciclovir sodium; incompatibilities, dextrose, stability, storage, 2641  
gentamicin sulfate; storage, stability, ophthalmic solutions, 507  
human insulin; incompatibilities, plastic syringes, stability, storage, 2631  
hydromorphone hydrochloride; incompatibilities, tetracaine, injections, stability, efficacy, 1682  
injections; incompatibilities, polyolefin containers, storage, 2184  
methadone hydrochloride; incompatibilities, beverages, stability, storage, 1252; stability, storage, admixtures, 515  
methylprednisolone; stability, cimetidine admixtures, 1237  
metronidazole; incompatibilities, cefotaxime, storage, 2638  
nutrition; parenteral, incompatibilities, ceftazidime, storage, 1515  
octeotide acetate; incompatibilities, TPN, storage stability, 2172  
succinylcholine chloride; sterilization, storage, stability, 501  
terbutaline sulfate; suspensions, stability, storage, 293  
tetracaine hydrochloride; incompatibilities, hydromorphone, injections, stability, efficacy, 1682  
tobramycin sulfate; storage, human serum, stability, 520; storage, stability, ophthalmic solutions, 507  
zidovudine; stability, admixtures, 280
- Teratogenicity:** drugs; environmental toxicity, pregnant employees, 1281
- Terbutaline sulfate:** stability; sucrose vehicles, compounding, 293
- Tests**  
gloves; surgical, quality control, FDA standards, 392  
sterile products; compounding, quality assurance, 2387  
sterility; sterility; antibiotics, injections, USP methods, 2414; TPN, Septi-Chek, 2419
- Tests, laboratory**  
lithium; blood levels, protocols, hospital pharmacy, 1536  
reagents; chemicals, purchasing, market predictions, 194  
toxicity, environmental; antineoplastic agents, chromosomal damage, 1199
- Tetanus toxoids:** snakebites; therapy, 2190
- Tetracaine hydrochloride:** incompatibilities; hydromorphone, injections, stability, efficacy, 1682
- Therapeutic interchange:** see **Substitution; therapeutic**
- Thyroid drugs:** levothyroxine sodium; tablets, contamination, diethyl phthalate desiccants, 735
- Ticarcillin:** incompatibilities; fluconazole, injections, stability, 744
- Time studies**  
clinical pharmacists; services, hospitals, methodology, 1211  
compounding; TPN, computer programs, hospital pharmacy, 270  
drug distribution systems; bar codes, satellite pharmacy, 953  
hospital pharmacy; fax equipment, i.v. admixtures, 2653  
inventory; control, hospital pharmacy, bar codes vs. manual method, 1259  
morphine sulfate; dispensing, dosage forms, costs, 101  
pharmacists, hospital; medication order clarification, forms, documentation, 2649
- Tobramycin sulfate**  
incompatibilities; ciprofloxacin, stability, storage, lack, 2166  
interactions; cephalosporins, blood levels, 520  
solutions, ophthalmic; stability, concentration, storage, 507
- D,  $\alpha$ -tocopheryl acetate:** intravenous; unapproved marketing, criminal convictions, 747
- Topical preparations:** compounding; drug information needs, pharmacists, survey, 1205
- Toxicity**  
see also **Drugs, adverse reactions**  
analgesics and antipyretics; epidural injections, side effects, 2460  
benzodiazepines; patient consultation, pharmacists, 1291  
didanosine; side effects, AIDS therapy, 1298  
drugs; dosage monitoring, kidney failure, hospital pharmacy computers, 1965; patient compliance, education, 1978  
drugs, investigational; material safety data sheets, handling, 1679  
foscarnet sodium, comparison, ganciclovir sodium; side effects, 2478  
ganciclovir sodium, comparison, foscarnet sodium; side effects, 2478  
megestrol acetate; side effects, 2479  
penicillin G benzathine; medication errors, pediatrics, litigation, 1989  
pentamidine isethionate; aerosols, asthma, AIDS, 556  
perfluoramine, combination, perflunafene; blood substitutes, pharmacists, ethics, 2176  
shampoos; medicated, psychiatric facilities policies, 937  
D,  $\alpha$ -tocopheryl acetate; i.v., unapproved marketing, criminal convictions, 747  
tranquilizers; side effects, 1271  
transplantation; bone marrow, side effects, 127
- Toxicity, environmental**  
antihemophilic factor; HIV transmission, hospital pharmacists, 148  
antineoplastic agents; chromosomal damage, pharmacists, nurses, patients, 1199; hospital pharmacists, training, Kentucky, 119  
drugs, investigational; safe handling, material safety data sheets, 1679  
lead; cases, sex discrimination, women, 1281  
muromonab CD3; compounding, adverse reactions, topical exposure, 1442  
pentamidine isethionate; aerosols, health professions, 557  
waste disposal; pharmacy recycling programs, 118
- Tranquilizers**  
clozapine; distribution, treatment systems, problems, 2336; therapy, 1271  
haloperidol lactate; incompatibilities, sodium chloride, sodium nitroprusside, 1539  
incompatibilities; fluconazole, injections, stability, 744  
schizophrenia; therapy, review, 1271
- Transplantation**  
bone marrow; therapy, toxicity, 127  
heart; ethics, patient's suitability, pharmacist's role, 740
- Transplantin:** decomposition products; cisplatin, pH, light, 1500
- Trichloroamineplatinate(III):** decomposition products; cisplatin, pH, light, 1500
- Trimethoprim:** combination, sulfamethoxazole; incompatibilities, fluconazole, injections, 744
- Trophamine:** incompatibilities; indomethacin, injections, stability, 2442
- Tuberculosis:** toxicity, environmental; pentamidine, aerosols, AIDS, 557
- U**
- United States**  
drug abuse; programs, increased budgets, recommendations, 13; students, survey, 622  
education, pharmaceutical; specialties, practice, 700  
health care; committees, 102nd Congress, list, 862; future, health professions, educational programs, 1639; home, cost-effectiveness, need, regulations, 2548; problems, need for reform, 2133  
hospital pharmacy; practice, issues, 1990, review, 720  
sterile products, compounding, conferences, 2391; sterile products, compounding, policies, 2398

## Annual Index

litigation; cases, unapproved drug marketing, criminal convictions, 747  
 military; pharmacists' role, Operation Desert Storm, 467  
 pharmacists; licensure, regulations, continuing education, 2560  
 pharmacists, hospital; manpower, statistics, 1990, 1868; salaries, survey, 249  
 pharmacy; manpower, Pharmacy Manpower Database Project, development, 50; schools, relationships, Lithuania, 1035  
 prescription drugs; pricing, 1990, 1122  
 psychiatric facilities; pharmaceutical services, survey, 967  
**United States Air Force;** pharmacists, hospital; mailing addresses, Operation Desert Storm, 458  
**United States Army**  
 hospital pharmacy; services, Saudi Arabia, 533  
 pharmacists, hospital; mailing addresses, Operation Desert Storm, 458  
**United States Navy**  
 hospital pharmacy; ships, Persian Gulf, 530, 730  
 pharmacists, hospital; mailing addresses, Operation Desert Storm, 458  
**United States Olympic Committee;** drugs; banned, list, 76  
**United States Pharmacopeia;** tests; sterility, antibiotics, injections, 2414  
**United States Pharmacopeial Convention;** role; Medication Errors Reporting Program, 2562  
**United States v. Hiland;** cases; unapproved drug marketing, criminal convictions, 747  
**Urokinase;** incompatibilities; vehicles, containers, adsorption, 1511  
**USP Dispensing Information; Drug Information for the HealthCare Professional;** Dental Precaution Listing, sources, reliability, 1447

## V

**Vaccines**  
 biotechnology; pharmacy practice effects, Oct suppl 54  
 influenza; immunization, geriatric outpatients, hospi-

tal pharmacists' role, 256  
**Vancomycin;** enterocolitis; pseudomembranous, therapy, decision analysis, 1477  
**Vancomycin hydrochloride;** incompatibilities; ceftriaxone, injections, precipitation, 77  
**Vehicles**  
 cardioplegic solutions; formulations, compounding, review, 2444  
 ciprofloxacin; incompatibilities, injections, stability, storage, 2166  
 dextrose; amphotericin B, stability, high concentration, 283; amrinone stability, incompatibilities, cardiac drugs, 1245; cimetidine-methylprednisolone stability, admixtures, 1237; dobutamine stability, peritoneal dialysis solutions, 1234; fluorouracil, incompatibilities, mannitol, injections, lack, 2158; incompatibilities, amphotericin B, injections, 1681; incompatibilities, amphotericin B, stability, storage, 2635; incompatibilities, ganciclovir, stability, storage, 2641; incompatibilities, taxol, stability, storage, 1520; incompatibilities, urokinase, stability, 1511; zidovudine stability, admixtures, storage, 280  
 incompatibilities; methadone, oral, stability, 1252  
 sodium chloride; amrinone stability, incompatibilities, cardiac drugs, 1245; antipyrine-caffeine incompatibilities, stability, storage, 1267; doxorubicin injections, stability, storage, 1976; fluorouracil, incompatibilities, mannitol, injections, lack, 2158; incompatibilities, haloperidol, stability, 1539; incompatibilities, taxol, stability, storage, 1520; incompatibilities, urokinase, stability, 1511; methadone stability, storage, 515; phenytoin stability, pH variations, 510; zidovudine stability, admixtures, storage, 280  
 sucrose; terbutaline suspensions, compounding, 293  
**Vendors;** devices; medical, home care, exclusive contracts, legal issues, 1542  
**Verapamil;** formularies; selection models, multiattribute utility theory, 301  
**Verapamil hydrochloride;** incompatibilities; amrinone lactate, stability, i.v. admixtures, 1245  
**Vitamins**  
 sodium ascorbate; incompatibilities, stainless steel filters, 1191

D,  $\alpha$ -tocopheryl acetate; unapproved marketing, i.v., criminal convictions, 747

## W

**Washington;** litigation; drug administration, prisoner consent, 309  
**Washington v. Harper;** litigation; drug administration, prisoner consent, 309  
**Waste disposal**  
 hospital pharmacy; recycling programs, 6  
 pharmacy; intravenous therapy, recycling, 118  
**Water;** absorption; magnesium tablets, unit dose packaging, 1266  
**Wholesalers**  
 licensure; legislation, state activities, 2560  
 purchasing; drugs, selection, ASHP guidelines, 523  
**Women**  
 discrimination; environmental toxicity, 1281  
 pharmacists; hours, part-time, administration, 85  
**Workload**  
 clinical pharmacists; forms, documentation, cost-benefit analysis, 1467; methodology, 1211  
 hospitals; morphine sustained-action tablets, comparison, solutions, 101  
 nurses; forms, controlled substances, monitoring, 1262  
 pharmacists; home health care, i.v. therapy, databases, 1535  
 pharmacists, hospital; clinical, quality assurance, peer review, 1531  
**World Health Organization;** reports; pharmacists' role, health-care team, 391

## Z

**Zidovudine**  
 acquired immunodeficiency syndrome; dosage schedules, research, 1296  
 incompatibilities; admixtures, storage, temperature, 280

## Author Index

### A

**Abel, Steven R.** Affordability of cimetidine (letter), 943  
**Abramowitz, Michael** Paying the price for home care: costs are lower than at hospitals, but lack of regulation raises concerns (News), 2548  
**Abramowitz, Paul W.** see Seidel, Ann M., 270  
**Ahalt, Patricia A.** see Nahata, Milap C., 291  
**Akers, Michael J.** Sterility testing of antimicrobial-containing injectable solutions prepared in the pharmacy, 2414  
**Aldous, Stephen** see Holmes, Sandra E., 286  
**Alexander, Kenneth S.** Stability of acetazolamide in suspension compounded from tablets, 1241  
**Algozzine, Gary J.** see Caselnova, Dominick A. III, 1260  
**Allen, Loyd V. Jr.** see Stiles, M. Lou, 1727, 1976  
**Allington, Douglas R.** see Pennell, Andrew T., 520  
**Alvarez, Mar** see Calvo, M. Victoria, 1190  
**Anantea, Michael A.** Role of CD4 in HIV infection and therapy, 1300  
**Anderson, Eric R.** Opportunities for pharmacy students at the ASHP Annual Meeting (Student and Resident Forum), 664  
**Anderson, Eric R.** Special opportunities for students and residents at the 1991 Midyear Clinical Meeting (Student and Resident Forum), 2114  
**Anderson, Robert J.** Clinical service contracts between hospital pharmacy departments and colleges of pharmacy, 1994  
**Anderson, Roger W.** Idarubicin hydrochloride dosing guidelines might cause confusion (letter), 72  
**Anderson, Roger W.** see also Kwan, Jane W., Oct suppl 552  
**Anderson, Roger W.** see also Raiford, Elizabeth Dykes, 1948  
**Angaran, David M.** Quality assurance to quality improvement: measuring and monitoring pharmaceutical care, 1901

Selecting, developing, and evaluating indicators, 1931  
**Arkin, William W.** see Goughnour, Barry R., 101  
**Armistead, John A.** see Ivey, Marianne F., 2605  
**Armistead, John A.** see also Lobas, Nancy H., 1708  
**Armistead, John A.** see also Rosenbaum, Cathy L., 2154  
**ASHP Government Affairs Division** Summary of 1990 Medicaid drug rebate legislation, 114  
**Augustine, Sam C.** see Crawford, Stephanie Y., 2398  
**Avila, Juan R.** Thanks for the educational opportunity (letter), 2131

### B

**Baardsgaard, Gary** see Goldberg, Dean E., 1965  
**Bagby, Larry M.** see Summerfield, Marc R., 1463  
**Bailey, Leonard C.** Effect of syringe filter and i.v. administration set on delivery of propofol emulsion, 2627  
**Bair, Jan N.** see Guerrero, Rawley M., 249  
**Baldwin, H. John** Providing medication information as a professional obligation (letter), 77  
**Baldwin, Jeffrey N.** Book review, 1104  
**Baptista, Richard J.** see Mitrano, Francis P., 2635  
**Baptista, Richard J.** see also Outman, William R., 1538  
**Baptista, Richard J.** see also Silvestri, Anthony P., 2641  
**Barker, Kenneth N.** see Buchanan, Terry L., 2137  
**Barriere, Steven L.** Avoid Las Vegas as a meeting site for ASHP (letter), 939  
**Barriere, Steven L.** Formulary evaluation of second-generation cephamycin derivatives using decision analysis, 2146  
**Barthès, Danièle M. C.** see Rochard, Eric B., 1681  
**Batz, Forrest R.** Attitudes among Department of Veterans Affairs pharmacists toward postgraduate educa-

tion and training, 732  
**Bauwens, Steven F.** Book review, 1364  
**Bay, William** see Gora, Mary Lea, 1234  
**Beck, Shawn M.** see Swanson, Kathleen M., 1956  
**Bekker, Rhonda Eddy** see Avila, Juan R., 2131  
**Benedere, Katherine** see Smith, William E., 540, 1690  
**Benedict, Michael V.** Facsimile transmission of i.v. drug orders, 2653  
**Beresford, Rosemary** see Murphy, John E., 553  
**Berg, Jeffrey A.** Diethyl phthalate not dangerous (letter), 1448  
**Berger, Philip K.** see Sauer, Karen Ann, 119  
**Berman, Stephen M.** see Nakasato, Shariene K., 2440  
**Bermann, Lynaia** see Lawrenz, Candace A., 2150  
**Berod, Thierry** Resolving problems in the use of omeprazole (letter), 2382  
**Bickley, Susan K.** see Kirking, Duane M., 1722  
**Biedron, Greg** see Wojtynek, Jeff, 1679  
**Birdwell, Stephen W.** see Govern, Vicki L., 1228  
**Black, Arthur H.** see Black, Curtis D., 2532  
**Black, Beverly L.** see Liang, Fern Z., 2434  
**Black, Curtis D.** Book review, 2532  
**Black, Harold J.** Book review, 594  
**Black, Marilyn C.** see Black, Curtis D., 2532  
**Blake, Anne** see Vogel, David, 1878  
**Bleidt, Barry A.** see Montagne, Michael, 1035  
**Blum, Benjamin M.** see Grilley, Bambi J., 2616  
**Boatwright, Deborah E.** Safe use of benzodiazepines and other drugs: the pharmacist's duty to counsel, 1291  
**Bond, William S.** Detection methods and strategies for improving medication compliance, 1978  
**Bostrom, Bruce** see Seay, Russell, 945  
**Brace, Steven R.** Software review, 2324  
**Brandell, Renee** see Meyer, Gerald E., 953  
**Britton, Mark L.** Impact of medication profile review on prescribing in a general medicine clinic, 265  
**Brodie, Donald C.** The theoretical base of pharmacy, 536



- Brouard, Agnès H<sub>2</sub>-receptor antagonists and acute intermittent porphyria (letter), 1190
- Brouard, Agnès Switching from enalapril to lisinopril (letter), 2605
- Brouker, Mark E. Pharmaceutical services in the casualty reception area on the USNS *Comfort*, 730
- Brouker, Mark E. Pharmacy operations aboard a Navy hospital ship, 530
- Brown, Glen Assessing the clinical impact of pharmacists' interventions, 2644
- Brown, Thomas R. see Monk, Mary R., 464
- Brown-Son, Paula M. Environmental protection efforts by a home-care pharmacy, 118
- Brucker, Paul Jr. see Meyer, Gerald E., 953
- Brundage, Mary Lourdes see Chrymko, Margaret M., 230
- Brushwood, David B. Criminal conviction for distribution of a drug not approved by the FDA, 747
- Brushwood, David B. More to the E-Ferol case than presented (letter), 1894
- Brushwood, David B. State's right to treat a prisoner forcibly with antipsychotic drugs without a judicial hearing, 309
- Brushwood, David B. Women of childbearing capacity may not be excluded from working with hazardous substances because of their gender, 1281
- Buchanan, Clyde Book review, 2045
- Buchanan, Terry L. Illumination and errors in dispensing, 2137
- Buck, Gary W. Interaction of sodium ascorbate with stainless steel particulate-filter needles (letter), 1191
- Buice, Robert G. Book review, 596
- Bungay, Kathleen M. see Gouveia, William A., 1912
- Burch, Kelly J. Effect of an infusion device on the integrity of whole blood and packed red blood cells, 92
- Burkley, Wayne S. Affordability of cimetidine (letter), 945
- Burnakis, Thomas G. Translating mainframe computer data to spreadsheet format, 2619
- Burnakis, Thomas G. see Schweyen, Deborah H., 1536
- Burnett, Richard J. Physical stability of repackaged enteric-coated magnesium chloride tablets, 1266
- Byerly, Wesley G. Adverse reaction from topical exposure to muromonab-CD3 (letter), 1442
- Bynum, Lincoln see Mayo, Martha, 2128

## C

- Cafmeyer, Nancy R. Diethyl phthalate not dangerous (letter), 1448
- Cafmeyer, Nancy R. Possible leaching of diethyl phthalate into levothyroxine sodium tablets, 735
- Calvert, Robert T. see Cooke, Jonathan, 1199
- Calvo, M. Victoria H<sub>2</sub>-receptor antagonists and acute intermittent porphyria (letter), 1190
- Campbell, R. Keith see Tarr, Bryan D., 2631
- Canafax, Daniel M. see Carleton, Bruce C., 2422
- Cano, Steven B. Book review, 838
- Carey, Glen Jr. see Burnett, Richard J., 1266
- Carey, Donald F. Jr. Gentamicin dosing services in the absence of 24-hour pharmaceutical services (letter), 681
- Carleton, Bruce C. Method for evaluating drip-rate accuracy of intravenous flow-regulating devices, 2422
- Carlson, Kimberly A. see Akers, Michael J., 2414
- Carr, Linda J. see Patel, Jitendra P., 1511
- Carver, Peggy L. see Barriere, Steven L., 939
- Case, Barbara Use of an algorithm to evaluate published reports of adverse drug reactions, 121
- Caselnova, Dominick A. III A nontraditional approach to internship programs, 1260
- Chakhtoura, Fady see Berod, Thierry, 2382
- Chandler, Mary H. H. see Pennell, Andrew T., 520
- Chase, Patricia A. Controlling investigational drug use in community hospitals (Management Consultation), 61
- Chase, Patricia A. Coping with administrative turnover (Management Consultation), 2372
- Chase, Patricia A. Quality assurance for the JCAHO standards, 1550
- Chase, Patricia A. Transforming policies and procedures from burden to boon (Management Consultation), 926
- Cheung, Jolly F. Use of refractometers to detect controlled-substance tampering, 1488
- Chong, Saeho see Cheung, Jolly F., 1488
- Chrymko, Margaret M. How to build and organize a personal reference library (How To), 230
- Chrymko, Margaret M. How to do a performance appraisal (How To), 2600
- Ciancio, Sebastian G. Dental precaution listing needs

improvement (letter), 1447

- Cipolle, Robert J. see Carleton, Bruce C., 2422
- Cipolle, Robert J. see also Strand, Linda M., 547
- Clark, H. Westley see Boatwright, Deborah E., 1291
- Clark, Steven T. Book review, 1831
- Clark, Toby see Raiford, Elizabeth Dykes, 1948
- Cleary, John D. Automatic stop-order procedure for antibiotics needs evaluation (letter), 2602
- Cleary, John D. see also Barriere, Steven L., 939
- Clyne, Kurt E. Responding to a physician's request to mislabel a patient's prescription. Position 1: pharmacist should not mislabel medication, 296
- Coffey, Robert P. Effect of blood and serum on *in vitro* antibacterial activity of nitrofurazone, 1496
- Cole, Philip see Lawrenz, Candace A., 2150
- Colucci, Vince J. see Peterson, John P., 1962
- Coniglio, Mary see Meyer, Gerald E., 953
- Conort, Ornella see Brouard, Agnès, 1190, 2605
- Constance, Thomas D. see Burch, Kelly J., 92
- Contos, Rick Software review, 2324
- Cook, Richard L. see Lawrenz, Candace A., 2150
- Cooke, Jonathan Use of cytogenetic methods to determine mutagenic changes in the blood of pharmacy personnel and nurses who handle cytotoxic agents, 1199
- Cooke, Patricia see Cooke, Jonathan, 1199
- Coons, Stephen Joel see Sauer, Karen Ann, 119
- Cooper, Rhonda M. see Murgatroyd, Rebecca J., 2651
- Coté, David Pharmacy manager need not be pharmacist (letter), 2384
- Cotterell, Carey C. Comprehensive drug-use evaluation program in a health maintenance organization, 1712
- Courtois, Philippe Y. see Rochard, Eric B., 1681
- Coville, Peter F. see Murphy, John E., 553
- Cowen, David L. Book review, 847
- Cozonitis, Dimitri A. Let's forget (letter), 1689
- Cramer, Richard L. Caution advised with quality assurance consultants (letter), 1891
- Crane, Vicki S. Pharmacy participation in exit interviews (Management Consultation), 1433
- Crane, Vicki S. see also Holbein, M. E. Blair, 236
- Crawford, Stephanie Y. The ASHP national survey's definition of community hospitals (Questions and Answers), 1668
- Crawford, Stephanie Y. Extemporaneous compounding activities and the associated informational needs of pharmacists, 1205
- Crawford, Stephanie Y. FDA's role in drug product recalls (Questions and Answers), 2595
- Crawford, Stephanie Y. National survey of quality assurance activities for pharmacy-prepared sterile products in hospitals, 2398
- Crawford, Stephanie Y. Requirements for certifiers of biological-safety cabinets (Questions and Answers), 654
- Crews, James C. see Denson, Donald D., 515
- Crismon, M. Lynn see Ginsburg, Diane B., 2537
- Cummins, Britt A. Software review, 1104
- Cummins, Britt A. see also Benedict, Michael V., 2653

## D

- Dansereau, Raymond N. New ruling unfair to nuclear pharmacists (letter), 235
- Davis, Steven M. Benefits of training Pharm.D. students (letter), 240
- DeAngelis, Carlo see Walker, Scott E., 2161
- DeFlorio, Martin G. see Horvath, Michael A., 518
- Delfino Daria Pharmacists in New York say mandatory unit dose law will upgrade practice, patient care despite temporary challenges, 1374
- Denger, Sharon D. see Hartwig, Steven C., 2611
- Denson, Donald D. Stability of methadone hydrochloride in 0.9% sodium chloride injection in single-dose plastic containers, 515
- Djuric, Michael see Donnelly, Andrew J., 2444
- Dombrowski, Leona see Cotterell, Carey C., 1712
- Dombrowski, Susan R. Reliability of stability, compatibility, and compounding data in ASHP handbooks (Questions and Answers), 421
- Dombrowski, Susan R. Use of ASHP publications by pharmacy students (Questions and Answers), 2102
- Dombrowski, Susan R. see also Crawford, Stephanie Y., 1205
- Dominguez-Gil, Alfonso see Calvo, M. Victoria, 1190
- Donnelly, Andrew J. Cardiology solutions, 2444
- Dozier, Nicky see Anderson, Roger W., 72
- Dudley, Michael N. see Barriere, Steven L., 939
- Durthaler, Jeffrey M. see Avila, Juan R., 2131
- Durthaler, Jeffrey M. see also Turowski, Robert C., 2181

## E

- Ebert, Steven C. see Barriere, Steven L., 939
- Edgren, Bruce E. see Seay, Russell E., 1972
- Ehresman, David see Markowsky, Susan J., 510
- El-Chaar, Gladys M. see Wiest, Donald B., 2430
- Ellinoy, Brian J. Pharmacy needs a computer-rating group (letter), 938
- Ellis, Brian see Murphy, John E., 553
- Engle, Janet P. Leadership and professionalism in pharmacy, 1559
- Enright, Sharon Murphy Quality and outcome: pharmacy's professional imperative, 1908
- Ensor, Patricia A. How many hospital pharmacists? (Questions and Answers), 1868
- Eppel, J. Gary see Walker, Scott E., 2161
- Erenberg, Allen see Strayer, Andy H., 1970
- Evans, R. Lee see Sommi, Roger W., 1185

## F

- Faber, Elisabet M. Program for training staff pharmacists in total parenteral nutrition, 980
- Fant, William K. see Rosenbaum, Cathy L., 2154
- Fazio, Anthony see Lisi, Donna M., 987
- Fenninger, Leonard D. Directions for specialization in pharmacy practice, part 1. Specialization and specialty recognition in the healing professions, 476
- Ferguson, Lori see Paine, Fred J., 236
- Figge, Helen L. see Smith, Thomas A. II, 2190
- Finley, Rebecca S. Book review, 2710
- Fiscella, Richard G. Book review, 1103
- Fischermann, Edward A. see Cotterell, Carey C., 1712
- Fisher, William C. see Batz, Forrest R., 732
- Flagstad, Michael S. Assuming responsibility for improving quality (editorial), 1898
- Flagstad, Michael S. see also Enright, Sharon Murphy, 1908
- Flascha, Stephan T. see Shane, Rita, 2647
- Flohr, Anne M. see Ivey, Marianne F., 2605
- Force, Wendy see Ried, L. Douglas, 1211
- Ford, M. E. 9000 "treatment systems" register for new clozapine distribution plan; dissatisfaction remains with high cost, paperwork (News), 2336
- Foster, Michele D. see Hershey, Andrea G., 104
- Fouts, Michele M. Drug-use evaluation of adult total parenteral nutrition using modified ASPEN guidelines (letter), 1442
- Fox, Janet L. see Stiles, M. Lou, 1727
- Frackiewicz, Edith J. Use of a blood substitute in a patient who refuses to accept a transfusion. Position 1: pharmacist should dispense blood substitute, 2176
- Frankenfield, Diane L. Pharmacist-initiated poison prevention campaign in a rural community, 2657
- Frankenfield, Diane L. Refractometry of controlled substances (letter), 2129
- Franko, Thomas G. see Oh, Taeho, 1471
- Frisolone, Julie A. Book review, 2537
- Fruns, Ignacio see Calvo, M. Victoria, 1190
- Frye, Reginald F. Book review, 843
- Fung, Ho-Leung see Cheung, Jolly F., 1488

## G

- Gagnon, Jean Paul Which bottom line? (letter), 2130
- Gallilei, Joseph F. see Lam, Nancy P., 280
- Gallina, Joseph N. Dealing with unfair criticism from a superior (Management Consultation), 1884
- Gansbeke, B. Van Stability of oxybutynin chloride syrup after repackaging in unit doses, 1265
- Garner, Sandra S. see Wiest, Donald B., 2430
- Garrelts, James C. see Barriere, Steven L., 939
- Geibig, Charles B. Pharmacy-controlled documentation of drug allergies, 260
- Geiger, Daniel see Brouker, Mark E., 530, 730
- Giboney, Sherry see Leisure, Gregory P., 464
- Gibson, J. Tyrone see Buchanan, Terry L., 2137
- Gilliland, Barbara see Hirsch, John, 444
- Ginsburg, Diane B. Book review, 2537
- Gittlow, Howard S. Framework for continuous quality improvement in the provision of pharmaceutical care, 1917
- Godwin, Harold N. To a new beginning from converging paths, 1697
- Godwin, Harold N. see also Sanborn, Michael D., 2659
- Goldberg, Dean E. Computer-based program for identifying medication orders requiring dosage modification based on renal function, 1965

## Annual Index

- Goldspiel, Barry R.** Availability of dideoxynosine, 1299
- Goldspiel, Barry R.** Status of dideoxynosine in clinical trials, 1298
- Goldstein, Eric** Methylphenidate use in Michigan (letter), 2129
- Goldwater, Shannon H.** How to publish a pharmacy newsletter (How To), 2121
- Goodell, John** Book review, 2530
- Goodfriend, Theodore L.** see Lindgren-Furmaga, Elaine M., 276
- Goodwin, S. Diane** Compatibility of ciprofloxacin injection with selected drugs and solutions, 2166
- Gora, Mary Lea** Stability of dobutamine hydrochloride in peritoneal dialysis solutions, 1234
- Goughnour, Barry R.** Potential cost-avoidance with oral extended-release morphine sulfate tablets versus morphine sulfate solution, 101
- Gousse, Gregory C.** Choices confronting December graduate in search of residency training (Student and Resident Forum), 54
- Gouveia, William A.** Book review, 373
- Gouveia, William A.** Paradigm for the management of patient outcomes, 1912
- Govern, Vicki L.** Attitudes of Ohio hospital pharmacists toward pharmacy technicians, 1228
- Grabowski, Bonnie S.** Outcome-focused patient-care standards developed by a local society of hospital pharmacists, 1257
- Gray, David R.** Extended-release niacin not problem free (letter), 238
- Gray, David R.** Responding to a physician's request to mislabel a patient's prescription. Position 2: pharmacist should go along with prescriber's benevolent deception, 298
- Green, Jeffrey A.** see Leisure, Gregory P., 464
- Greene, Stan A.** Expansion of clinical pharmacy services through staff development, 1704
- Grilley, Bambi J.** Design and implementation of an electronic investigational drug accountability system, 2616
- Grilley, Bambi J.** see Trissel, Lawrence A., 988
- Grunmich, Karl W.** see Denson, Donald D., 515
- Guerrero, Rawley M.** Pharmacist salaries and hiring practices in teaching hospitals, 249
- Gurwirth, Karen D.** see Summerfield, Marc R., 1463
- H**
- Haig, George M.** Effect of pharmacist participation on a medical team on costs, charges, and length of stay, 1457
- Hall, Maureen C.** see Avila, Juan R., 2131
- Hamburg, Margaret A.** see Minor, James R., 2662
- Hancock, Dorothy** see Pritts, Diane, 77
- Hanish, Lynn R.** Resolving problems in the use of omeprazole (letter), 2380
- Hansen, Lea Ann** see Peterson, Andrew M., 1477
- Hanson, Don B.** see Black, Harold J., 594
- Haribhakti, Rajiv P.** see Alexander, Kenneth S., 1241
- Harkness, Brenda J.** Change needed for i.v. rifampin preparation instructions (letter), 2127
- Harrell, Tracy T.** see Carey, Donald F., Jr., 681
- Harry, Donald J.** see Rainville, Edward C., 1531
- Hartwig, Steven C.** Severity-indexed, incident report-based medication error-reporting program, 2611
- Hasegawa, Guy R.** How to be interviewed for a job (How To), 1180
- Hatoum, Hind T.** see Kraus, Donna M., 97
- Hatton, Jimmi** Stability of nizatidine in total nutrient admixtures, 1507
- Hatton, Randy C.** see Reents, Stan, 1553
- Haydon-Greath, Starlin** see Goldwater, Shannon H., 2121
- Hazebrook, Lucy S.** Computer system for determining trends in controlled-substance discrepancies, 1262
- Healy, Daniel P.** Benefits of training Pharm.D. students (letter), 240
- Helms, Harold A.** see McBride, H. Anthony, 507
- Henry, David W.** Irreversibility of procainamide-dextrose complex in plasma in vitro, 2426
- Henry, David W.** see also Strayer, Andy H., 1970
- Hepler, Charles D.** Directions for specialization in pharmacy practice, part 1. The impact of pharmacy specialties on the profession and the public, 487
- Herfindal, Eric T.** see Koda-Kimble, Mary Anne, 700
- Hernandez, Pilar** see Bauwens, Steven F., 1364
- Hershey, Andrea G.** Audit of ranitidine administration in parenteral nutrient solutions, 104
- Heyd, Allen** see Goodwin, S. Diane, 2166
- Himmelberg, Cheryl J.** Use of antimicrobial drugs in adults before and after removal of a restriction policy, 1220
- Hiner, William O. Jr.** see Pierson, Jerome F., 1259
- Hines, Jeffrey L.** see Zieske, Paul A., 1500
- Hipple, Thomas F.** see Nahata, Milap C., 682
- Hirsch, John D.** see Hatton, Jimmi, 1507
- Hirsch, John D.** see also Ritchie, David J., 2172
- Hirsh, John D.** Inspiring staff to invest time in professional organizations (Management Consultation), 444
- Hoar, M. E.** Ethics of cardiac transplantation (letter), 1690
- Holbein, M. E. Blair** Cephalosporin confusion—one simple solution? (letter), 236
- Holmes, Sandra E.** Stability of miconazole in peritoneal dialysis fluid, 286
- Holstad, Sheldon G.** see Hatton, Jimmi, 1507
- Holstad, Sheldon G.** see also Ritchie, David J., 2172
- Horner, Ruth K.** Stability of an extemporaneously compounded terbutaline sulfate oral liquid, 293
- Horvath, Michael A.** Drug-use evaluation in a small community hospital, 518
- Houlihan, Gregory M.** Labeling of nonprescription quinine needs revision (letter), 1892
- Huffman, Monty D.** On being an HIV-positive pharmacist, 148
- Huffman, Monty D.** Staff pharmacist-driven clinical pharmacy program (letter), 680
- Hulstrand, Elizabeth P.** Comments on "War" editorial (letter), 1449
- Hunter, Wesley B.** see Swanson, Kathleen M., 1956
- Husain, Roshan A.** Disturbing susceptibility pattern for ciprofloxacin (letter), 1892
- Hussar, Daniel A.** see Bond, William S., 1978
- Hutchinson, Richard A.** see Wojtynek, Jeffrey E., 72
- Hutson, Paul R.** see Mutch, Rebecca S., 1267
- Hynman, Clifford E.** Preparing pharmacists for future technology. Drug product distribution systems and departmental operations, Oct suppl 524
- I**
- Iazzetta, John** see Walker, Scott E., 2161
- International Committee of Medical Journal Editors** Updated guidelines on competing manuscripts based on the same study, 2668
- International Committee of Medical Journal Editors** Update to "Uniform requirements for manuscripts submitted to biomedical journals," 1784
- Ishisaka, Denis Y.** Visual compatibility of indomethacin sodium trihydrate with drugs given to neonates by continuous infusion, 2442
- Iten, Scott A.** Pharmacists and animal research (letter), 76
- Ivey, Marianne F.** Alternative term for intervention needed (letter), 2605
- Ivey, Marianne F.** see also Lobas, Nancy H., 1708
- J**
- Jackson, Dhanawanti S.** see Nahata, Milap C., 992
- Jarosinski, Paul F.** see Lam, Nancy P., 280
- Jiang, Bernard C.** see Buchanan, Terry L., 2137
- Job, Martin L.** Book review, 2032
- Johnson, Cary E.** see Horner, Ruth K., 293
- Johnson, David S.** see Hershey, Andrea G., 104
- Johnson, Keith W.** see Ciancio, Sebastian G., 1447
- Johnson, Mark T.** see Goldberg, Dean E., 1965
- Johnson, Rolley E.** see Frankenfield, Diane L., 2129
- Jolowsky, Christine M.** see Goldberg, Dean E., 1965
- Jones, William N.** see Batz, Forrest R., 732
- Jungnickel, Paul W.** Extended-release niacin not problem free (letter), 237
- Junkin, Pamela** see Riley, Christopher M., 1245
- K**
- Kaatz, Brian** Determining a patient's suitability for cardiac transplantation. Position 2: the patient is medically suitable, 741
- Karabelas, A. N.** see Murabito, Anthony S., 943
- Karnes, H. Thomas** see Sarkar, Mohamadi A., 2184
- Kasperek, Marcia M.** Pharmacist clarification of medication orders as a pharmacy management tool, 2649
- Kathman, M. Susan** see Taylor, Jeffrey T., 1467
- Kendall, James D.** Considerations in employing a pharmacist recovering from chemical dependence, 326
- Kennedy, Paul E.** see Kintzel, P. E., 283, 1681
- Kennedy, Paul E.** see also Lam, Nancy P., 280
- Kepple, Stephen R.** Why journal manuscripts are edited (Questions and Answers), 909
- Kessler, John M.** see Himmelberg, Cheryl J., 1220
- Kilsdonk, Gary** Book review, 2041
- King, Charles M. Jr.** Preparing pharmacists for future technology. Introduction, Oct suppl S3
- Kintzel, P. E.** Stability of amphotericin B in 5% dextrose injection at concentrations used for administration through a central venous line, 283
- Kintzel, P. E.** Stability of amphotericin B in 5% dextrose injection at 25 °C (letter), 1681
- Kirk, Kenneth W.** see Rascati, E. Joseph, 974
- Kirking, Duane M.** Physician opinion of pharmacist-initiated change from injectable to oral administration of histamine H<sub>2</sub>-receptor antagonists, 1722
- Kirkwood, Craig F.** see Peterson, Andrew M., 1477
- Kiser, Lori A.** see Haig, George M., 1457
- Kitrenos, Jack G.** Book review, 1359
- Kittleson, Jack G.** see also Cheung, Jolly F., 1488
- Kittel, John** Pharmacists should initiate as well as prevent (letter), 2383
- Klein, Catherine Nichols** Benefits of peer-reviewed publication (Questions and Answers), 1424
- Klein, Catherine Nichols** Stability papers and equal publishing opportunities (editorial), 1454
- Klutman, Neil E.** see Henry, David W., 2426
- Knapp, Cynthia A.** Preparing manuscripts based on clinical seminars (Student and Resident Forum), 442
- Knapp, Judith A.** see Chrymko, Margaret M., 230
- Knapp, Katherine K.** Directions for specialization in pharmacy practice, part 2. The impact of specialization on pharmacy manpower, 691
- Knapp, Katherine K.** Promoting residencies to pharmacy students, 1717
- Knight, Cory C.** see Zieske, Paul A., 1500
- Knoll, Karen R.** Influenza vaccination program for elderly outpatients, 256
- Knox, Margot G.** see McPhee, Judith A., 1484
- Koberda, Michael** see Zieske, Paul A., 1500
- Koch, Karen E.** Use of ampicillin-sulbactam before and after formulary inclusion, 1492
- Koda-Kimble, Mary Anne** Directions for specialization in pharmacy practice, part 2. Impact of specialization on pharmacy education, 700
- Kohls, Philip R.** see Markowsky, Susan J., 510
- Koren, James F.** My dad the pharmacist—the American dream came true, 1039
- Koshko, Nancy** see Pane, Fred J., 236
- Kostrzewa, Dennis M.** Is ketorolac more cost-effective? (letter), 2128
- Kotzin, David A.** Thanks for the complimentary subscription (letter), 463
- Kraus, Donna M.** Program to improve nurses' knowledge of pediatric emergency medications, 97
- Kreling, David H.** Potential economic impact of changes in Medicaid drug program purchasing (letter), 678
- Krieger, Judith** see Hershey, Andrea G., 104
- Krivaneck, Frank J.** see Benedict, Michael V., 2653
- Kuhn, Robert J.** Do we know what we are really looking for? (letter), 2383
- Kulunis, Robert** see Montagne, Michael, 1035
- Kwan, Jane W.** Preparing pharmacists for future technology. High-technology i.v. infusion devices, Oct suppl S36
- Kwan, Jane W.** Preparing pharmacists for future technology. Pharmacists' knowledge of infusion devices, Oct suppl S52
- L**
- Lacerte, Judith A.** see Henry, David W., 2426
- Lake, Raymond T.** Home-care group needed within ASHP (letter), 75
- Lam, Nancy P.** Stability of zidovudine in 5% dextrose injection and 0.9% sodium chloride injection, 280
- Lampasona, Victor** see Wade, Catherine S., 1515
- Lander, Roger D.** see McBride, H. Anthony, 507
- Larson, Stella D.** see Carleton, Bruce C., 2422
- Larson, Timothy J.** Software review, 1622
- Laurialt, Ginette** Stability of methadone in four vehicles for oral administration, 1252
- Lawrenz, Candace A.** Therapeutic interchange of ampicillin-sulbactam for cefoxitin, 2150
- LeBelle, Michael J.** see Laurialt, Ginette, 1252
- Lee, Ann** see Lee, Derek K. T., 108, 111
- Lee, Derek K. T.** Compatibility of cefoperazone sodium and cimetidine hydrochloride in 5% dextrose injection, 111
- Lee, Derek K. T.** Compatibility of cefoperazone sodium and furosemide in 5% dextrose injection, 108
- Lee, Jeff T.** Interpretation of "cost-effective" and soundness of economic evaluations in the pharmacy literature (Questions and Answers), 909

- ture, 2622
- Lee, Marilyn D. see Prevost, Rebecca Rogers, 1533
- Lee, Robert U. of a blood substitute in a patient who refuses to accept a transfusion. Position 2: pharmacist should insist that patient receive a blood transfusion, 2178
- Leeds, Andrew L. see Knoell, Karen R., 256
- Leff, Richard D. see Strayer, Andy H., 1970
- Leisure, Gregory P. Time clocks in health-care institutions (letter), 464
- Lepinski, Penny W. see Lobas, Nancy H., 1189
- Leppik, Ilo see Markowsky, Susan J., 510
- Letassky, Nancy A. Book review, 1822
- Levchuk, John W. Sterility of extemporaneously compounded preservative-free injections (letter), 71
- Levine, Marc Book review, 2025
- Liang, Fern Z. Medicare and Medicaid fraud and abuse regulations, 2434
- Lindgren-Furmaga, Elaine M. Cost of switching hypertensive patients from enalapril maleate to lisinopril, 276
- Lindgren-Furmaga, Elaine M. Switching from enalapril to lisinopril (letter), 2605
- Lindon, James see Brodie, Donald C., 536
- Lisi, Donna M. Instructions provided by manufacturers for proper use of nonprescription ophthalmic drops, 987
- Littrell, Robert A. Epidural analgesia, 2460
- Lobas, Nancy H. Expanding staff pharmacists' responsibilities to maintain pharmacy services in a neonatal intensive-care unit, 1708
- Lobas, Nancy H. Satisfaction of physicians and nurses with clinical pharmacy services (letter), 1189
- Lobner, Tim see Turner, George H. III, 533
- Lodge, Bruce A. see Laurialt, Ginette, 1252
- Loeb, Jerod M. Animal research is necessary (letter), 2606
- Lomax, Christopher Pharmacists stationed in the Persian Gulf (letter), 458
- Lor, Edward Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration, 744
- Lowe, Stan Jr. ACCRUE: ASHP's management certificate program, 1992
- Lowes, Mariëtte M. J. More information on hardening of carbamazepine tablets (letter), 2130
- Lurvey, Patricia L. see Britton, Mark L., 265
- M**
- Mack, Wende B. Why authors no longer receive typeset galley proofs (Questions and Answers), 222
- MacKinnon, George E. III Applying business principles to pharmaceutical care (letter), 78
- Maddox, Ray R. Directions for specialization in pharmacy practice, part 1. Specialty recognition in pharmacy, 480
- Maginn, Christine M. see Pink, Laurence A., 1680
- Mahayni, Houda Antiretroviral activity of naloxone and naltrexone, 2480
- Mahayni, Houda Megestrol acetate in AIDS-related cachexia, 2479
- Main, John W. see Abel, Steven R., 943
- Maish, William A. see Wiest, Donald B., 2430
- Maloley, Pierre A. see Jungnickel, Paul W., 237
- Malouf, Eliana see Smythe, Maureen, 125
- Mansour, Jeannell M. see Geibig, Charles B., 260
- Marble, Earl L. Software review, 2053
- Marken, Patricia A. see Grabowski, Bonnie S., 1257
- Markowsky, Susan J. Stability and pH variability of four injectable phenytoin sodium products, 510
- Marquardt, Eric see Ishisaka, Denis Y., 2442
- Martin, Phil see Ried, L. Douglas, 1211
- Martinez, Domingo R. Book review, 2035
- Martinez, Domingo R. see also McBride, H. Anthony, 507
- Martinez, Thirsa Thanks from Persian Gulf pharmacist (letter), 1449
- Martir-Herrero, Maria L. see Hershey, Andrea G., 104
- Mason, Nancy A. Alternative work schedules for female pharmacists, 85
- Massaro, Frank J. see Gouveia, William A., 1912
- Matzke, Gary R. see Frye, Reginald F., 843
- Mauger, John W. see Robinson, Dennis H., Oct suppl 514
- Mayo, Martha Is ketorolac more cost-effective? (letter), 2128
- Mayor, Gilbert H. see Berg, Jeffrey A., 1448
- McAllister, James C. III Committed to confronting new challenges, 1749
- McBride, H. Anthony Stability of gentamicin sulfate and tobramycin sulfate in extemporaneously prepared ophthalmic solutions at 8 °C, 507
- McBride, H. Anthony see also Rivers, Thomas E., 2638
- McCart, Gary M. Waivers for military use of investigational agents. Position 2: pharmacist should follow orders and dispense investigational agents, 1526
- McCarthy, Judith A. see Brouker, Mark E., 530, 730
- McCarthy, Robert L. Determining a patient's suitability for cardiac transplantation. Position 1: the patient is not medically suitable, 740
- McFadden, David B. see Fouts, Michele M., 1442
- McGhan, William F. see Brodie, Donald C., 536
- McIntyre, William F. see Parr, Michael D., 127
- McKee, Jerry R. National survey of pharmaceutical services in psychiatric hospitals, 967
- McLaughlin, Susan S. Finding common ground: two pharmacists on Capitol Hill (News), 1840
- McPhee, Judith A. Effect of pharmacy-conducted education on prescribing of postoperative narcotics, 1484
- Medema, Pamela G. see Geibig, Charles B., 260
- Melby, Michael J. A mid-sized hospital's experience in indicator data collection, 1937
- Melby, Michael J. see also Gitlow, Howard S., 1917
- Merryfield, David W. see Grabowski, Bonnie S., 1257
- Messino, Michael J. see Parr, Michael D., 127
- Meyer, Gerald E. Use of bar codes in inpatient drug distribution, 953
- Milewski, Frank J. Jr. see Meyer, Gerald E., 953
- Miller, Dawn M. see McPhee, Judith A., 1484
- Miller, Susan W. see Strom, J. Grady Jr., 1237
- Minard, Patrick D. see Grabowski, Bonnie S., 1257
- Minor, James R. The AIDS research agenda at the National Institutes of Health, 2662
- Minor, James R. Foscarnet versus ganciclovir in the management of cytomegalovirus disease in patients with AIDS, 2478
- Minor, James R. Ten years' experience with AIDS: current status and future prospects, 1296
- Minor, James R. see also Mahayni, Houda, 2479, 2480
- Minor, James R. see also Shelton, Mark J., 556, 557
- Mitchell, John F. Pharmacists and drug company gifts (letter), 457
- Mitrano, Francis P. Chemical and visual stability of amphotericin B in 5% dextrose injection stored at 4 °C for 35 days, 2635
- Mitrano, Francis P. see also Outman, William R., 1538
- Mitrano, Francis P. see also Silvestri, Anthony P., 2641
- Miyagawa, Clyde I. see Rosenbaum, Cathy L., 2154
- Molitor, Richard E. Competition in the home infusion industry (letter), 1441
- Monk, Mary R. Time clocks in health-care institutions (letter), 464
- Monolakis, Jim see Outman, William R., 1539
- Montagne, Michael Pharmacy in Lithuania and the development of a sister-school relationship between colleges of pharmacy, 1035
- Montoro, Jose B. Comment on stability of ranitidine hydrochloride in total nutrient admixtures (letter), 2384
- Moran, Lance see Avila, Juan R., 2131
- Morgan, Robert J. see Cooke, Jonathan, 1199
- Morley, Peter C. see Strand, Linda M., 547
- Morris, Theresa L. see Himmelberg, Cheryl J., 1220
- Mott, David A. see Kreling, David H., 678
- Mueller, Roy D. Further update on stability of thrombin topical powder at room temperature (letter), 465
- Mühlebach, Stefan F. see Schmutz, Christian W., 501
- Mullins, Richard E. see Wade, Catherine S., 1515
- Mulot, Franck see Berod, Thierry, 2382
- Murabito, Anthony S. Affordability of cimetidine (letter), 943
- Murgatroyd, Rebecca J. Readability of informed consent forms, 2651
- Murphy, John E. Book review, 2532
- Murphy, John E. Observations on pharmacy practice and advanced pharmacy education in New Zealand, 553
- Murray, Patrick R. Sterility testing of a total nutrient admixture with a biphasic blood-culture system, 2419
- Mutch, Rebecca S. Stability of antipyrene plus caffeine in intravenous solution, 1267
- Myers, Charles E. Frequency of JCAHO-mandated medication inspections (Joint Commission Dialogue), 914
- Myers, Charles E. Locked storage of refrigerated controlled substances (Questions and Answers), 2368
- Myers, Charles E. Working toward uniformity in evaluation of ADR-reporting programs (Joint Commission Dialogue), 1428
- N**
- Nadzam, Deborah M. Development of medication-use indicators by the Joint Commission on Accreditation of Healthcare Organizations, 1925
- Nahata, Milap C. Clarifications to *Pediatric Drug Formulations* (letter), 682
- Nahata, Milap C. Stability of cefadroxil in reconstituted suspension under refrigeration and at room temperature, 992
- Nahata, Milap C. Stability of cefazolin sodium in peritoneal dialysis solutions, 291
- Nahman, Corey Keep Las Vegas as a meeting site for ASHP (letter), 1895
- Nakasato, Sharlene K. Impact of treatment guidelines on the use of aerosolized pentamidine for prevention of *Pneumocystis carinii* pneumonia, 2440
- Narducci, Warren A. see Crawford, Stephanie Y., 2398
- Neels, John T. Compatibility of hydromorphone hydrochloride and tetracaine hydrochloride (letter), 1682
- Nelson, Richard W. Book review, 1103
- Ness, Chuck see Avila, Juan R., 2131
- Nickman, Nancy A. see Guerrero, Rawley M., 249
- Nix, David E. Software review, 2049
- Nix, David E. see also Goodwin, S. Diane, 2166
- Nolan, Rathel L. see Cleary, John D., 2602
- Nold, Edward G. Book review, 2045
- Nold, Edward G. Hospital pharmacy in 1990: the year in review, 720
- Nold, Edward G. see also Geibig, Charles B., 260
- Nunnally, Paul J. Drug information services provided by pharmaceutical manufacturers (letter), 1683
- O**
- O'Brien, Patrick see Wojtynek, Jeffrey E., 72
- Oddis, Joseph A. Meeting the challenge of pharmacy practice, 1764
- O'Dorisio, Thomas M. see Ritchie, David J., 2172
- Oh, Sandra M. see Hershey, Andrea G., 104
- Oh, Taeho Comprehensive therapeutic interchange program in a community hospital, 1471
- O'Leary, Dennis S. Joint Commission begins shrinking accreditation manual (Joint Commission Dialogue), 434
- Oliary, Juliette see Brouard, Agnès, 2605
- O'Neil, Christine K. Pharmacist-managed medication training in personal-care homes, 1530
- Oszko, Michael A. see Case, Barbara, 121
- Outman, William R. Visual compatibility of ganciclovir sodium and total parenteral nutrient solution during simulated Y-site injection, 1538
- Outman, William R. Visual compatibility of haloperidol lactate with 0.9% sodium chloride injection or injectable critical-care drugs during simulated Y-site injection, 1539
- Outman, William R. see also Mitrano, Francis P., 2635
- P**
- Pabis, Dennis J. see Pugh, Carol B., 123, 946
- Palmer, Robert see Murabito, Anthony S., 943
- Palombo, John D. see Mitrano, Francis P., 2635
- Paloucek, Frank see Tyree, David J., 937
- Pane, Fred J. Notifying patients of adverse drug reactions (letter), 236
- Parker, Gordon A. see Alexander, Kenneth S., 1241
- Parker, Robert B. Software review, 1364
- Parks, N. Pauline Thomas see Trissel, Lawrence A., 2186
- Parks, Robert B. see Wade, Catherine S., 1515
- Parr, Michael D. Allogeneic bone marrow transplantation: procedures and complications, 127
- Parrish, Richard H. Understanding physician prescribing behavior (letter), 463
- Parrish, Richard H. see also Harkness, Brenda J., 2127
- Patel, Jitendra P. Activity of urokinase diluted in 0.9% sodium chloride injection or 5% dextrose injection and stored in glass or plastic syringes, 1511
- Patrick, James see Turner, George H. III, 533
- Pearson, Robert E. see Buchanan, Terry L., 2137
- Pediatric Pharmacy Administrative Group Committee on Pediatric Pharmacy Practice Pediatric pharmacy practice guidelines, 2475
- Pennell, Andrew T. Effect of ceftazidime, cefotaxime, and cefoperazone on serum tobramycin concentrations, 520
- Perrier, Donald G. see Strand, Linda M., 547
- Perry, Wendy R. see Mason, Nancy A., 85
- Pessetto, James D. see Sanborn, Michael D., 2659



Peterson, Andrew M. Influence of a decision analysis model on selection of drug therapy, 1477  
 Peterson, Charles D. see Goldberg, Dean E., 1965  
 Peterson, John P. Using serum creatinine concentrations to screen for inappropriate dosage of renally eliminated drugs, 1962  
 Petroff, Barbara J. Database program used by a home infusion therapy provider, 1535  
 Pham, Tu T. see Nakasato, Sharlene K., 2440  
 Phelps, Stephanie J. see Burch, Kelly J., 92  
 Piascik, Mary M. Preparing pharmacists for future technology. Research and development of drugs and biologic entities, Oct suppl 54  
 Pierson, Jerome F. Time requirements associated with three pharmacy inventory-control methods, 1259  
 Pink, Laurence A. Educational qualifications of hospital pharmacy managers (letter), 1680  
 Pittman, Donald G. Clinical pharmacy for all (letter), 239  
 Pleasants, Roy A. see Himmelberg, Cheryl J., 1220  
 Ploetz, Pamela A. see Hazebrook, Lucy S., 1262  
 Poikonen, John Comments on "War" editorial (letter), 1449  
 Poikonen, John Ethics of war (letter), 463  
 Poikonen, John Let's we forget (letter), 1689  
 Poikonen, John Waivers for military use of investigational agents. Position 1: medical experimentation without informed consent is unethical, 1525  
 Possidente, Carl J. see Rainville, Edward C., 1531  
 Pou, Leonor see Montoro, Jose B., 2384  
 Powell, C W see Greene, Stan A., 1704  
 Prevost, Rebecca Rogers Pharmacy services on obstetrics and gynecology and neonatology units, 1533  
 Price, Karen Overstreet Banned drugs in amateur athletics (letter), 76  
 Pritts, Diane Incompatibility of ceftriaxone with vancomycin (letter), 77  
 Pruemer, Jane M. see Woloschuk, Donna M. M., 2158  
 Puckett, William H. Book review, 592  
 Pugh, Carol B. Error in January note (letter), 946  
 Pugh, Carol B. Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection, 123

**R**

Rabinow, Barrett E. see Zieske, Paul A., 1500  
 Raghavan, Neeravur V. see Zieske, Paul A., 1500  
 Raiford, Elizabeth Dykes Hospital administrators' perceptions of pharmacy directors, 1948  
 Rainville, Edward C. A peer review-based quality assurance system, 1531  
 Raleigh, Fred R. Book review, 2534  
 Rascati, E. Joseph National survey of state psychiatric hospital pharmacies, 974  
 Ray, Max D. Rethinking the term "intervention" (letter), 1679  
 Reardon, Gregory see Benedict, Michael V., 2653  
 Reents, Stan Influence of methods on the evaluation of therapeutic drug-monitoring services, 1553  
 Regina, Darlene A. see Frankenfield, Diane L., 2657  
 Reilly, Mary Jo Status of the Pharmacy Manpower Database Project (Questions and Answers), 50  
 Reinhard, Mark see Sarkar, Mohamadi A., 2184  
 Reynolds, Dan R. see Frankenfield, Diane L., 2657  
 Reynolds, Lois A. Guidelines for the preparation of sterile ophthalmic products, 2438  
 Rice, Ted L. see Coffey, Robert P., 1496  
 Rich, Darryl S. Software review, 847  
 Ried, L. Douglas Book review, 1359  
 Ried, L. Douglas Multidimensional work sampling to study the activities of decentralized clinical pharmacists, 1211  
 Riley, Christopher M. Stability of amrinone and digoxin, procainamide hydrochloride, propranolol hydrochloride, sodium bicarbonate, potassium chloride, or verapamil hydrochloride in intravenous admixtures, 1245  
 Riley, Christopher M. see also Henry, David W., 2426  
 Ringer, Linda see Pane, Fred J., 236  
 Ritchie, David J. Activity of octreotide acetate in a total nutrient admixture, 2172  
 Rivers, Thomas E. Stability of cefotaxime sodium and metronidazole in an i.v. admixture at 8 °C, 2638  
 Robinson, Dennis H. Preparing pharmacists for future technology. Drug delivery systems, Oct suppl 514  
 Rochard, Eric B. Stability of cimetidine hydrochloride in Sondalis Iso-enteral nutrition formula (letter), 1681  
 Rodman, John H. Directions for specialization in pharmacy practice, part 2. Developing a specialty structure for the pharmacy profession, 706

Rodriguez, Charlene see Pugh, Carol B., 123, 946  
 Roerig, James L. Reactions to Lake Mindbegen (letter), 682  
 Rogeron, Brigitte see Rochard, Eric B., 1681  
 Rogers, Earl see Sarkar, Mohamadi A., 2184  
 Rogozinski, Barbara A. see Bailey, Leonard C., 2627  
 Rosen, Gail H. see Hershey, Andrea G., 104  
 Rosenbaum, Cathy L. Inability to justify a part-time clinical pharmacist in a community hospital intensive-care unit, 2154  
 Rosenbloom, Aaron D. see Hatton, Jimmi, 1507  
 Ross, Steven R. How to conduct a job interview (How To), 670  
 Ross, Steven R. More to the E-Ferol case than presented (letter), 1894  
 Ross, Thomas W. see Hazebrook, Lucy S., 1262  
 Roy, Peter D. see McPhee, Judith A., 1484  
 Rudd, Christine C. see Davis, Steven M., 240  
 Ryan, Kay M. see Prevost, Rebecca Rogers, 1533  
 Ryan, Michael L. see Mason, Nancy A., 85  
 Ryan, Patricia M. Epidemiology, etiology, diagnosis, and treatment of schizophrenia, 1271  
 Rybak, Michael J. see Barriere, Steven L., 939

**S**

Sakata, Kumiko Dental precaution listing needs improvement (letter), 1447  
 Saltiel, Emmanuel see Shane, Rita, 2647  
 Samsa, Gregory P. see Himmelberg, Cheryl J., 1220  
 Sanborn, Michael D. FDA drug classification system, 2659  
 Sanchez, Lisa A. see Lee, Jeff T., 2622  
 Sandrock, Maura J. see Murray, Patrick R., 2419  
 Santiago, Nayda M. see Trissel, Lawrence A., 2186  
 Sarkar, Mohamadi A. Stability of clindamycin phosphate, ranitidine hydrochloride, and piperacillin sodium in polyolefin containers, 2184  
 Sarrazin, Edward F. see Fouts, Michele M., 1442  
 Sauer, Karen Ann Survey of training, handling practices, and risk perceptions of Kentucky pharmacists working with antineoplastic agents, 119  
 Savard, Céline see Lauriault, Ginette, 1252  
 Schiff, Steve E. see Peterson, John P., 1962  
 Schilling, Craig G. see Seay, Russell E., 1972  
 Schmutz, Christian W. Stability of succinylcholine chloride injection, 501  
 Schnabel, Joe Extended-release niacin not problem free (letter), 238  
 Schneider, Philip J. see Hartwig, Steven C., 2611  
 Schollen, Stephanie L. Correction to *AHFS Drug Information* 91 (letter), 2606  
 Scholz, Robert L. see Summerfield, Marc R., 1463  
 Schulz, Jodi L. see Roerig, James L., 682  
 Schumacher, Gerald E. Multitribute evaluation in formulary decision making as applied to calcium-channel blockers, 301  
 Schumock, Glen T. Comparison of pharmacy-based concurrent surveillance and medical record retrospective reporting of adverse drug reactions, 1974  
 Schuna, Arthur A. see Lindgren-Furmaga, Elaine M., 276, 2605  
 Schwartz, Neil Affordability of cimetidine (letter), 943  
 Schweyen, Deborah H. Evaluation of serum lithium concentration determinations, 1536  
 Seay, Russell Antineoplastic admixtures (letter), 945  
 Seay, Russell E. Cost avoidance using syringe pumps to administer fat emulsion in a neonatal intensive-care unit, 1972  
 Seidel, Ann M. Effect of computer software on time required to prepare parenteral nutrient solutions, 270  
 Senst, Bonnie see Woller, Thomas W., 1952  
 Seth, Shiv see Gora, Mary Lea, 1234  
 Shafer, Mark S. see Barriere, Steven L., 939  
 Shalansky, Stephen J. Antibiotic interchange through educational interventions in a community hospital, 2655  
 Shane, Rita Using documentation of pharmacists' clinical activity, 2647  
 Shane, Rita Which bottom line? (letter), 2130  
 Shelton, Mark J. Aerosolized pentamidine in AIDS patients with asthma, 556  
 Shelton, Mark J. Occupational exposure to aerosolized pentamidine isethionate, 557  
 Shepherd, Michele see Goldberg, Dean E., 1965  
 Sherrin, Thomas P. see Govern, Vicki L., 1228  
 Sheybani, Taher see Lor, Edward, 744  
 Shields, Brenda see Gora, Mary Lea, 1234  
 Silvestri, Anthony P. Stability and compatibility of gan-

ciclovir sodium in 5% dextrose injection over 35 days, 2641  
 Simon, Lee S. Counseling a staff member after errors in dispensing (Management Consultation), 1675  
 Simonetti, Elizabeth M. Presenting the findings of residency projects in poster sessions or platform sessions (Student and Resident Forum), 228  
 Simpson, Tom Extended-release niacin not problem free (letter), 237  
 Sinai, Wendy J. see Patel, Jitendra P., 1511  
 Slack, Marion K. Book review, 2711  
 Slimowitz, Richard Antineoplastic admixtures (letter), 945  
 Slimowitz, Richard Standardized cancer chemotherapy order form (letter), 1683  
 Small, Ronald H. Clinical pharmacy term is outdated (letter), 1443  
 Smith, Dancer Reactions to Lake Mindbegen (letter), 683  
 Smith, Joe E. A strong financial position for achieving ASHP's goals, 1757  
 Smith, Joe E. see also Meyer, Gerald E., 953  
 Smith, Marie A. Access to PharmNet, ASHP's electronic bulletin board (Questions and Answers), 1174  
 Smith, Thomas A. II Treatment of snakebite poisoning, 2190  
 Smith, William E. Comments on levels of pharmaceutical care (letter), 1690  
 Smith, William E. Levels of pharmaceutical care: a theoretical model, 540  
 Smythe, Maureen Visual compatibility of insulin with secondary intravenous drugs in admixtures, 125  
 Soares, Michael S. State pharmacy boards adopting topic-specific CE requirements (News), 2560  
 Somani, Shabir see Seidel, Ann M., 270  
 Sommi, Roger W. Growth of psychopharmacy (letter), 1185  
 Sopchak, Andrew see Nunnally, Paul J., 1683  
 Sorby, Donald L. see Knapp, Katherine K., 691  
 Soucy, Donna see Gousse, Gregory C., 54  
 Spinler, Sarah A. How to prepare and deliver pharmacy presentations, 1730  
 Spivey, J. Michael see Himmelberg, Cheryl J., 1220  
 Sporka, Michael C. see Schweyen, Deborah H., 1536  
 Spratto, George R. Book review, 175  
 Sprenger, Rebecca L. see Caselnova, Dominick A. III, 1260  
 Sriram, Rajaram see Zieske, Paul A., 1500  
 Stack, David M. see Sudol, Thaddeus E., 1684  
 Stajich, Gregory V. Fetal attraction, 1998  
 Stanislav, Steven E. see Sommi, Roger W., 1185  
 Steffen, William M. Reserve-duty pharmacist proud to serve (letter), 2131  
 Steinhauer, Kenneth J. The theory of ADD-MORE (letter), 2383  
 Stella, Valentino J. see Waugh, Wanda N., 1520  
 Sterchele, James A. Room-temperature stability of allergenic extracts (letter), 683  
 Steward, Kristine Training community pharmacists to fill hospital vacancies (Management Consultation), 666  
 Stewart, Mary C. see Harkness, Brenda J., 2127  
 Stierer, Raymond C. see Sterchele, James A., 683  
 Stifter, Janet see Kraus, Donna M., 97  
 Stiles, M. Lou Gas production of three brands of cefazidime, 1727  
 Stiles, M. Lou Stability of doxorubicin hydrochloride in portable pump reservoirs, 1976  
 Stirr, Eric J. see Denson, Donald D., 515  
 Stivender, Deborah A. Animal research is necessary (letter), 2606  
 Stivender, Deborah A. No more animal research (letter), 1684  
 St. Jean, Audrey D. State societies make headway in formalizing technician role (ASHP Affiliates), 2346  
 Strand, Linda M. Levels of pharmaceutical care: a needs-based approach, 547  
 Strayer, Andy H. Administration of whole blood, packed red blood cells, and platelets using a multipurpose infusion pump, 1970  
 Strom, J. Grady Jr. Stability and compatibility of methylprednisolone sodium succinate and cimetidine hydrochloride in 5% dextrose injection, 1237  
 Stuart, James see Woller, Thomas W., 1952  
 Sudol, Thaddeus E. Do not forget medical staff education (letter), 1684  
 Sue, Caron A. see Denson, Donald D., 515  
 Summerfield, Marc R. Establishing a pharmacy department for a large pediatric hospital: managerial problems, opportunities, and lessons, 1463  
 Swanson, Kathleen M. Pharmacist career ladder with clinical privilege categories, 1956  
 Swartz, Allan J. Easing tension through flexible leadership style (Management Consultation), 2598



## T

- Takagi, Jane see Lor, Edward, 744  
 Talley, C. Richard Advice, 1999  
 Talley, C. Richard Authors' acknowledgment of potential conflicts of interest (Questions and Answers), 1168  
 Talley, C. Richard Counseling patients about drug use (editorial), 1196  
 Talley, C. Richard Tracking manuscripts and reviewers electronically (editorial), 950  
 Talley, C. Richard What have you done to my manuscript? (editorial), 2388  
 Tang, Kin T. see Bailey, Leonard C., 2627  
 Tarasevicius, Eduardas see Montagne, Michael, 1035  
 Tarr, Bryan D. Stability and sterility of biosynthetic human insulin stored in plastic insulin syringes for 28 days, 2631  
 Task Force on Specialty Recognition of Psychopharmacy Practice Executive summary of petition requesting recognition of psychopharmacy, 1284  
 Taylor, Jeffrey T. Documentation of cost savings from decentralized clinical pharmacy services at a community hospital, 1467  
 Taylor, Jerry W. see Cleary, John D., 2602  
 Taylor, Max R. see Koch, Karen E., 1492  
 Teagarden, J. Russell Reactions to Lake Mindbegone (letter), 683  
 Terrier, Jean Loup see Brouard, Agnès, 1190, 2605  
 Theodorou, Anna see Lawrenz, Candace A., 2150  
 Theriault, Burton C. see Horvath, Michael A., 518  
 Thomson, James E. Public policy protects hospital quality assurance documents from discovery in litigation, 1989  
 Thompson, Barbara Book review, 1614  
 Thompson, Cheryl A. Pharmacies recycle (News), 6  
 Thompson, John F. Comments on levels of pharmaceutical care (letter), 1689  
 Thomson, P. D. see Coffey, Robert P., 1496  
 Thornton, John P. see Schumock, Glen T., 1974  
 Thornton, John P. see also Wojtynek, Jeffrey E., 72  
 Thorson, Dean W. Beginning clinical clerkships (Student and Resident Forum), 1671  
 Tramoto, Sharon M. see Trissel, Lawrence A., 988  
 Tran, Loan T. see Patel, Jitendra P., 1511  
 Trang, John M. see McBride, H. Anthony, 507  
 Trang, John M. see also Rivers, Thomas E., 2638  
 Trask, Sandra J. see Swanson, Kathleen M., 1956  
 Trissel, Lawrence A. Visual compatibility of fludaurine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection, 2186  
 Trissel, Lawrence A. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection, 988  
 Trissel, Lawrence A. see also Grille, Bambi J., 2616  
 Trissel, Lawrence A. see also Waugh, Wanda N., 1520  
 Troutman, William G. Book review, 2041  
 Turner, George H. III Pharmaceutical services required during setup of an Army combat support hospital, 533  
 Turowski, Robert C. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection, 2181  
 Tyree, David J. Personal shampoos and safety considerations (letter), 937

## V

- Vaida, Allen J. Making job descriptions functional (Management Consultation), 2118  
 Vance, James Robert Book review, 175  
 Van Vleet, John see Ishisaka, Denis Y., 2442  
 Veatch, Robert M. Determining a patient's suitability for cardiac transplantation. Analysis and commentary, 742  
 Veatch, Robert M. Ethics of cardiac transplantation (letter), 1690  
 Veatch, Robert M. Responding to a physician's request to mislabel a patient's prescription. Analysis and commentary, 299  
 Veatch, Robert M. Use of a blood substitute in a patient who refuses to accept a transfusion. Analysis and commentary, 2179  
 Veatch, Robert M. Waivers for military use of investigational agents. Analysis and commentary, 1527  
 Visconti, James A. see Gora, Mary Lea, 1234  
 Vivian, Jesse C. Hospitals' exclusive contractual arrangements with vendors of durable medical equipment violate antitrust laws, 1542  
 Vogel, David Why pursue a residency? (Student and Resident Forum), 1878  
 Volger, Burgunda W. Book review, 2322  
 Vrabl, Ray see Woller, Thomas W., 1952

## W

- Wade, Catherine S. Stability of ceftazidime and amino acids in parenteral nutrient solutions, 1515  
 Wade, Dorothy A. Calling all former NPC interns (letter), 78  
 Wagner, Jon C. Software review, 596  
 Walker, Scott E. Compatibility of dexamethasone sodium phosphate with hydromorphone hydrochloride or diphenhydramine hydrochloride, 2161  
 Walsh, Karen Clarifications to *Pediatric Drug Formulations* (letter), 682  
 Wang, Da-Peng see Lee, Derek K. T., 108, 111  
 Ware, John E. Jr. see Gouveia, William A., 1912  
 Wasserman, Marcy L. see Kirking, Duane M., 1722  
 Waugh, Wanda N. Stability, compatibility, and plasticizer extraction of taxol (NSC-125973) injection diluted in infusion solutions and stored in various containers, 1520  
 Weber, David J. see Himmelberg, Cheryl J., 1220  
 Wells, Brian see Sarkar, Mohamadi A., 2184  
 Wermeling, Joseph R. see Woloschuk, Donna M. M., 2158  
 West, Thomas E. see Ried, L. Douglas, 1211  
 Westrich, Thomas J. see Hatton, Jimmi, 1507  
 Westrich, Thomas J. see also Ritchie, David J., 2172  
 Wetmore, Robert W. see Kasperek, Marcia M., 2649  
 White, Janet Y. see Shane, Rita, 2647  
 Wiest, Donald B. Stability of amphotericin B in four concentrations of dextrose injection, 2430  
 Wilgosh, Charles P. see McPhee, Judith A., 1484  
 Williams, David A. see Silvestri, Anthony P., 2641  
 Williams, Deanne see Harkness, Brenda J., 2127  
 Williams, Dennis M. see Thorson, Dean W., 1671  
 Williams, Jeffrey see Cooke, Jonathan, 1199  
 Williams, Robert B. Empowerment, 1754  
 Williams, Robert B. see also Flagstad, Michael S., 1898

- Wilton, John H. see Goodwin, S. Diane, 2166  
 Winslow, Robert see Byerly, Wesley G., 1442  
 Witte, Kenneth W. see Schumock, Glen T., 1974  
 Wojtynek, Jeff Material safety data sheets for investigational drugs (letter), 1679  
 Wojtynek, Jeffrey E. Institutional review boards and quality assurance activities (letter), 72  
 Wolfe, Kelly R. see Buck, Gary W., 1191  
 Wolff, Nancy L. see Lindgren-Furmaga, Elaine M., 276  
 Wolfson, Bernard B. see Cafmeyer, Nancy R., 735, 1448  
 Woller, Thomas W. Checking of unit dose cassettes by pharmacy technicians at three Minnesota hospitals, 1952  
 Woller, Thomas W. see also Lobas, Nancy H., 1189  
 Woller, Thomas W. see also Seidel, Ann M., 270  
 Woloschuk, Donna M. M. Stability and compatibility of fluorouracil and mannitol during simulated Y-site administration, 2158  
 Woodson, Henry A. Jr. Frequency of JCAHO-mandated medication inspections (Joint Commission Dialogue), 914  
 Woodson, Henry A. Jr. Working toward uniformity in evaluation of ADR-reporting programs (Joint Commission Dialogue), 1428  
 Workman, Theresa M. see Tarr, Bryan D., 2631  
 Wright, Glenn E. see Akers, Michael J., 2414  
 Wu, Faye F. see Gray, David R., 238  
 Wuest, J. Richard Book review, 374

## Z

- Zellmer, William A. Advice on writing for the beginner (editorial), 687  
 Zellmer, William A. Degrees of equity (editorial), 2607  
 Zellmer, William A. Expressing the mission of pharmacy practice (editorial), 1195  
 Zellmer, William A. Gaining external support for pharmacy's new mission (editorial), 949  
 Zellmer, William A. Goals for health-care reform (editorial), 2133  
 Zellmer, William A. Measuring and improving quality (editorial), 1897  
 Zellmer, William A. The mission of *AJHP* (editorial), 81  
 Zellmer, William A. A model for ambulatory-care pharmaceutical services (editorial), 245  
 Zellmer, William A. Pharmaceutical promotion and pharmacist probity (editorial), 1693  
 Zellmer, William A. Reassessing patient counseling (editorial), 1453  
 Zellmer, William A. Upgrading quality assurance for pharmacy-prepared sterile products (editorial), 2387  
 Zellmer, William A. War (editorial), 467  
 Zieske, Paul A. Characterization of cisplatin degradation as affected by pH and light, 1500  
 Zimmer, Gabriel S. see Casanova, Dominick A. III, 1260  
 Zoloth, Arthur M. The need for ethical guidelines for relationships between pharmacists and the pharmaceutical industry, 551  
 Zurawski, Douglas J. see Fouts, Michele M., 1442